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ABSTRACT

DEVELOPMENT OF CLINICALLY RELEVANT IN VITRO PERFORMANCE TESTS FOR
POWDER INHALERS
By Xiangyin Wei, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2015
Major Director: Peter R. Byron, Ph.D.
Professor, Department of Pharmaceutics

While realistic in vitro testing of dry powder inhalers (DPIs) can be used to establish
in vitro–in vivo correlations (IVIVCs) and predict in vivo lung doses, the aerodynamic
particle size distributions (APSDs) of those doses and their regional lung deposition
remains unclear. Four studies were designed to improve testing centered on the behavior
of Novolizer®. Different oropharyngeal geometries were assessed by testing different
mouth-throat (MT) models across a realistic range of inhalation profiles (IPs) with
Salbulin® Novolizer®. Small and large Virginia Commonwealth University (VCU) and
Oropharyngeal Consortium (OPC) models produced similar ranges for total lung dose in
vitro (TLDin vitro), while results for medium models differed significantly. While either group
xxiii

may be selected to represent variations in oropharyngeal geometry, OPC models were
more difficult to use, indicating that VCU models were preferable. To facilitate simulation
of human IPs through DPIs, inhalation profile data from a VCU clinical trial were analyzed.
Equations were developed to represent the range of flow rate vs. time curves for use with
DPIs of known airflow resistance. A new method was developed to couple testing using
VCU MT models and simulated IPs with cascade impaction to assess the APSDs of TLDin
vitro

for Budelin® Novolizer®. This method produced IVIVCs for Budelin’s total lung dose,

TLD, and was sufficiently precise to distinguish between values of TLDin vitro and their
APSDs, resulting from tests using appropriately selected MT models and IPs. For
example, for slow inhalation, TLD values were comparable in vivo and in vitro; TLDin vitro
ranged from 12.2±2.9 to 66.8±1.7 mcg aerosolized budesonide while APSDs in vitro had
mass median aerodynamic diameters of 3.26±0.27 and 2.17±0.03 µm, respectively. To
explore the clinical importance of these variations, a published computational fluid
dynamic (CFD) model was modified and coupled to accept the output of realistic in vitro
tests as initial conditions at the tracheal inlet. While simplified aerosol size metrics and
flow conditions used to shorten CFD simulations produced small differences in theoretical
predictions of regional lung deposition, the results broadly agreed with the literature and
were generally consistent with the median values reported clinically for Budelin.

xxiv

CHAPTER 1
INTRODUCTION

1.1

BACKGROUND
The history of inhalation therapy can be traced back some 4,000 years, when

ancient Indian herbal smoke preparations with bronchodilating properties were used to
treat asthma and other respiratory conditions (Anderson, 2005). But it was not until 1956,
and the launch of the first pressurized metered dose inhaler (pMDI), that the modern era
of pulmonary drug delivery began (Sanders, 2007). In the last 60 years we have seen
great advances in aerosol delivery technology, and the emergence of safer and more
effective drugs to treat pulmonary diseases like asthma and chronic obstructive
pulmonary disease (COPD). At the time of this thesis, there are 32 branded orally inhaled
drug products covering 19 active pharmaceutical ingredients (APIs) approved by the U.S.
Food and Drug Administration (FDA) for treatment of asthma and COPD (U.S. Food and
Drug Administration, 2015a). With the exception of some nebulizer solutions however,
none of these products have generic competitors in the USA. Patients are forced to pay
for branded inhalers and unless they have top-notch insurance or high income, disease
treatment can be difficult to maintain due to the high cost of these combination products
that combine a drug formulation with a device to deliver it as an aerosol (Rosenthal, 2013).
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Ideally, as products come off patent, the launch for cheaper generic equivalents
should alleviate the problem. Unfortunately, even though a number of patents for inhaled
drugs are expiring [e.g. Advair® Diskus®, U.S. patent 5,873,360 expires on Feb 23, 2016;
(U.S. Food and Drug Administration, 2015b)], product development scientists and the
regulators experience problems proving that a new inhaler delivers drug in the same way
as the “innovator”.

1.2

DRY POWDER INHALER
Dry powder inhalers (DPIs) are a major developing platform for aerosol drug

delivery that has been replacing propellant based devices in recent years, in part because
of the environmental effects of chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA)
propellants. Most commercial DPIs are passive DPIs that require the patient’s inhalation
power to generate the drug aerosol cloud. Passive DPIs can be classified into three
categories: (a) unit dose, where the drug formulation is stored in a single capsule, blister
or cartridge (e.g. Foradil® Aerolizer®); (b) multiple unit dose, where the drug formulation
is stored in blisters fixed on strips or disks (e.g. Advair® Diskus®); (c) multi-dose, where
the drug formulation is stored in a reservoir (e.g. Budelin® Novolizer®) and the powder
metered by the device itself.
A typical powder formulation contains micronized drugs milled to a respirable
particle size (usually 1–5 µm), blended with larger carriers (e.g. α-lactose monohydrate)
to facilitate flow and reduce the aggregation of micronized drug powders (Telko & Hickey,
2005). When a patient activates a DPI and inhales, air is introduced into the device that
causes the drug-carrier blend to be dispersed and to deaggregate due to air turbulence
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and mechanical impaction with the device (Telko & Hickey, 2005). The extent of powder
dispersion and the efficiency in generating small particles for pulmonary delivery from a
DPI is dependent on device design (which determines powder dispersion mechanism),
drug formulation (which determines the cohesive and adhesive forces between particles),
and the patient’s inhalation maneuver (which determines the forces available for
aerosolization). General principles of powder metering and dispersion from a typical DPI
are illustrated in Figure 1.1.

Figure 1.1. General principles of powder metering and dispersion from a DPI (Telko &
Hickey, 2005). A typical powder formulation contains micronized drugs blended with much
larger carrier particles that when inhaled, deaggregate to generate small respirable
particles for pulmonary delivery.

Although different DPIs adopt similar principle for powder dispersion (Figure 1.1),
their device design and powder dispersion mechanisms differ significantly. For example,
Aerolizer® contains pre-metered drug in a single hard capsule. The patient activates the
inhaler by piecing the capsule ends with eight pins at the device base (four pins on each
side). Upon inhalation, the capsule spins in the capsule chamber and releases powder
3

into the airstream due to vibration and centrifugal forces; drug-carrier deaggregation
occurs largely through particle-device collisions and air turbulence (Coates et al., 2005).
Novolizer® contains drug formulations in a cartridge that may or may not be replaceable
and may deliver up to 200 metered doses (Fenton et al., 2003). The device uses “Air
Classifier Technology (ACT)” that enables collisions to occur within a “cyclone” inside the
device so that during inhalation, tangential air is introduced at different point inside a multichannel classifier which consequently, causes the drug-carrier agglomerates to
deaggregate under centrifugal, collision and frictional forces (de Boer et al., 2003). The
device is designed to favor the retention of large carrier particles within the classifier,
while small drug particles are easily released from the device (de Boer et al., 2003). In
vitro testing under compendial conditions (see section 1.4) showed that Novolizer delivers
consistent doses in the early, middle, and late stages of cartridge emptying with a
comparatively small relative standard deviation (RSD) of 5.56% (de Boer et al., 2004).
More detailed reviews on this topic and recent advances can be found at (Chan et al.,
2014; Son & McConville, 2008; Zhou et al., 2014).
Of the many variations in DPI design, airflow resistance across the device is an
important factor that affects a patient’s inhalation maneuver. Clark and Hollingworth (1993)
found that the mean peak inhalation flow rate (PIFR) generated by healthy volunteers at
their maximum inhalation efforts reached over 150 L/min for a low resistance DPI device
(Rotahaler®), while the value was only 50 L/min for a high resistance DPI device
(Inhalator®). In the same study, the authors also found that PIFR dropped to 80 L/min
and 30 L/min respectively for the two DPIs when subjects reduced their inhalation efforts
to a “comfortable level” (Clark & Hollingworth, 1993). As passive DPIs rely upon a
4

patient’s inhalation to disperse the formulation and deliver drug to the lung, changes in
inhalation effort through a DPI can significantly affect drug deposition in the airways.
Borgström et al. (1994) reported that total lung deposition of budesonide inhaled via
Turbuhaler® reached 27.7% of the metered dose when subjects inhaled at a PIFR of 60
L/min, while the value decreased to 14.8% for a lower PIFR of 35 L/min. Similarly,
Newman et al. evaluated budesonide deposition from “ASTA Medica”, a prototype inhaler
that became the commercially available Budelin® Novolizer®, and found on average,
using gamma scintigraphy, that this inhaler delivered higher doses to the lung at a PIFR
of 99 L/min (32.1% of the metered dose) than at 65 L/min or 54 L/min (25.0% and 19.9%
of the metered dose, respectively) (Newman et al., 2000). To ensure optimal drug delivery,
patients are usually instructed to inhale fast and deeply through a DPI, and training tools
such as In-Check Dial™ (a peak flow meter integrated with different resistance orifices to
mimic DPI resistances) may be used to help patients reach a desired PIFR for a given
device (Chrystyn, 2003; Lavorini et al., 2010). Even with trained inhalation maneuvers
however, large inter-subject variations are still observed in the clinical lung deposition
studies (Borgström et al., 2006). Because of this variability, and because powder inhalers
are likely to dominate the aerosol marketplace of the future, this thesis is focused on the
development and application of realistic (“bio-relevant”) testing of DPIs. Indeed, most of
the work in this thesis seek to explain the variability seen in lung deposition for “ASTA
Medica”, the Budelin prototype. Newman et al. (2000) explained the wide variations in
drug delivery to the lung based on variations in the way normal subjects inhaled. In this
thesis, experiments and results are presented that offer insights both to the effects of
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inhalation profiles and orphyaryngeal geometry on pulmonary drug deposition from the
same inhaler.

1.3

INHALER BIOEQUIVALENCE: STATUS AND CHALLENGES
FDA approval of generic products requires that bioequivalence be demonstrated

between the proposed drug product and the “innovator” or reference listed drug (RLD)
(U.S. Food and Drug Administration, 2013). This requires comparative testing between
the generic and the RLD, where the applicants must prove “no significant difference in
the rate and extent to which the active ingredient or active moiety in pharmaceutical
equivalents or pharmaceutical alternatives becomes available at the site of drug action
when administered at the same molar dose under similar conditions in an appropriately
designed study” ("Code of Federal Regulations," 2015). While pharmacokinetic (PK)
studies alone are usually considered sufficient for establishing bioequivalence of orally
administered drugs with systemic action (Saluja et al., 2014), situations are far more
complex for pulmonary delivered drugs with local or “topical” activity. As illustrated in
Figure 1.1, aerosolized drugs from an inhaler are designed to be delivered via oral
inhalation. Because the mouth is the conduit, the drug deposits in both the oropharynx
and lung. Drug depositing in the oropharyngeal region will be swallowed into the
gastrointestinal (GI) tract, and only the dose entering the lung can induce local therapeutic
effects. Furthermore, because local effects in the airways depend on regional dose and
distribution (Anderson & Newman, 2009; Usmani, 2015; Usmani & Barnes, 2012; Usmani
et al., 2005), the way in which an aerosol deposits in the lung can influence product and
drug efficacy. Given that the aerosols produced from inhalers may vary in size depending
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on drug formulation, device design and patient-related human factors, this “proof of
similarity” or bioequivalence becomes quite a challenge, especially because some
inhalers contain multiple drugs with different aerosol characteristics (Daley-Yates et al.,
2014; Daley-Yates et al., 2009; Tarsin et al., 2006). Taken overall, because drug
concentration at the “site of action” does not rely upon the systemic circulation (the plasma
is “downstream” of drug absorption from either the GI tract or the lung; Figure 1.2), PK
studies alone are not considered adequate to establish bioequivalence of orally inhaled
drug products in the USA (Saluja et al., 2014). In practice, PK may assure equivalent
systemic exposure but it fails to assure local exposure in the airways.

Lung
Deposition

Inhaler
Lung

Oropharyngeal
Deposition

Gastrointestinal Tract

Systemic Circulation

Figure 1.2. Schematic of drug deposition and disposition in the human body after
delivery through the pulmonary route. Figure was redrawn from (Anderson & Newman,
2009).

FDA’s current thinking about inhaler bioequivalence is based on an aggregate
“weight of evidence” approach (Lee et al., 2009; Saluja et al., 2014); for DPIs, this includes
demonstration of comparative in vitro performance [single actuation content and
aerodynamic particle size distribution (APSD) tests], comparative systemic exposure (PK
studies), comparative local action (clinical end point studies), and comparative device and
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formulation design (Figure 1.3). Product-specific draft guidance has also been released
for DPIs containing fluticasone propionate and salmeterol xinafoate based on this
approach (U.S. Food and Drug Admiistration, 2013).
Comparative
Pharmacokinetic Studies

Comparative
In Vitro Studies

Bioequivalence

Comparative
Clinical Endpoint Studies

Device and Formulation Design

Figure 1.3. FDA’s aggregate “weight of evidence” approach for establishing
bioequivalence of dry powder inhalers. Figure was redrawn from (Lee et al., 2009).

Of the two major types of multi-dose inhalers, DPIs are arguably a greater
challenge to regulators because they rely on the patient’s inhalation to produce the
aerosol, and aerosol properties can depend on the way the patient inhales (Tarsin et al.,
2006). Even for low-variance inhalers [e.g. Novolizer®, (Delvadia et al., 2012)], it appears
to be difficult to select individuals that even when trained, inhale in such a way that the
lung dose in vivo is reproducible. In practice, topical delivery from DPIs is variable even
in normal trained subjects (Newman et al., 2000), and this variability needs to be
recognized when attempting to assess the equivalence of two inhalers. In addition to this,
when comparing in vitro properties, a performance characteristic should be chosen that
has a proven relationship to efficacy in the clinic. In short, it is necessary to show an in
vitro–in vivo correlation (IVIVC) for example, between inhaler in vitro attributes (e.g.
APSDs) and in vivo drug deposition in the lung (Newman & Chan, 2008), before using
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the in vitro attribute to judge the similarity of two devices. This raises uncertainties for
product development scientists and the regulators concerning the meaningful definition
of in vitro equivalence between the test and reference products. In short, the answer to
the question “If the two products show equivalence in vitro, will they have potentially
equivalent in vivo performance?” is presently unknown. A good example to illustrate the
complexity of this topic is the studies published by Daley-Yates et al. (2014; 2009), where
test and reference DPIs showed comparable in vitro performance, but in vivo PK studies
suggested significant differences in systemic exposure and lung absorption of fluticasone
between the two inhalers. One possible reason for those discrepancies is that compendial
(e.g. United States Pharmacopeia, or USP) in vitro test methods for measurement of
APSDs (U.S. Pharmacopeial Convention, 2013) do not readily reflect the real situation of
inhaler use in the clinic (see section 1.4), so that apparent “equivalence” in vitro does not
necessarily relate to the clinical performance of the inhalers (Daley-Yates et al., 2014).
As we enter an era where generic inhalers are needed, it will be necessary and beneficial
for both drug developers and regulators if more predictive in vitro test methods are
researched and established for orally inhaled drug products.

1.4

IN VITRO PREDICTION OF AEROSOL DEPOSITION IN THE HUMAN LUNG
The study of aerosol deposition in the human lung dates back to the 1950s, when

the deposition of hazardous environmental aerosols in the lung were of major concerns
to the public. Specifically, the dosimetry, proportion and position of aerosol deposition
and how the human lung could remove certain aerosols, after deposition had occurred
were studied for humans breathing tidally (Gerrity, 1989). In those studies, human
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subjects were instructed to inhale radiolabeled, monodisperse, insoluble particles through
a large mouthpiece using required breathing patterns. Subsequently, aerosol deposition
and clearance in the lung were monitored externally using scintillation detectors. A large
meta-analysis of these deposition studies was performed by Stahlhofen et al. (1989) in
the late 1980s with the goal of reducing discrepancies in existing deposition data and
providing reliable, less variable, empirical equations for predicting aerosol dosimetry in
different regions of the respiratory tract. Factors including particle characteristics, subjects’
breathing patterns and airway geometries were considered important determinants of
aerosol deposition in the human lung.
Table 1.1. Aerosol deposition study characteristics: Environmental aerosols vs. drug
aerosols delivered from DPIs.
Environmental Aerosols
a. Monodisperse dilute aerosols

Drug Aerosols from DPIs
a. Polydisperse concentrated aerosol
clouds

b. Particles are insoluble

b. Particles are soluble and absorbable

c. Particle size do not change – aerosols

c. Drug-carrier deaggregation and APSDs

are stable

depends on patient-device interactions
– aerosols are not stable;
deagglomeration and/or hygroscopic
effects may occur during administration

d. Subjects inhale tidally from a stable

d. Subjects inhale once only, fast and

aerosol reservoir

deeply through the inhaler; aerosols
are created during this process
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The semi-empirical models developed by Stahlhofen et al. (1989) and others [e.g.
the ICRP model (International Commission on Radiological Protection (ICRP), 1994)]
provided valuable information for pharmaceutical scientists wishing to study aerosol drug
deposition in the human lung. However, caution should be applied when using these
models to predict drug deposition from inhalers. Stahlhofen’s work (Stahlhofen et al.,
1989) generally employed insoluble dilute stable aerosols that did not change size during
entry into the human subjects following or during tidal inhalation in each study. DPIs on
the other hand involve single deep inspirations of powder mixtures; such concentrated
aerosols are created and administered at the same time. That situation is far more
complex than those involved in early lung deposition studies (Table 1.1).
The present compendial methods (U.S. Pharmacopeial Convention, 2013)
determine the APSD of the drug leaving a powder inhaler under fixed conditions (airflow
rate and volume are specified). Often the data is processed to yield the mass of drug
exiting the inhaler with aerodynamic diameters smaller than about 5 µm because this is
often construed as most likely to penetrate the lung. Indeed, the “fine particle fraction”
(FPF, designated as drug fraction with particle size < ~5 µm) is usually considered to be
an important in vitro parameter that predicts inhaler performance in vivo. The
pharmacopeial methods were initially designed for quality control (QC) and batch release
purposes, while offering an approximation of inhaler use in the clinic to capture key
performance characteristics. For example, with DPIs, APSD is tested at a constant flow
rate equivalent to the maintenance of a 4 kPa pressure drop across the inhaler (to
approximate the inhalation effort that humans can potentially achieve), with 4 L air (to
approximate the vital capacity of a human adult). The aerosol exiting the inhaler is then
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passed through the 90° bent induction port into a standardized, calibrated cascade
impactor (U.S. Pharmacopeial Convention, 2013) (Figure 1.4). While the methods are still
far from realistic, as human oropharyngeal geometries are much more complex than the
induction port (Swift, 1994), and the square wave profile during testing does not resemble
a patients’ breath profile, attempts have been made to correlate the particle size
distribution data collected from DPIs with the human lung deposition results in vivo.
USP Induction Port
DPI

Next Generation Pharmaceutical Impactor

Pre-separator
Vacuum Pump
(Constant Flow)

Figure 1.4. Illustration of compendial (pharmacopeial) methods to determine
aerodynamic particle size distributions (APSDs) for DPIs at a fixed air flow rate and
volume. Aerosol exiting the inhaler is passed through the 90° bent induction port into a
standardized, calibrated Next Generation Pharmaceutical Impactor (NGI; a commonly
used cascade impactor for testing pharmaceutical aerosols). A pre-separator is used to
remove large particles in the aerosol cloud before it enters NGI.

Newman and Chan (2008) performed a meta-analysis of the literature data on this
topic and found that in general, FPF6.8µm appeared to over-predict the fraction of the drug
dose depositing in the lung tested using gamma scintigraphy, while FPF3µm appeared to
produce a correlation with the mean in vivo lung deposition data (Figure 1.5). The study
was a nice exploration of the use of convential APSD data (collected during QC testing)
to predict the mean in vivo lung dose. In spite of those findings however, clinical variations
in lung deposition, which may even exceed 100% coefficient of variation (CV) for low dose
12

DPIs (Borgström et al., 2006), shows that DPI deposition remains “patient specific” and
unpredictable.
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Figure 1.5. Correlations between mean total lung deposition (by gamma scintigraphy)
and the mean drug fraction with aerodynamic diameters smaller than 6.8 µm (left panel)
and 3 µm (right panel), respectively. Figures were redrawn from Newman and Chan
(2008). Only data for DPIs were included. Individual variations between subjects were not
shown.

Other than trying to correlate particle size distribution with total lung deposition, a
lot of efforts have been devoted to developing more realistic in vitro test methods and
improve our ability to predict inhaler in vivo performance. These studies have been mainly
focused on developing realistic human mouth-throat (MT) models and inhalation profiles
(IP) to mimic inhaler use in the clinic, with the ultimate goal of achieving better in vitro–in
vivo correlations (IVIVCs). Recent advances relevant to DPI testing in this area are
summarized below.
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Realistic Mouth-Throat Models
The human upper airway has long been recognized as a barrier to sucessful
pulmonary drug delivery, where aerosolized drugs must bypass the right-angled
oropharyngeal region in order to reach the lung (Swift, 1994). Borgström et al. (2006)
found that throat deposition was the major source of inter-subject variations observed in
clinical lung deposition studies. They suggested that upper airway geometries may
significantly affect aerosol deposition in the lung. Three dimensional (3D) geometries of
the oropharyngeal region can be obtained from cadaver casts or medical imaging like
computed tomography (CT) using scans from x-ray or magnetic resonance imaging (MRI);
the latter has become the major tool for studying airway geometries because cadaver
casts usually suffer from distortion from postmortem tissue shrinkage (Byron et al., 2010).
While individual upper airway geometries have been studied and used to improve IVIVCs
(Olsson et al., 1996), more “representative” human oropharyngeal geometries and the
corresponding physical models remain uncertain. Questions like, “What is the most
representative geometry?” and “Can the model(s) cover inter-subject variations?”, remain
difficult to answer and controversial. Different approaches have been proposed regarding
this topic (Burnell et al., 2007; Delvadia et al., 2012; Olsson et al., 2013; Stapleton et al.,
2000; Xi & Longest, 2007; Zhang et al., 2007) and three main types of realistic MT models
developed based on oropharyngeal geometry studies of healthy human adults (Figure
1.6). MT models for children and infants have also been developed (Carrigy et al., 2014;
Ruzycki et al., 2014), but the topic of pediatric models is beyond the scope of this thesis
and will not be discussed.
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(a) Side View

OPCL

VCUL

OPCM

VCUM

OPCS

VCUS

AIT

(b) View from the Mouth Entry

OPCL
OPCL*
84.4

OPCM
OPCM*
91.7

OPCS
VCUL
VCUM
(c) Internal Geometry or Diagram
OPCS*
27.6

VCUL
96.1

VCUM
61.6

VCUS
VCUS
26.6

AIT
AIT*
75.4

*Determined experimentally using water

(d) Internal Volume (cm3)
Figure 1.6. Realistic mouth-throat (MT) models developed for inhaler in vitro testing:
Oropharyngeal Consortium (OPC) Large (OPCL), OPC Medium (OPCM), OPC Small
(OPCS) (Burnell et al., 2007; Oropharyngeal Consortium, 2013), Virginia Commonwealth
University (VCU) Large (VCUL), VCU Medium (VCUM), VCU Small (VCUS) (Delvadia et
al., 2012; Longest, 2012), Alberta Idealized Throat (AIT; Medium) (Stapleton et al., 2000).
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Small, medium and large Virginia Commonwealth University (VCU) MT models
(Longest, 2012) were designed and built in our laboratories using well-documented
anatomical data from the literature. In brief, the VCU medium MT model (Figure 1.6) is a
geometrically realistic physical model of the mouth-throat that was constructed by rapid
prototyping (Byron et al., 2010). The model is derived from CT imaging of a male human
oropharynx as described by Xi and Longest (2007) and Xi et al. (2008). The imaging data
was processed and simplified by computer-aided design (CAD) to preserve important
anatomical details but enable reliable prototyping. VCU small and VCU large MT models
(Figure 1.6) were scaled by volume to cover approximately 95% of the volumetric
variations seen in mixed gender healthy human adults as described in Delvadia et al.
(2012). The internal MT volumes for the VCU small, medium and large models of 26.6,
61.6, and 96.1 cm3, respectively, were consistent with 95% confidence intervals (CI)
derived from Burnell et al.’s values for mean±2SD (Burnell et al., 2007).
Small, medium and large Oropharyngeal Consortium (OPC) MT models
(Oropharyngeal Consortium, 2013) were also developed by an industry consortium
(AstraZeneca, GlaxoSmithKline and sanofi-aventis) to represent the medium and
extremes for in vitro aerosol drug capture in mixed gender human subjects inhaling
through different mouthpieces (Burnell et al., 2007). OPC models were constructed using
real human oropharyngeal geometries produced from MRI imaging, with slight
modifications of the mouth opening of each geometry to facilitate in vitro testing
(Oropharyngeal Consortium, 2013). Notably, the selection of the small, medium and large
OPC models was based on the Consortium’s assessment of aerosol deposition, not on
measurements of the internal geometries of the models themselves (Burnell et al., 2007).
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The Alberta Idealized Throat (AIT) is an idealized model developed (a) to represent the
“average geometry” of the human mouth-throat and its major fluid dynamic properties
(with respect to aerosol capture) and (b) enable ease of manufacturing in metal (Stapleton
et al., 2000). The 3D geometry of AIT was designed based on dimensions from MRI
images, CT images, and visual observations to mimic those features in a real human
mouth-throat that cause aerosol deposition (Warren H Finlay et al., 2010). Currently only
a medium AIT model is available, although a ±30% scaling factor was proposed to cover
inter-subject variability in aerosol deposition (Warren H Finlay et al., 2010). All models
shown in Figure 1.6 are geometrically different and tailored in different ways to enable
their manufacture and use. One feature in common, however, is that the interior surfaces
of all models are unrealistically smooth, and they also neglect the entry of the
nasopharyngeal airways into the back of the throat. Additionally, these models require an
airtight adapter to locate and to angle an inhaler “correctly” into the mouth opening of the
model.
Inhalation Profiles
The commercially available DPIs for treatment of asthma and COPD are all breath
actuated, which requires a patient’s inhalation to disperse powdered drug formulations.
These formulations usually contain micronized drugs blended with lactose as the carrier.
Different types of lactose are employed that result in different lactose and drug aerosols
for lung delivery. The extent of drug-carrier de-aggregation, and thereafter the size
distribution of drug aerosols, depends on the combined effects of inhaler design, powder
formulation, and patient’s inhalation maneuver (Telko & Hickey, 2005). While inhaler
design is important however, it is likely that the patient’s inhalation profile (IP) is the most
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significant feature defining pulmonary drug delivery from DPIs. Aerosol dispersion and
release from a selected DPI is known to be affected by many factors like a patient’s peak
inhalation flow rate (PIFR), flow increase rate (FIR; the rate at which the air flow
accelerates to PIFR) and inhaled volume (V) (Chavan & Dalby, 2002; de Boer et al., 1997).
Realistic IPs therefore, if appropriately collected and chosen, are likely to enable studies
that provide more complete information on DPI performance than we presently see from
compendial tests alone (Burnell et al., 1998a).
The general method to collect IPs from a group of healthy subjects or patients is
to use an “inhalation flow rate recorder”, where a flow meter and/or flow-calibrated
pressure transducer is attached to a placebo DPI or an orifice plate with equivalent
resistance to the test inhaler (Azouz et al., 2015b; Harris & Willoughby, 2010; Tiddens et
al., 2006; Weers et al., 2013). Each subject’s inhalation can then be recorded, after
instruction, as flow rate vs. time or pressure drop vs. time profiles using methods
described by Clark and Hollingworth (1993). While the methods for collecting inhalation
profiles are generally similar across different research groups, variable approaches have
been used to select “representative” IPs from each group’s database for inhaler in vitro
testing. Weers et al. (2013) chose four individual IPs with peak pressure drop
representing the ranges of patients’ inhalation efforts in their study. A similar approach
was applied by Casaro et al. (2014) where five individual IPs were selected to cover the
medium and ranges of PIFRs in the database. Olsson et al. (2013) proposed select IPs
representative of the medium and 95 percentile variations for both PIFR and PIF; this
method was adopted by Chrystyn et al. (2015) in a recent study. Besides using individual
IPs, well simulated IPs based on measured key inhalation parameters also show great
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potential for use in vitro tests to predict lung deposition (Delvadia et al., 2013a; Delvadia
et al., 2012).

1.5

CURRENT STATUS AND CHALLENGES
Realistic in vitro testing of DPIs can be performed essentially by coupling well-

designed MT models to selected IPs that mimic inhaler use in the clinic or in practice. The
approach has already been found helpful while building IVIVCs for inhaled drug products.
The system most typically employed is shown in Figure 1.7.

DPI

Mouth-Throat (MT) Model

ASL 5000-XL Breath Simulator

Pulmoguard II™ Filter

Figure 1.7. Experimental setup for realistic in vitro testing. A DPI is primed and inserted
into a realistic mouth-throat (MT) model. Internal surface of the MT is coated to retain
powder particles. A breath simulator with sufficient capacity is programmed to withdraw
realistic inhalation profiles (IPs) through a low resistance filter. The mass of drug that
reaches the filter, TLDin vitro, depends on the product, and the MT-IP combinations.

The in vitro predicted lung dose (TLDin vitro; designated as the drug dose exiting the
MT model; Figure 1.7) can be compared with the in vivo lung deposition data for the same
inhaler obtained either from gamma scintigraphy studies (Delvadia et al., 2013a; Delvadia
et al., 2012; Zhang et al., 2007), or from PK studies performed using a charcoal block
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technique to prevent drug absorption from the GI tract (Olsson et al., 2013; Weers et al.,
2014). The test methods have also been used as predictive tools to estimate the drug
dose likely to penetrate patients’ lungs as part of the product development process
(Chrystyn et al., 2015; Pitcairn et al., 2012; Weers et al., 2013). Although such methods
are more clinically relevant and shown to produce better IVIVCs than the standard
compendial methods, their application remains challenging. At this stage, industry
scientists and regulators are left to debate which MT models to select and how to choose
representative IPs. No effort has yet been made to standardize the approach.
Another question relates to the importance of regional drug distribution in the lung;
this may well be relevant to the therapeutic effects of certain inhaled drugs (Anderson &
Newman, 2009; Usmani et al., 2005), but in vitro methods have yet to be developed that
are predictive of regional drug deposition from DPIs in vivo. Recent advances on the topic
have been to couple realistic in vitro testing with compendial cascade impactor methods
to measure the size distribution of aerosol drugs leaving the MT model. These require the
use of flow-balancing devices like the Nephele Mixing Inlet (NMI) or Electronic Lung™ to
enable particle size distributions for drugs exiting the MT model to be measured at
constant cascade impactor flow rates, following aerosol dispersion and release from an
inhaler under realistic (variable flow) inhalation conditions (Casaro et al., 2014; Chrystyn
et al., 2015; Olsson et al., 2013; Tarsin et al., 2006). But it remains unclear (a) how to
measure APSDs under all inhalation conditions and (b) how even “realistic” size
distribution data could be used to predict regional drug deposition in the lung. Overall,
methods need to be developed, validated, standardized and improved to better evaluate
DPI performance under realistic conditions. Emergent modeling approaches like CFD
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simulations (Longest & Holbrook, 2012; Wong et al., 2012), that allow the motion of air
flow and inhaled particles in human airways to be predicted based on principles of fluid
mechanics, have been shown to be promising for aerosol deposition predictions in the
lung. If these methods are to be used in bridging lung doses and particle size distribution
data with in vivo regional lung deposition data, considerable method development and
improved lung modeling is needed.

1.6

PROJECT AIM
This thesis is designed to further our understanding of DPI performance in vitro

and in vivo. It describes efforts to improve realistic in vitro test methods for DPIs to explore
the truth about the ranges of total lung dose and the particle size distributions of drugs
that are likely to enter the lung from a marketed DPI. Methods have been developed to:
(a) compare and select MT models for realistic in vitro testing (Chapter 3); (b) choose
appropriate IPs for realistic testing of a wide range of DPIs (Chapter 4); (c) measure
APSDs for DPIs across a range of IPs that extends beyond the currently permitted
maximum flow rate for compendial cascade impactors (Chapter 5); (d) evaluate one
proposed CFD method for its ability to predict regional lung depositions for a single inhaler
based both on realistic APSD data for the inhaler and the in vivo data for regional drug
distribution in the lung taken from the literature (Chapter 6).
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CHAPTER 2
HYPOTHESES AND SPECIFIC AIMS

The goal of this research was to develop clinically relevant in vitro performance
test methods for powder inhalers that enable variations in aerodynamic particle size
distributions (APSDs) of drug aerosols to be characterized at the exit of selected mouththroat (MT) models, across the range of breath profiles likely to be used by healthy human
adults. To accomplish this objective, the project was subdivided into a series of
hypotheses and specific aims:
Hypothesis I. Representative MT models with human oropharyngeal geometries
can be selected from the literature, manufactured and evaluated experimentally for use
in realistic in vitro performance tests for DPIs.
Specific Aim I. Different types of MT models and the USP cascade impactor
induction port will be compared for ease of use and drug retention when tested across a
realistic range of inhalation profiles (IPs) with Salbulin® Novolizer®. Values for total lung
dose in vitro (TLDin vitro, or the dose exiting each internally-coated MT model) will be
compared statistically across MTs, and the practical advantages and disadvantages of
different models will be explored.
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Hypothesis II. A general method for simulating a range of representative IPs for
use with any powder inhaler of known air flow resistance can be derived from existing
Virginia Commonwealth University (VCU) clinical trial data for healthy adults, provided
the general instructions for inhalation from the chosen device during use are consistent
with those that normally accompany passive powder inhalers.
Specific Aim II. VCU clinical trial data collected from healthy adults by Delvadia
(2012) will be analyzed further. A statistically valid range of IPs and associated algorithms
will be tested for their ability to adequately fit the experimentally generated IP data across
a population of mixed gender normal human adult volunteers inhaling through a range of
air flow resistances typical of those in marketed DPIs.

Hypothesis III. When realistic IPs are used to generate aerosol drugs from a
typical DPI, Budelin® Novolizer® (budesonide 200 mcg/dose), reliable methods can be
developed to determine the APSD of TLDin vitro, the dose exiting the MT model.
Specific Aim III. The Pharmacopeial Next Generation Pharmaceutical Impactor
(NGI) will be modified and recalibrated to enable its use at high air flow rates consistent
with the measurement of the budesonide APSD exiting MT models in excess of 100 L/min.
The modified, recalibrated NGI will be used to characterize the drug clouds from Budelin®
Novolizer® exiting each MT model across a range of realistic IPs, by using an aerosol
mixing inlet supplied with dilution air to maintain constant air flow through the impactor.
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Hypothesis IV. Computational fluid dynamic (CFD) modeling can be employed
with initial conditions that describe the APSD of drug aerosols exiting MT to predict
regional lung deposition of budesonide aerosols from Budelin® Novolizer® and the
results can be compared with clinical data.
Specific Aim IV. The stochastic individual pathway (SIP) lung model and
associated CFD methods, as developed by Tian et al. (2015a) for use with realistic IPs,
will be evaluated for its ability to predict regional budesonide deposition in the lung from
Budelin® Novolizer® following (a) experimental APSD characterization of TLDin vitro and
(b) assumed entry of the APSD to the trachea of Tian et al.’s model at the chosen IPs.
The predicted regional deposition results from CFD will be compared with those reported
in the literature for the same inhaler following its collection based on two dimensional (2D)
gamma scintigraphy (Newman et al., 2000).

24

CHAPTER 3
SELECTING REPRESENTATIVE HUMAN MOUTH-THROAT MODELS FOR
REALISTIC DPI TESTING

3.1

INTRODUCTION

Realistic in vitro testing methods that are able to discriminate between inhalers and
inhaler formulations and predict drug doses likely to deposit in the human lung (total lung
dose; TLD) should offer significant benefits to personnel involved in clinical planning for
inhaled product development. Such predictions can be made by collecting and analyzing
the aerosol drug escaping a realistic mouth-throat (MT) model following delivery from an
inhaler using inhaled flow rate vs. time profiles (IPs) likely to be used by the relevant
patient population. At this time, three main types of MT models have been developed and
all have shown promising in vitro–in vivo correlations (IVIVCs) (Delvadia et al., 2013a;
Delvadia et al., 2012; Olsson et al., 2013; Weers et al., 2014; Zhang et al., 2007).
However, there are significant differences in their development philosophies, geometries
and manufacture. Product developers wishing to predict TLD values in humans are left to
select an MT model (perhaps in several sizes) and couple these to a range of IPs that are
expected to span the likely inspiratory maneuvers to be used with their chosen inhaler.
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This chapter is an attempt to describe the issues that are currently associated with
these choices, with the ultimate view of rationalizing the selection of the Virginia
Commonwealth University (VCU) MT models used in the remainder of this thesis to
describe the further development of in vitro performance test methods for dry powder
inhalers (DPIs). Salbulin® Novolizer® (Meda Pharmaceuticals, Hertfordshire, U.K.) was
selected and used as the test inhaler in this chapter to compare drug retention across MT
models with different geometries. Budelin® Novolizer® (Meda Pharmaceuticals,
Hertfordshire, U.K.) was selected as the test inhaler in the remainder of the thesis to
compare drug retention in VCU MT models.

3.2

MATERIALS AND METHODS

Mouth-Throat Models
Small, medium and large VCU models (Delvadia et al., 2012) were made from
ultraviolet-laser-cured resin (Accura® 60, 3D System, Valencia, CA) using a rapid
prototyping process of stereolithography (Viper si2™ SLA® system, 3D Systems,
Valencia, CA), with vertical layer thickness of 0.1 mm. The three dimensional (3D)
geometries of VCU models are available to download at www.rddonline.com (Longest,
2012). Small, medium and large Oropharyngeal Consortium (OPC) models (Burnell et al.,
2007) were purchased from Emmace Consulting AB (Södra Sandby, Sweden). These
models were designed by the Oropharyngeal Consortium (AstraZeneca, GlaxoSmithKline
and sanofi aventis) and manufactured using polyamide, also by rapid prototyping. The 3D
geometries of OPC models are available to download at www.isam.org (Oropharyngeal
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Consortium, 2013). The medium Alberta Idealized Throat (AIT) (Warren H Finlay et al.,
2010) and the USP inlet (U.S. Pharmacopeial Convention, 2013) were purchased from
Copley Scientific (Nottingham, U.K.). Unlike VCU and OPC models that are constructed
from plastic, AIT model and USP inlet are manufactured in aluminum. The three types of
realistic MT models and the USP inlet are shown Figure 3.1; further detail and
descriptions of these models was provided in Chapter 1 and Figure 1.6.

Figure 3.1. Realistic mouth-throat (MT) models developed for inhaler in vitro testing.
From Left: Oropharyngeal Consortium (OPC) Large, OPC Medium, OPC Small (Burnell
et al., 2007; Oropharyngeal Consortium, 2013), Virginia Commonwealth University (VCU)
Large, VCU Medium, VCU Small (Delvadia et al., 2012; Longest, 2012), Alberta Idealized
Throat (AIT; Medium) (Stapleton et al., 2000) and USP Inlet (U.S. Pharmacopeial
Convention, 2013).

Inhalation Profiles
The clinical study data and methods described by Delvadia to simulate IPs for
realistic DPI testing (Delvadia, 2012) was used to simulate IPs suitable for test of Salbulin
Novolizer (airflow resistance = 0.0241 kPa0.5L-1min) as shown in Figure 3.2. Three IPs
representing the typical range of these DPI-trained profiles were determined based on
Delvadia’s statistical treatment where individual flow rate (FR) profiles were ranked at
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each time point, and the 10, 50 and 90 percentile values selected to produce the three
red inhalation profiles (Figure 3.2).
160

Flow Rate (L/min)

140
120
100
80
60
40
20
0
0

1

2

3

4

5

6

Time (sec)

Figure 3.2. Individual flow profiles (gray; volumetric flow rates entering mouth vs. time)
from DPI-trained normal adult volunteers inhaling through an inhalation flow recorder with
an identical airflow resistance to Novolizer [data from (Delvadia, 2012)]. Red profiles are
the 10, 50 and 90 percentile results that illustrate the range of profiles seen across this
population. The smoothed profiles shown in black are the simulated profiles used to
program the breath simulator for the in vitro MT model comparisons described below
following simulation according to Delvadia using Equations 3.1 to 3.4 with parameters
described in Table 3.1 (Delvadia, 2012; Delvadia et al., 2012).

The red FR vs. time, t, profiles were then simulated using Equations 3.1 to 3.3
below (Delvadia, 2012; Delvadia et al., 2012) to produce the black profiles shown in the
figure. Values for the inhalation parameters used in the equations are shown in Table 3.1,
where peak inhalation flow rate (PIFR), time at which PIFR occurs (TPIFR), and total
inhaled volume (V, area under the curve) were obtained directly from the red profiles, and
duration of inhalation (T) was calculated from Equation 3.4. The three simulated IPs were
used for the realistic in vitro testing of Salbulin with each of the MT models shown in
Figure 3.1.
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Table 3.1. Peak inhalation flow rate, PIFR, time at which PIFR occurs, TPIFR, total inhaled
volume, V and duration of inhalation, T values for 10, 50 and 90 percentile simulated IPs
according to the method described by Delvadia (Delvadia, 2012; Delvadia et al., 2012)
and shown in Figure 3.2.

a

IPa

PIFR (L/min)

TPIFR (sec)

V (L)

T (sec)

10 Percentile

76.9

0.550

1.43

1.667

50 Percentile

98.2

0.450

2.72

2.525

90 Percentile

126.2

0.610

4.64

3.380

Figure 3.2, black profiles

Experimental Setup for Realistic In Vitro Testing
Figure 3.3 is a schematic of the experimental apparatus to evaluate aerosol drug
deposition and the in vitro total lung dose (TLDin vitro) for a powder inhaler under realistic
conditions. Salbulin® Novolizer® (label claim: 120 mcg albuterol sulfate per delivered
dose) was donated by Meda Pharmaceuticals (Hertfordshire, U.K.) and used to compare
the eight MT models shown in Figure 3.1.
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DPI

Mouth-Throat (MT) Model

ASL 5000-XL Breath Simulator

Pulmoguard II™ Filter

Figure 3.3. Schematic of experimental setup for measurement of total lung dose in vitro
(TLDin vitro), or the dose exiting the MT model, under simulated, realistic human inhalation
conditions.

During testing, the inhaler was primed and inserted into an adapter manufactured
to form an airtight junction between the inhaler mouthpiece and the MT model. Adapters
for VCU MT models are described at www.rddonline.com (Longest, 2012), and were
identical to those used previously (Delvadia et al., 2012). Adapters for OPC MT models
were obtained from Emmace Consulting AB, while those for the AIT and USP inlet were
manufactured in-house from Ten-to-One / High Tear Strength Mold Rubber (Micro-Mark,
Berkeley Heights, NJ) positioned to site the inhaler exit at the center of the opening to the
chosen MT model. During each simulated IP, air was drawn through the newly primed
inhaler (single actuation) and MT model into a low resistance filter (Pulmoguard IITM,
Queset Medical, North Easton, MA) capable of retaining all of the aerosolized drug that
passed through the model. The filter was connected to a programmable breath simulator
(ASL 5000-XL, IngMar Medical, Pittsburgh, PA) to produce the standard IP at the mouth
opening of the MT model. The internal surfaces of the VCU and OPC models were coated
using two applications of 2% (w/v) Brij™ 35 (ACROS Organics™, Thermo Fisher
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Scientific, Waltham, MA) in glycerol followed by allowing excess solution to drip and
evaporate from the model for at least 2 h (Mitchell, 2003; Olsson et al., 2013). Because
Brij solutions failed to adequately wet the metal surfaces of the AIT model and the USP
inlet port, those models were coated instead using two spray applications of Molykote®
316 Silicone Release Spray (Dow Corning, Midland, MI) followed by solvent evaporation
prior to each experiment (Hindle et al., 1996). A randomized experimental design was
implemented to vary the MT models and recover the drug from the filter (TLDin vitro; Figure
3.3) following withdrawal of individual actuations (doses) by triggering the breath
simulator programmed for the black IPs shown in Figure 3.2. The apparatus was
disassembled after each dose, and albuterol sulfate was recovered by rinsing the inhaler
(with drug cartridge removed), MT and filter using known volumes of 65% methanol: 35%
20mM ammonium formate buffer (v/v) and analyzed using high-performance liquid
chromatography (HPLC). Albuterol sulfate assay was performed using Allure® PFP
Propyl column (5µm, 3.2×150mm, Restek Corporation, Bellefonte, PA), 65% methanol:
35% 20mM ammonium formate buffer (v/v) as mobile phase (flow rate: 0.75 mL/min), and
UV detection at 276 nm (2998 Photodiode Array Detector, e2695 Seperation Module,
Waters, Milford, MA). Injection volume was 100 µL and calibration curves were linear in
the range of 0.2–10.0 mcg/mL (r2 > 0.999). Each experiment was performed at least 9
times. Statistical analyses were performed for drug doses retained on and delivered from
the inhaler, and TLDin vitro using one-way ANOVA and Tukey’s HSD in JMP Pro 11 (SAS
Institute Inc., Cary, NC). Further analyses to evaluate the effects of the MT models, IPs,
and model sizes on values for mean TLDin vitro were performed by two-way ANOVA (MT
models and IPs) and three-way ANOVA respectively.
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3.3

RESULTS

Effects of IP Selection on Inhaler Performance
Drug doses retained on and delivered from the Novolizer device were analyzed for
the 10, 50 and 90 percentile IPs. Data were pooled across the eight MT models for each
IP (n≥72), and were presented as percent of manufacturer’s label claim (120 mcg
albuterol sulfate per delivered dose) in Figure 3.4.
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Device Retention
Delivered Dose
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10% IP
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Figure 3.4. Percent of manufacturer’s label claim (120 mcg albuterol sulfate per delivered
dose) for drugs retained in the mouthpiece or delivered from the Novolizer device (device
retention and delivered dose, respectively) for the 10, 50 and 90 percentile IPs. Data were
pooled across eight MT models for each IP and presented as mean±SD (n≥72).
Statistically significant differences were observed for both the mean device retention and
mean delivered dose between different IPs in all cases (Student’s t-test, p<0.05).

The 10 percentile IP produced the highest value for mean device retention (31.0%
label claim), while this value reduced to 10.2% label claim for the 50 percentile IP and
3.4% label claim for the 90 percentile IP. Most notably, when tested with the 10 percentile
IP, Salbulin only delivered a mean of 81.3% of label claim. Statistically significant
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differences were observed for both the mean device retention and mean delivered dose
between different IPs (one-way ANOVA, p<0.05), consistent with the literature reports for
this device (Delvadia et al., 2012).

Effects of IP Selection on TLDin vitro
Values for TLDin vitro, designated as the drug dose escaping the MT model and
collected on the filter from Salbulin, are shown in Figure 3.5 for each MT model tested
using the 10, 50 and 90 percentile IPs typical of trained adults inhaling through a

Total Lung Dose In Vitro (%Label Claim)

resistance equivalent to that of Novolizer.
70

60

50

40

30

20

VCUL

VCUM

VCUS

OPCL

OPC M

OPC S

AIT

USP

10 Percentile IP
50 Percentile IP
90 Percentile IP

Figure 3.5. Percent of manufacturer’s label claim (120 mcg albuterol sulfate) exiting the
MT model (TLDin Vitro) from Salbulin Novolizer after randomized testing using the 10, 50
and 90 percentile IPs. The subscripts L, M and S represent Large, Medium and Small MT
models, respectively (Figure 3.1).
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Notably, the change of test IPs produced large variations in TLDin vitro for each MT
model, and the larger MTs generally produced a larger range of results for TLDin vitro than
was seen for smaller MTs. For a selected MT model, the 90 percentile IP produced
highest values for TLDin vitro, while the 10 percentile IP produced the lowest values. The
effects of IP variations on TLDin vitro indicate that more efficient drug-carrier deaggregation
occurred when larger IPs were used for Salbulin testing; for this inhaler and others, the
effects of improved powder deaggregation seen with larger flow rates may be expected
to exceed the effects of the increased inertia of drug particles passing into the MTs (i.e.
impacting and depositing in MT) due to the higher values of TLDin vitro seen with larger IPs.
While the approach used to generate the 10, 50 and 90 percentile flow rate vs.
time curves in Figure 3.2 will be analyzed more thoroughly in Chapter 4 that describes an
improved simulation technique for a spectrum of standard IPs for use with DPIs of
different airflow resistances, the significant variations in TLDin vitro observed in this study
suggested that it is important to include both the medium (the 50 percentile IP) and the
extremes (the 10 and 90 percentile IPs) to fully evaluate the likely clinical performance of
a powder inhaler like Salbulin Novolizer. Powder inhaler performance, even for a welldesigned DPI like Salbulin Novolizer, was highly dependent on the selected IP. The
ranges with which TLDin vitro could be determined when using a single IP in these models
was of the order of 5–12% of label claim (Figure 3.5); this increased to 15–30% of label
claim when Novolizer was tested at the extremes (the 10 or 90 percentile IP), even though
these simulated IPs were based on the inhalation maneuvers recorded following
Delvadia’s study of trained adult subjects of both genders (Delvadia, 2012).

34

Effects of MT Model Selection on TLDin vitro
This investigation showed that the choice of MT model clearly impacts the value
of TLDin vitro and thus the anticipated values for TLD in the clinic (Figure 3.6). Statistical
differences between the mean values are illustrated in Figure 3.6. Perhaps most
surprising from Figure 3.6, was the finding of a statistical difference between the results
shown among the three “medium” models (VCU medium, OPC medium and AIT). Notably,
for all three IPs, the VCU medium and AIT models produced statistically comparable
results while the OPC medium model produced a value for TLDin vitro that was significantly
smaller than its counterparts. The USP inlet also produced statistically comparable results
to VCU medium and AIT models in all three cases, illustrating that this pharmacopeial
standard conduit (used to connect an inhaler to a cascade impactor) can sometimes
produce comparable results with MT models that were designed with “realistic
geometries”, provided its internal surfaces are coated to ensure impacted powder
retention. The comparison of two “small” models also showed statistical differences for
the 50 and 90 percentile IPs, where OPC small produced a significantly smaller value for
TLDin vitro than VCU small. Notably however, these two models produced comparable
results for the 10 percentile IP. The two “large” models, in contrast, showed statistically
comparable results for all three IPs.
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Figure 3.6. Percent of manufacturer’s label claim (120 mcg albuterol sulfate) escaping
the MT model (mean TLDin Vitro) from Salbulin Novolizer after randomized testing using
10, 50 and 90 percentile IPs. Results are presented as mean±SD (n≥9). The subscripts
L, M and S represent large, medium and small MT models, respectively. Statistically
significant differences () in mean values are shown after one-way ANOVA (p<0.05) and
Tukey’s HSD. Further statistical analyses following two- and three-way ANOVA to
evaluate the effects of the MT models, IPs and model sizes on values for mean TLDin Vitro
are described in the text.
36

The direct one-way ANOVA comparisons (above and Figure 3.6) were mirrored by
two-way ANOVA to evaluate the effects of MTs (VCU vs. OPC vs. AIT vs. USP) and IPs
(10 percentile vs. 50 percentile vs. 90 percentile) on TLDin vitro. The following hypotheses
were tested:
H1: MTs have no effect on TLDin vitro
H2: IPs have no effect on TLDin vitro
H3: There is no interaction between MTs and IPs
The results showed that both MTs and IPs had significant effects on TLDin vitro
(p<0.0001 in both cases; H1 and H2 were rejected), while no significant interaction was
observed between the two factors (p=0.6523>0.05; H3 was not rejected). Tukey’s HSD
indicated that effects of MT on TLDin vitro appeared to be: VCU = AIT = USP > OPC, while
effects of IP on TLDin vitro showed that: 90 percentile IP > 50 percentile IP > 10 percentile
IP.
Three-way ANOVA was used to compare the VCU and OPC MTs. The effects of
MTs (VCU vs. OPC), model sizes (small vs. medium vs. large) and IPs (10 percentile vs.
50 percentile vs. 90 percentile) on TLDin

vitro

were evaluated by testing the following

hypotheses:
H4: MTs have no effect on TLDin vitro
H5: Model sizes have no effect on TLDin vitro
H6: IPs have no effect on TLDin vitro
H7: There is no interaction between MTs and model sizes
H8: There is no interaction between MTs and IPs
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H9: There is no interaction between model sizes and IPs
H10: There is no interaction between MTs, model sizes and IPs
The results showed that there was no significant interaction between the three
factors (MT*size*IP, p=0.8812>0.05; H10 was not rejected), while significant interactions
were observed for MTs and model sizes (MT*size, p<0.0001; H7 was rejected), MTs and
IPs (MT*IP, p=0.0419<0.05; H8 was rejected), and model sizes and IPs (size*IP,
p<0.0001; H9 was rejected). Tukey’s HSD indicated that effects of MT*size on TLDin vitro
appeared to be: VCU Large MT = OPC Large MT, VCU Medium MT > OPC Medium MT,
VCU Small MT > OPC Small MT. Tukey’s HSD furthermore showed the effects of MT*IP
on TLDin vitro appeared to be: VCU > OPC for both the 50 and 90 percentile IPs while VCU
= OPC for the 10 percentile IP. Effects of size*IP on TLDin vitro appeared to be: Large MT >
Medium MT > Small MT, and Large IP > Medium IP > Small IP.

3.4

DISCUSSION

The TLDin

vitro

results of Delvadia et al. (2012) for Budelin Novolizer (200 mcg

budesonide per delivered dose) appeared to correlate well with reported literature values
for TLDin vivo when experiments were conducted in VCU MT models and the simulated IPs
were based on those used in the clinic (Newman et al., 2000). Most notable from that
work (Delvadia et al., 2012), was the apparent agreement between the overall range of
results for TLDin vitro when the results were derived from tests across IPs using the small,
medium and large VCU MT models, compared with the literature values for TLDin vivo (for
example, TLDin vivo ranged from 9.4–41.0% of the metered dose for fast inhalation, while
that of in vitro spanned 9.7–40.4%). In the work discussed in this chapter, the
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experimental range of TLDin vitro in VCU models was 22–59% label claim, while in OPC
models it was 21–63% label claim. In these terms, VCU and OPC models were similar.
Because in vivo results are not available for Salbulin however, there was no way that a
preference can be stated for either model on this basis. Nevertheless, the medium VCU
and OPC geometries produced statistically significant differences in values for TLDin vitro
from Salbulin Novolizer at all tested inhalation profiles. While the meaning of this
difference in “medium result” needs to be further explored, the predicted range of possible
deposition results across an adult population was more consistent between the differently
sized VCU and OPC models, indicating that a much smaller number of in vitro
experiments than those described in this paper may be sufficient to provide reliable
estimates of TLDin vitro at the extremes (e.g. small IP–small MT to large IP–large MT, from
either model series). Figure 3.7 and Table 3.2 show the range of results for TLDin vitro from
all the tests conducted with Salbulin Novolizer.

Figure 3.7. The range of mean results for Salbulin Novolizer’s TLDin vitro (% label claim)
tested across all MT Models using 10, 50 and 90 percentile IPs. Results for the single
geometry AIT and USP models show the range of results due solely to the change in IP.
Results are percent of manufacturer’s label claim (120 mcg albuterol sulfate as delivered
dose). Upper and lower error bars are SD values from the large IP–large model and small
IP–small model, respectively, as shown numerically in Table 3.3.
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Table 3.2. Numerical results from Figure 3.7; a statistically significant difference between
VCU and OPC model results (p<0.05; n=18) occurred when testing to determine the value
for the mean minimum TLDin vitro.
Mean (SD)a
Small

Large

VCU

27.0 (3.5)

55.5 (2.2)

OPC

23.8 (2.6)

54.3 (3.6)

AIT

33.9 (2.1)

51.9 (1.8)

USP

34.8 (3.6)

49.9 (1.8)

a

Mean and standard deviations (SD) of TLDin vitro following testing with small model and
10 percentile IP (“Small”) vs. large model and 90 percentile IP (“Large”). For AIT and USP,
where only a single model is available, “Small” and “Large” refer to the results from testing
with 10 and 90 percentile IPs, respectively.

The colored portion in each of the bar graphs of Figure 3.7 shows the range
between the mean results when the 10 percentile IP was tested with the small MT model
(mean minimum TLDin vitro) and the 90 percentile IP was tested with the large MT model
(mean maximum TLDin vitro); the error bars in Figure 3.7 show a single standard deviation
about those means in each case. While the means for minimum TLDin

vitro

showed

statistically significant differences (Student’s t test, p<0.05; Table 3.3), there was a distinct
overlap in the experimental results (Figure 3.7) and no statistically significant difference
between each model series for mean maximum TLDin vitro. Clearly, this range of values
could be collected using only the small and large versions of each set of MT models, at
least as far as this inhaler was concerned. Moreover, because the experimental range of
results for TLDin vitro seen by Delvadia et al. (2012) was much more representative of the
results seen in vivo, there is good evidence to suggest that DPI testing needs to be
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conducted across a range of MT geometries (and not a single model as seen with either
AIT or USP; Figure 3.7).
The choice between the three VCU and three OPC MT models became one in
which the advantages and disadvantages of these models needed to be compared in
order to practically justify the use of one over the other. While further studies are possibly
needed to thoroughly compare values of in vitro lung doses for the different models, the
practical advantages and disadvantages of these MT models were listed in Table 3.3 to
facilitate selection of the MT models for realistic in vitro testing. As shown in this table,
OPC models are not provided with a standardized mouth opening. Moreover, their
complex internal structure (Figure 1.6) required solvent based drug extraction for periods
up to 10 minutes, in order to ensure complete drug recovery (for albuterol sulfate in this
study, VCU models could be extracted in less than 1 minute). In this thesis therefore, the
VCU models were selected for all further studies because their advantages outweighed
their disadvantages, the models were readily available, and they had already been shown
to produce an apparent IVIVCs with Budelin Novolizer and four other marketed DPIs
(Delvadia et al., 2013a; Delvadia et al., 2012). In addition, the results from the VCU
models were similar to those from the OPC models when tested with Salbulin Novolizer.
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Table 3.3. Practical advantages and disadvantages of the test MT models.
Advantages
VCU








OPC 




AIT




USP





Disadvantages

Small, medium and large MTs are
available
Polyurethane versions are now
available for use with an attached NGI
adapter
Constructed in one piece for ease of
use
Clear and easy to observe particle
deposition
Geometrically validated via the
literature (Delvadia et al., 2012)
IVIVC validated to five marketed DPIs
Small, medium and large MTs are
available
Constructed in one piece for ease of
use
Universal outer geometry allows a
single mouth-piece adapter to be
used
NGI/ACI adapter attached



Accura 60 is not resistant to use of all
solvents




Robust construction in polished
aluminum
Particle deposition site can be
observed after splitting into twohalves
NGI/ACI adapter attached
Constructed in one piece for ease of
use
NGI/ACI adapter attached





Chunky and less easy to handle
Internal volumes inconsistent with
those reported in the literature*
(Burnell et al., 2007); not
geometrically validated
Mouth entrance arbitrarily occluded
due to selection of individual subject
geometries (Oropharyngeal
Consortium, 2013)
Only the medium model is available
Constructed in two-halves with a
gasket that can leak
Not easy to handle




Geometry is not realistic
Only one model is available



*The internal volumes of the small, medium and large OPC models (constructed from
sintered polyamide) were determined experimentally to be 27.6, 91.7 and 84.4 cm3,
respectively, compared to reported internal volumes of 25.8 (small), 78.1 (medium) and
71.0 cm3 (large) (Burnell et al., 2007).
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CHAPTER 4
SIMULATING VARIATIONS IN HUMAN BREATH PROFILES FOR REALISTIC DPI
TESTING

This Chapter is in press. It is to be published in the Journal of Aerosol Medicine
and Pulmonary. Drug Delivery. In the Journal it carries the title and authors: In Vitro Tests
for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for
Realistic DPI Testing. Renishkumar R. Delvadia, Xiangyin Wei, P. Worth Longest,
Jurgen Venitz and Peter R. Byron. Renishkumar Delvadia performed the clinical trial with
assistance from Xiangyin Wei. The raw breath profile data and statistical analyses of the
descriptive inhalation parameters (PIFR, V, etc.) were performed by Renishkumar
Delvadia with the assistance of Jurgen Venitz and included in his thesis in 2012 (Delvadia,
2012). In this thesis, Peter Byron and Worth Longest advised Xiangyin Wei during her
reanalysis, simulation and curve fitting of the data describing the 10, 50 and 90 percentile
inhalation profiles under the various conditions described in full below. The chapter is
reproduced entirely as it is to be published below.
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4.1

INTRODUCTION
In this series of publications on realistic inhaler testing we sought to offer improved,

clinically-relevant test methods for aerosol drugs and possible in vitro-in vivo correlations
(IVIVC) for lung deposition (Delvadia et al., 2013a; Delvadia et al., 2012; Delvadia et al.,
2013b). The experimental setup and brief description of the test method is shown in
Figure 4.1.
Powder Inhaler

Mouth-Throat (MT) Model

ASL 5000-XL Breath Simulator

Pulmoguard IITM Filter

Figure 4.1. Experimental setup for realistic in vitro testing. A passive powder inhaler
with known airflow resistance, R, is primed and inserted into small, medium or large
mouth-throat (MT) model(s) that span 95% of the volumetric range seen in human
adults. Internal surfaces of MT are coated to retain powder particles. A breath simulator
with sufficient capacity is programmed to withdraw a volume V through a low resistance
filter using a range of simulated IPs, as described in this paper. The mass of drug that
reaches the filter, TLDin vitro, depends on the product, and the MT-IP combination (Byron
et al., 2010; Byron et al., 2013; Delvadia et al., 2013a; Delvadia et al., 2012; Delvadia
et al., 2013b; Longest, 2012; Olsson et al., 2013; Wei et al., 2014).
By assessing the aerosol drug dose exiting small, medium and large realistic
mouth-throat (MT) models (Longest, 2012) while using inhalation profiles (IPs) believed
to simulate the breathing maneuvers used during clinical testing, we found that (a) the
mean value for TLDin vitro, from several different dry powder inhalers (DPIs) was consistent
with literature values for lung deposition following clinical testing (Delvadia et al., 2013a)
and (b) the range of values from a single DPI agreed with the published range of values
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for TLDin vivo following gamma-scintigraphic testing in a mixed-gender adult population
(Delvadia et al., 2012). It is well known that performance of passive DPIs is air flow rate
dependent; indeed the seminal work of Clark and Hollingworth (1993), led to compendial
test methods requiring that dose emissions and size distributions be determined at flow
rates that maintain an appropriate pressure drop across each inhaler (U.S.
Pharmacopeial Convention, 2013). It is also well known that DPI performance depends
on the way that patients use these inhalers. While this can be influenced by instruction
leaflets, training and of course, the subject’s lung capacity, present DPI development is
largely empirical and often retrospective because of in vitro performance testing that fails
to concern itself with the way that patients actually inhale through a chosen device.
Reports that a large proportion of patients fail to use DPIs correctly are common; failure
to exhale before inhalation, failure to inhale rapidly and deeply, as well as incorrect
mouthpiece positioning may all influence regional drug deposition and clinical outcome
(Broeders et al., 2009; van Beerendonk et al., 1998).
In this article we report the results of a clinical study that enabled us to document
the variability in the IPs of inhaler-naïve normal adults inhaling through a series of air flow
resistances typical of those used in commercial DPIs. The study enabled us to
recommend a range of IPs for testing DPIs with different airflow resistances. The IPs may
be simulated using sinusoidal equations that adequately describe the flow rate vs. time
profiles spanning the 10 through 90 percentile values for a mixed-gender, lung-normal,
adult population. Because inhaler-naïve volunteers were recruited for the study, it was
also possible to compare the effectiveness of “training by package insert” to formalized
training from a pharmacist in the use of passive DPIs; this by comparing the different IPs
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elicited by the two procedures in the same subjects. Use of the protocol described here
should enable IPs to be selected for inhaler testing to span those likely to be used by
normal human volunteers in clinical trials. While recognizing that inhalation profiles may
differ in patient groups with different demographics and lung disease (Baba et al., 2011;
Broeders et al., 2004; Malmberg et al., 2010; Sarinas et al., 1998), the approach to data
analysis and IP simulation that is described here can likely be generalized to cover
different populations so that product development scientists can select IPs for inhaler
testing in vitro that are realistic and representative of the way new inhalers should
eventually be used.

4.2

MATERIALS AND METHODS
A protocol was designed to document the IPs commonly used by healthy

volunteers inhaling through powder inhalers. Volunteers were trained first by reading the
directions for use provided in a typical package insert, and second, by receiving a
demonstration and direct oral instructions from a pharmacist. The objectives were (a) to
collect a range of typical flow rate vs. time profiles from normal adult subjects inhaling
through air flow resistances that mimicked those seen in commercial DPIs, (b) curve-fit
and analyze those IPs before and after receipt of training and thus, (c) establish a data
base and equations for simulation of typical IPs used by normal subjects inhaling through
different air flow resistances. We envisaged the use of these equations by inhaler
designers seeking to optimize product performance in vitro, in advance of clinical trials.
As it is well known that aerosol drug delivery performance of passive DPIs is dependent
on air flow rate and air flow resistance (Clark & Hollingworth, 1993; U.S. Pharmacopeial
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Convention, 2013), a drug-free “inhalation flow cell (IFC)” with a disposable mouthpiece
and variable airflow resistances was constructed and instrumented with a digital
volumetric flow meter, as shown in Figure 4.2, to record the air flow rate vs. time profiles
used by each of the volunteers.

Figure 4.2. The inhalation flow cell (IFC) with top views of two “Resistance Tubes” with
identical external, but different internal, dimensions. Six IFC resistances were chosen for
IP recordings in the clinic: 0.0179, 0.0200, 0.0241, 0.0344, 0.0432 and 0.0462 kPa0.5 L-1
min. These values were determined experimentally from the slope of plots measured
pressure drop0.5 (flowmeter inlet to mouthpiece) vs. the volumetric airflow rate exiting the
mouthpiece (ASL 5000-XL, Ingmar Medical, Pittsburgh, PA). In the clinic, flow rates
entering IFC were recorded every 50msec using a calibrated digital flow meter (EM1,
Sensirion Inc., CA). All flow rates in this paper are expressed as the volumetric flow rate
exiting the mouthpiece and are identical to those used to program the breath simulator
(Figure 4.1).

Each recorded flow rate value was converted to the volumetric flow rate exiting the
mouthpiece using an algorithm to account for the change in the volumetric gas flow into
and out of the IFC with variations in pressure and resistance (Delvadia, 2012). All of the
IPs and flow rates described in this paper are flow rates exiting the mouthpiece.
Therefore, all IP data can be used directly to program breath simulators in the “realistic”
in vitro tests we described elsewhere (Byron et al., 2010; Byron et al., 2013; Delvadia et
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al., 2013a; Delvadia et al., 2012; Delvadia et al., 2013b; Olsson et al., 2013; Wei et al.,
2014). Air flow resistance values [kPa0.5.L-1 min] for the IFC were determined from the
slope of experimental plots of (pressure drop across IFC)0.5 vs. volumetric flow rate out of
the mouthpiece, by linear regression.

Clinical Study: Collection of inhalation profiles (IPs)
Adult human volunteers were recruited from the general population of Richmond,
Virginia, via advertisements. Healthy, non-pregnant, non-smoking subjects were recruited
who were 18 to 65 years old, above 147 cm in height, 50 to 120 kg in weight, without
history of recent congestion, lung disease and/or inhaler use. Volunteers had never used,
or been trained to use, a DPI before admission to the study. The study was approved by
VCU’s Institutional Review Board and entered on www.clinicaltrials.gov. Eligible subjects
were enrolled; twenty (10M, 10F) completed the study. None had evidence of acute
medical or psychiatric illness and all were found to have FEV1 > the predicted lower limit
of normal (LLN) after spirometric screening performed during an initial visit.(Marion et al.,
2001; M. R. Miller et al., 2005) On the second visit, each volunteer was asked to inhale
approximately 18 times through the IFC (Figure 4.2). Individual IPs were recorded digitally
every 50 msec as the volumetric flow rate vs. time profile of air exiting the mouthpiece of
the calibrated inhalation cell after Instruction A and B were provided, sequentially, to each
volunteer.
Instruction A. Each volunteer was asked to read the instructions shown in Figure
4.3. Those written instructions were based on leaflets, supplied as package inserts with
marketed powder inhalers, showing patients how to inhale from a primed DPI. After
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reading the instructions, volunteers were asked to inhale through the drug-free IFC, as if
they were conforming to the written instructions. Inhalation profiles were recorded for
each of six different resistance tubes placed in the IFC in random order. Subjects were
allowed to rest between inhalations to avoid fatigue.
Instruction B. Verbal instruction and a practical demonstration of how to use a
powder inhaler correctly was then delivered individually to each volunteer by a pharmacist
trained and experienced in the use of powder inhalers. The same pharmacist provided
the same demonstration and instructions to each volunteer that emphasized: (Step 1)
breathe out completely, (Step 2) ensure good lip closure around the IFC mouthpiece,
(Step 3) inhale as fast and deep as possible through the mouth; and to continue until
replete, (Step 4) hold breath and remove IFC from mouth.
Following this formal training, volunteers were again asked to inhale through the
IFC in the way they had been instructed and, during each inhalation, they were
encouraged to continue inhaling as they began to show signs of reduced effort. IPs were
recorded for each of the six different resistance tubes placed in the IFC in random order.
Each flow profile was repeated to give a second IP, or flow rate exiting the mouthpiece
vs. time, for each subject and resistance. The results from these duplicate experiments
were designated “Instruction B1” and “Instruction B2”.
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Figure 4.3. Written instructions for inhalation. Instruction A (Artwork adapted from
patient information leaflets).

Data Analysis and Statistics
Overall, the trial produced a series of 20 IPs per air flow resistance (total = 120)
for each of three instruction conditions: A, B1 and B2. These IPs were analyzed to
determine their overall dependence on airflow resistance, R, and training status. In order
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to do this, the parameters defined in Figure 4.4 were extracted from each IP and
tabulated. The descriptive statistics: mean, median, standard deviation, minimum and
maximum values, coefficient of variation [CV (%) = 100*standard deviation/mean] were
estimated for each of the inhalation variables (PIFR, TPIFR`, V and T; Figure 4.4) by gender
and across gender. Further inferential statistics were estimated as follows: for each
individual dataset (Instruction A, B1 or B2) for a given volunteer, the quantitative
relationship between each inhalation variable and air flow resistance (R) was assessed
by linear regression analysis. Four functions of R, [f(R)], were explored in this way: R,
1/R, LogR and R0.5. Best f(R) was selected based on the best fit (e.g. the coefficient of
determination, r2, that was largest). To assess the effects of training on IP statistically
(e.g. comparing instruction A, B1 or B2) it was necessary to pool the results for each
training condition. Accordingly, secondary variables were derived that were resistanceindependent: in cases where significant relationships existed between the inhalation
variable and R (e.g. PIFR), the values of that variable were normalized by resistance and
averaged across all resistances in order to obtain a secondary, resistance-independent,
normalized, inhalation variable. In case of insignificant relationships between a variable
and R, the inhalation variables were averaged across resistances, without normalization,
again to obtain a secondary, resistance-independent, inhalation variable. The effect of
formal training (Instruction B1 and B2) on these secondary inhalation variables was
assessed using repeated-measures ANOVA. The level of significance was preset at 0.05.
Normality of the residuals was judged by normal quantile plots and visual inspection of
the distribution of residuals. JMP 8.0 (SAS Corp, RTP, NC) was used for all statistical
analyses.
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PIFR

AUC = V

TPIFR

T

Figure 4.4. Idealized IP and the primary variables: PIFR = peak inspiratory flow rate;
TPIFR, the time at which PIFR occurs; AUC = Area Under the Curve = Inhaled Volume,
V. Total inhalation time, T, is a secondary variable, dependent on PIFR and V.

4.3

RESULTS

Air flow resistances of the Inhalation Flow Cell (Figure 4.2) were 0.0462, 0.0432,
0.0344, 0.0241, 0.0200 and 0.0179 kPa0.5 L-1 min. These were comparable with the
values 0.0467, 0.0435, 0.0352, 0.0241, 0.0198 and 0.0176 kPa0.5 L-1 min, determined
from linear regression of pressure drop0.5 vs. flow rate data for Spiriva® HandiHaler®,
Salbutamol Easyhaler®, Pulmicort® Turbuhaler®, Budelin® Novolizer®, Relenza®
Diskhaler® and Foradil® Aerolizer®, respectively. Twenty (10F, 10M) of an initial 22
volunteers, with the demographics and pulmonary function results shown in Table 4.1,
completed the study. Each subject followed the instructions and inhaled through the six,
randomly-presented, airflow resistances that are typical of those in marketed DPIs, using
the apparatus shown in Figure 4.2. The resulting IPs are used in the discussion to provide
data on the type and range of inspiratory maneuvers that need to be catered for by powder
inhaler designers seeking to deliver aerosol drug clouds to the lungs of inhaler-naïve
human adults with essentially normal pulmonary function, and where the subjects
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selected for product development trials have either been given written instructions on how
to inhale or received formal training in DPI use by a professional.
Table 4.1. Summary of subject demographics and pulmonary function tests (mean±SD).
Males

Females

Overall

Total

10

10

20

Caucasian

6

3

9

African

1

3

4

Asian

1

2

3

Hispanic

0

1

1

Others

2

1

3

Age [yrs]

31.1 ± 10.31

34.0 ± 8.81

32.6±9.23

Height [cm]

176.6 ± 5.64

161.8 ± 6.49

169.2±9.40

Weight [kg]

81.7 ± 16.75

60.7 ± 7.29

71.2±16.16

FVC [L]

5.02 ± 0.60

3.31 ± 0.35

4.15±0.98

FEV1 [L]

4.23 ± 0.41

2.81 ± 0.32

3.51±0.80

FEV1/FVC

0.84 ± 0.04

0.85 ± 0.06

0.85±0.05

FEF 25-75% [L/s]

4.72 ± 0.70

3.29 ± 0.87

3.99±1.03

PEF [L/s]

10.08 ± 1.28

7.12 ± 0.77

9.15±1.92

FET [s]
Pulmonary function tests

6.46 ± 1.01

6.91 ± 3.77

6.69±2.63

PFTa

a

Dependence of inhalation variables on air flow resistance and training
A complete and detailed description of the analyses performed on the inhalation
variables collected clinically is available in Delvadia (2012); the thesis included analyses
of residual distributions, normal quantile plots, statistical evaluation of gender effects,
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assessment of interactions between training status, gender and data from pulmonary
function tests and a complete compilation of all numerical data on which the analyses in
this paper are based. While those results enable us to present IP data, conclusions and
equations for IP simulation at each resistance and training condition, the material is too
lengthy to present in its entirety. Therefore, essential material in Delvadia (2012) is
presented to justify our recommendations to test dry powder inhalers in vitro, using the
apparatus shown in Figure 4.1, with a range of differently simulated IPs that describe the
pooled data including confidence limits at each resistance and training condition.
The experimental values for PIFR, TPIFR and V (Figure 4.4) were assessed for
functional dependence on airflow resistance, R. The results showed that 1/R gave the
best fit for PIFR from the four functions tested, while TPIFR and V showed no detectable
dependence on resistance. Accordingly, the statistics describing the mean, median,
standard deviation, minimum and maximum values and coefficient of variation [CV (%) =
100*standard deviation/mean] for each “resistance-normalized” variable (Figure 4.4;
R*PIFR, TPIFR and V) are presented in Table 4.2 by gender, across gender and by training
status to show the effects of gender and training.
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Female
Male
Overall
Instr. A
Instr. B1
Instr. B2
Instr. A
Instr. B1
Instr. B2
Instr. A
Instr. B1
Instr. B2
Mean
Mean
Mean
Mean
Mean
Mean
Mean
Mean
Mean
(R*PIFR)
(R*PIFR)
(R*PIFR)
(R*PIFR)
(R*PIFR) (R*PIFR) (R*PIFR) (R*PIFR) (R*PIFR)
Mean
1.895
2.402
2.381
2.619
3.029
2.920
2.257
2.715
2.650
SD
0.432
0.287
0.316
0.589
0.259
0.235
0.625
0.417
0.387
Min
0.893
2.012
1.900
1.291
2.529
2.510
0.893
2.012
1.900
Max
2.507
3.009
3.033
3.391
3.376
3.287
3.391
3.376
3.287
CV
22.8
11.9
13.3
22.5
8.5
8.1
27.7
15.4
14.6
Median
1.879
2.375
2.372
2.654
3.053
2.920
2.244
2.661
2.583
Mean V
Mean V
Mean V
Mean V
Mean V
Mean V
Mean V
Mean V
Mean V
(L)
(L)
(L)
(L)
(L)
(L)
(L)
(L)
(L)
Mean
1.562
2.025
2.100
3.009
3.781
3.793
2.285
2.903
2.947
SD
0.532
0.410
0.370
0.925
0.758
0.814
1.044
1.078
1.064
Min
1.065
1.393
1.486
2.366
2.982
2.713
1.065
1.393
1.486
Max
2.484
2.687
2.679
5.349
5.595
5.488
5.349
5.595
5.488
CV
34.0
20.2
17.6
30.7
20.0
21.5
45.7
37.2
36.1
Median
1.384
2.031
2.167
2.620
3.688
3.799
2.384
2.834
2.696
Mean TPIFR Mean TPIFR Mean TPIFR Mean TPIFR Mean TPIFR Mean TPIFR Mean TPIFR Mean TPIFR Mean TPIFR
(sec)
(sec)
(sec)
(sec)
(sec)
(sec)
(sec)
(sec)
(sec)
Mean
0.803
0.497
0.529
0.914
0.614
0.582
0.858
0.555
0.555
SD
0.447
0.153
0.210
0.456
0.192
0.275
0.443
0.179
0.240
Min
0.453
0.222
0.255
0.540
0.225
0.250
0.453
0.222
0.250
Max
1.893
0.734
0.978
1.944
0.872
1.179
1.944
0.872
1.179
CV
55.7
30.8
39.6
49.9
31.3
47.3
51.7
32.3
43.2
Median
0.667
0.473
0.491
0.744
0.619
0.520
0.683
0.550
0.495

Table 4.2. Descriptive result summary of the IP data for “resistance-normalized”, R*PIFR (kPa0.5), mean volume, V (L),
and mean TPIFR (sec), by training status and gender.

While the move from Instruction A to Instruction B1 or B2 showed the importance
of formal training, the data from the duplicate IPs designated “Instruction B1” or
“Instruction B2” showed no statistical difference between the pooled first or second
measurement sets. Accordingly, data from B1 and B2 were pooled for further analysis
and designated “Instruction B”.
Gray profiles in Figures 4.5 and 4.6 show the IP results from all subjects (M and
F) following Instructions A and B, respectively. The profiles shown in red at each
resistance and training condition, are taken from the gray profiles after processing to show
the 10, 50 and 90 percentile flow rate for the population at each 50 msec sampling time.
The functional dependence of the 10, 50 (median) and 90 percentile PIFR values
(Figures 4.5 and 4.6) on reciprocal resistance is plotted in Figure 4.7 for this population.
Figure 4.7 is valid for values of R in the range 0.018 – 0.046 kPa0.5 L-1 min although
beyond this range, curvature of PIFR vs. 1/R is expected (in order to meet a zero intercept
as R tends to infinity). There was no need to explore curvature at impractically large
resistance values however, as the selected linear functions were clearly appropriate for
resistances that are encountered practically.
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Figure 4.5. Individual flow profiles (gray) or volumetric flow rates exiting the mouthpiece of IFC vs. time from 20 volunteers
(10M, 10F; 20 gray profiles per panel) after reading written instruction A (Figure 4.3). IFC airflow resistance, R, is shown in
each panel. Red profiles show the 10, 50 and 90 percentile IP in each case.
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Figure 4.6. Individual flow profiles (gray) or volumetric flow rates exiting the mouthpiece of IFC vs. time from 20 volunteers
(10M, 10F) after Instruction B (40 gray profiles, from B1 and B2, per panel). IFC airflow resistance, R is shown in each
panel. Red profiles show the 10, 50 and 90 percentile IP in each case.
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Figure 4.7. PIFR vs. I/R from pooled data collected after (a) Instruction A (reading only)
and (b) Instruction B (training by professional; r2>0.995). 10, 50 and 90 percentile values
can be predicted based on a pre-selected value for R in the range of 0.018–0.046 kPa0.5.L1
min.

Inhalation profiles were less erratic after subjects received professional training
(Instruction B) and values for PIFR appeared to increase. Equations 4.1–4.3 and Figure
4.7a describe the 90, 50 and 10 percentile values for PIFR in this population due to
Instruction A; Equations 4.4–4.6 and Figure 4.7b apply to Instruction B.

Instruction A:
PIFR90% = 2.48 (1/R) + 19.1

Equation 4.1

PIFR50% = 1.52 (1/R) + 21.1

Equation 4.2

PIFR10% = 0.58 (1/R) + 18.6

Equation 4.3
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Instruction B:
PIFR90% = 2.56 (1/R) + 19.3

Equation 4.4

PIFR50% = 1.82 (1/R) + 21.0

Equation 4.5

PIFR10% = 1.44 (1/R) + 17.7

Equation 4.6

Where R < 0.046 > 0.018 kPa0.5.L-1 min and PIFR and R have units of L min-1 and kPa0.5.L1

min, respectively. Overall (Table 4.2), males had higher mean PIFR compared to

females and volunteers inhaled at larger flow rates with lower inter-subject variability
when formally trained (Instruction B; there was no significant difference between
normalized PIFR values for Instruction B1 and B2). Residuals from plots of PIFR vs. 1/R
were randomly distributed and the observed positive linear relationship between PIFR
and 1/R was consistent with the physiological literature where the slope of the regression
line of PIFR vs. 1/R has been reported to give the square root of the “maximum” pressure
drop across an inhaler for a given volunteer; this pressure drop reportedly stays
approximately constant across the air flow resistances seen in marketed DPIs (Smutney
et al., 2009).
Values for inhaled volume, V, and the time to the peak inspiratory flow rate, TPIFR,
(Table 4.2) were resistance-independent. As expected however, V was clearly influenced
by gender. Consistent with their larger total lung capacity (Hankinson et al., 1999) males
had a mean value for V = 3.009 L after Instruction A. This was 1.45 L more than females
(mean V = 1.562 L). After Instruction B, these values increased to 3.787 and 2.063 L,
respectively. Formal training (Instruction B), caused a statistically significant improvement
in V across gender (n = 20); mean V overall was 0.64 L greater than that seen after
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Instruction A (p < 0.0001). There was no apparent effect of gender on TPIFR but training
once again was influential. A significant reduction of 0.3 seconds in mean TPIFR was
observed after formal training (p < 0.0001).

4.4

DISCUSSION
This study describes the data resulting from a clinical study of the breath profiles

produced by differently trained, inhaler-naïve, normal human adults inhaling through
variable resistances typical of those seen in marketed DPIs (Delvadia et al., 2013a;
Delvadia et al., 2012). Because the leaflets supplied with different powder inhalers use
different phrases to describe the actual inhalation maneuver, we adopted a standardized
phrase for Step 3 of our written Instruction A: “breathe in as quickly and as deeply as you
can” (Figure 4.3). Our choice of phrase may have influenced the profiles shown in Figure
4.5 given that the respective phrases in leaflets for Aerolizer®, Diskhaler®, Novolizer®,
Turbuhaler®, Easyhaler® and HandiHaler® were: “breathe in quickly and deeply”,
“breathe in through your mouth steadily and as deeply as you can” “inhale the powder
with a deep breath”, “breathe in as deeply and as hard as you can”, “take a strong and
deep breath” and “breathe in deeply until your lungs are full”. Nevertheless, volunteers
inhaled faster and deeper when they were trained using written instructions in
combination with formal training from a pharmacist skilled in the use of inhalers,
compared to the use of written instructions alone. The study showed that formal training
helped to reduce inter-subject variability in inhalation flow rate vs. time profiles; an
observation that may translate into reduced variability in aerosol drug deposition in the
lung. IP analysis showed that decreased air flow resistance produced increases in PIFR
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while V was unchanged. The results also showed that males inhaled faster and more
deeply than females although no significant relationships were observed between the
spirometric results (Table 4.1) of volunteers and their observed inhalation variables
(Figure 4.4). Because the scope of the present study was limited to 20 healthy volunteers,
most of whom were in their prime, the reported IPs probably do not reflect those for
subjects with significant reductions in lung capacity. While the time of PIFR, TPIFR, and
the total inhaled volume V were unrelated to R in this study, the findings may not hold in
all subjects. Sarinas et al. (1998), for example, showed that in CF, COPD and asthma, V
fell as resistance was increased. Gender and age, that influence mouth inspiratory
pressure, MIP, have also been shown to influence inspiratory flow (Baba et al., 2011;
Broeders et al., 2004; Malmberg et al., 2010). In spite of this limitation, the analysis below
shows a general way of selecting standard IPs for use in realistic in vitro tests of inhalers
during development. Indeed, because many drug and device development efforts,
including aerosol deposition studies used for bridging purposes, begin with normal
volunteers or largely asymptomatic patients, the present study was designed to ensure
that the equations and general procedures for IP simulation that were developed could
span the likely range of “normal” IPs needed to program a breath simulator for use with a
realistic in vitro test method (Figure 4.1). In addition we sought to offer IP ranges for
volunteers who were representative of patients who had to teach themselves how to
inhale after reading an instruction leaflet.
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Simulating Inhalation Profiles for DPIs with Different Airflow Resistances
Even though it is possible to program breath simulators with IPs that are almost
identical to the individual breath profiles of volunteers, or the 10, 50 and 90 percentile IPs
shown in red in Figures 4.5 and 4.6, and this is practiced by some scientists (Olsson et
al., 2013), profiles that are statistically representative of groups of subjects, that can be
selected a priori, seem preferable for testing and development purposes.
To program a breath simulator to mimic IPs that were representative of those
shown in Figures 4.5 and 4.6, we sought suitable equations and functions able to
adequately describe the red profiles representing the 10, 50 and 90 percentile flow rate
vs. time curves shown in each panel. Ideally, parameters in the resulting equations should
have physiologic meanings that relate to the variables shown in Figure 4.4. While we and
others have described and used alternate methods previously,(Delvadia et al., 2013a;
Delvadia et al., 2012; Delvadia et al., 2013b; Longest et al., 2012a; Longest et al., 2012b)
we sought a simplified approach for use in future research with DPIs, in which it was only
necessary to select the inhaler resistance, R, in order then to be able to define ranges of
PIFR, TPIFR and V; whence to generate a fan of appropriate IPs with which to test a new
DPI. Because the approach and algorithm is simple, we hope that the method proposed
here can be generalized to include realistic tests that extend to treatment of different
patient groups with differently designed inhalers and use instructions.
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Figure 4.8. Simulated inhalation profiles (black curves) generated using Equations 4.7–4.10 for resistances shown in each
panel and the algorithm described in the text. PIFR was calculated from Equations 4.4–4.6 (Instruction B); TPIFR = TPIFR50%
= 0.49s for all black curves while values for V10%, V50% and V90% were 1.4, 2.7 and 4.6 L. Red curves shown for comparison
are the 10, 50 and 90 percentile IPs from Figure 4.6.

The black curves in Figure 4.8 are the simulated flow rate vs. time profiles that
resulted from the following routine. They are clearly good descriptions of the real profiles
(reproduced from Figure 4.6) that represent the 10, 50 and 90 percentile IPs (Instruction
B). The same approach can be used to generate curves that follow the red profiles in
Figure 4.5 (Instruction A; not shown), while intermediate curves, for testing inhalers with
different resistances can also be generated. Each panel of IPs (black curves; Figure 4.8)
was generated as follows from Equations 4.7–4.10:

 t 
FR(t )  PIFR  sin 

 2 TPIFR 

0  t  TPIFR

   t  TPIFR  
FR(t )  PIFR  cos 

 2 T  TPIFR  

TPIFR  t  T

Equation 4.7

Equation 4.8

Because AUC = V (Figure 4.4) is given by integrating and adding Equations 4.7 and 4.8,

PIFR[ L  min 1 ]  T [ s]
V [ L] 
30

Equation 4.9

Therefore,

T [s] 

30  V [ L]
PIFR[ L  min 1 ]

Equation 4.10

First, PIFR90%, PIFR50%, PIFR10% was calculated based on the DPI resistance, R
(quoted in panel of Figure 4.8) using Equations 4.4, 4.5, 4.6, respectively, assuming that
we were concerned with well-trained normal subjects. Second, a median value for
TPIFR50% = 0.49 sec was selected and held constant; if required however, alternate values
for TPIFR50% may be employed to produce different values for airflow acceleration (see
distribution and legend in Figure 4.9). Notably, TPIFR was independent of R and log65

normally distributed across the 240 IPs from this population. In spite of that observation,
because the rising slope d(FR)/dt falls with decreasing PIFR (Figure 4.6) and PIFR
decreases with increasing R (Figure 4.7), de Boer et al.’s reported relationship between
the “flow increase rate (FIR)” and device resistance (de Boer et al., 1997) still holds.

Figure 4.9. Distribution of values for TPIFR (seconds) across genders after Instruction B.
The 10, 50 and 90 percentile values were 0.28, 0.49 and 0.88 seconds, respectively.
Instruction A yielded a similar distribution with 10, 50 and 90 percentile values of 0.43,
0.66 and 1.68 seconds, respectively. Selection of the values for TPIFR and PIFR permits
the study of device behavior at different flow accelerations according to Equation 4.7.

Third, V90%, V50% and V10% values were assigned (4.6, 2.7 and 1.4 L, respectively),
based on “across gender” data for V (Table 4.2; because values for V in males and
females differ significantly, IPs simulated for single gender studies should be adjusted).
Fourth, values were calculated for the inhalation time T90%, T50% and T10% from Equation
4.10. Coupling the calculated and assigned values for PIFR, TPIFR, V and T at their chosen
percentiles, enables the calculation of flow rates leaving the mouthpiece at each value of
time, t, from Equations 4.7 (t<TPIFR) and 4.8 (t≥TPIFR). These simulated profiles were
plotted as the large, medium and small profiles shown in black on Figure 4.8. In practice,
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breath simulators, such as the ASL 5000-XL can be programmed directly using these
sine wave equations, or data may be supplied directly in the form of a spreadsheet of
simulated flow rates over time. An example of the use of these IPs to test a DPI with
known resistance was described previously (Byron et al., 2014).

4.5

CONCLUSION
A general method of selecting and simulating a range of inhaled flow rate vs. time

profiles for use in the realistic testing of powder inhalers has been described. Equations
and an algorithm are presented that enable simulation of the range of inhalation flow rate
vs. time curves used by normal human adult volunteers of both genders both before and
after formal training in the use of powder inhalers. The approach enables the product
designer to select breath profiles with which to study aerosol device performance across
the likely inter-subject variability seen with DPIs of different resistances following either
leaflet training alone, or formal training from a professional in addition to leaflet training.
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CHAPTER 5
DETERMINING AERODYNAMIC PARTICLE SIZE DISTRIBUTIONS OF IN VITRO
LUNG DOSES FOR BUDELIN® NOVOLIZER® UNDER REALISTIC INHALATION
CONDITIONS

5.1

INTRODUCTION
Coupling realistic mouth-throat (MT) models with simulated, but representative

human inhalation profiles (IP) that mimic inhaler use in the clinic (as described in Chapter
4) has been found to be promising when building in vitro–in vivo correlations (IVIVCs) for
orally inhaled drug products. Studies of several inhalers have shown that the in vitro
measured lung doses (designated as the drug doses exiting the MT models) appear to
predict the mean and extreme values for the in vivo total lung deposition data obtained
from gamma scintigraphic or pharmacokinetic (PK) methods (Delvadia et al., 2013a;
Delvadia et al., 2012; Olsson et al., 2013; Weers et al., 2014; Zhang et al., 2007). While
total lung dose (TLD) is important in evaluating inhaler in vivo performance, regional drug
deposition in the lung may also be a determinant of the therapeutic effects of inhaled
drugs, especially for compounds intended for topical activity like budesonide (Anderson
& Newman, 2009; Usmani & Barnes, 2012; Usmani et al., 2005).
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As particle size is one of the major factors affecting aerosol drug deposition, and it
is known to be influenced significantly by the airflow through Novolizer (de Boer et al.,
2004), evaluating size distribution of drug aerosols able to enter the lung, following
deaggregation and dispersion under realistic inhalation conditions, is an essential part of
realistic in vitro testing. We may expect that the drug deposition patterns in gamma
scintigraphy studies, usually reported as P/C ratios [designated as radioactive counts in
the peripheral (P) to central (C) lung ratio] are some function of the aerodynamic particle
size distribution (APSD) of the TLD. A summary of the mean values and variations for
P/C ratio obtained from gamma scintigraphy studies in the literature for different DPIs is
provided in Appendix I. While variations in regional deposition may be caused by
combined effects of variations in APSDs, inhalation flow rates, and airway geometries, if
we are to fully evaluate the variations in regional drug distribution in the lung using
modeling approaches like computational fluid dynamic (CFD) simulations (Longest &
Holbrook, 2012), it is necessary to evaluate the possible ranges of APSDs of drugs exiting
the MT models during realistic testing.
The challenge of coupling realistic IP conditions for aerosol generation with the
constant flow demand of cascade impactor testing can be overcome by using devices like
the Electronic Lung™ (Burnell et al., 1998b) or the Nephele Mixing Inlet (N. C. Miller,
1997; N. C. Miller et al., 2000). The Electronic Lung™ was developed by GlaxoSmithKline
scientists who created powder aerosols using different IPs in a large chamber; aerosols
were subsequently drawn into a calibrated cascade impactor at a fixed flow rate (Brindley
et al., 1994; Burnell et al., 1998a; Burnell et al., 1998b). The method, that generates an
apparent APSDs of the sampled drug cloud, suffers from a significant problem because
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of settling and drug losses in the sample chamber (Burnell et al., 1998b). The use of the
Nephele Mixing Inlet to provide variable aerosol dilution over time in a “flow balancing”
set up (described in Figure 5.3 later in this chapter) can overcome this difficulty under
certain circumstances. Several examples of using this approach to measure particle size
distributions exiting MT models have been reported (Below et al., 2013; Casaro et al.,
2014; Chrystyn et al., 2015; Olsson et al., 2013). Because the method is obliged to use
additional makeup air to create the constant air flow required by the cascade impactor,
the highest flow rate possible for a test IP, i.e. peak inhalation flow rate (PIFR), is presently
limited by the upper flow limit of the calibration range of the chosen cascade impactor.
The most accepted cascade impactor for pharmaceutical studies of inhalers with a high
flow rate calibration is the Next Generation Pharmaceutical Impactor [NGI; Apparatus 5,
USP (U.S. Pharmacopeial Convention, 2013)]. The NGI is calibrated for use at air flow
rates between 15 and 100 L/min, so that presently, the maximum usable PIFR in the set
up used in the literature is 100 L/min (Below et al., 2013; Casaro et al., 2014; Chrystyn et
al., 2015; Olsson et al., 2013). This is a big limitation of the method given that Chapter 4
and other studies have reported that both healthy subjects and patients may generate
PIFRs much greater than 100 L/min through DPIs, especially when the inhalers in use
are low resistance devices (Azouz et al., 2015a; Azouz et al., 2015b; Virchow et al., 2014).
The present study sought to develop and evaluate methods for measuring APSDs
of drug aerosols from Budelin® Novolizer® 200 mcg (Meda Pharmaceuticals,
Hertfordshire, U.K.) exiting the Virginia Commonwealth University (VCU) MT models
under a range of realistic IPs. While Budelin was chosen for this study in part because its
regional distribution in the lung has been reported in the literature (Newman et al., 2000),
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the method sought to extend the range of testable IPs to allow the assessment of APSDs
of TLDin vitro from Budelin at flow rates over 100 L/min. The chapter describes methods of
extending the test limit of NGI to allow the APSDs of the in vitro lung doses to be
determined across a range of realistic IPs. A recalibration of NGI using polydisperse
budesonide aerosols is also described. The details of Budelin Novolizer 200 mcg regional
distribution are summarized from the literature (Newman et al., 2000) in Appendix I.

5.2

MATERIALS AND METHODS

Mouth-Throat Models
Small, medium and large Virginia Commonwealth University (VCU) MT models
[(Longest, 2012); noted as VCU-MTs, VCU-MTM, VCU-MTL in the following text],
previously designed and validated to describe the geometric variations seen in adult
humans (Delvadia et al., 2012), were externally modified to improve connectivity to the
NGI and Nephele Mixing Inlet (NMI) (N. C. Miller, 1997; N. C. Miller et al., 2000) (Figure
5.1). Internal dimensions of these models were not changed. The three-dimensional (3D)
geometry of the MT models were altered in Autodesk® Inventor® 2014 (Autodesk, Inc.,
San Rafael, CA), and a quick-fit adapter to NGI was added to the trachea of each model
to ensure an airtight connection between MT, NGI and NMI. The tapered “quick-fit” female
dimensions atop the NGI inlet and NMI inlet are identical. The NMI outlet also has a
tapered male connection designed to mate with the NGI inlet. Dimensions of the modified
MT geometry can be found in Appendix II. Physical models were constructed in
ultraviolet-laser-cured resin (Accura® 60, 3D System, Valencia, CA) using a rapid
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prototyping process of stereolithography (Viper si2™ SLA® system, 3D Systems,
Valencia, CA), with vertical layer thickness of 0.1 mm.

Medium

Large

Small

Figure 5.1. Small, medium and large Virginia Commonwealth University (VCU) mouththroat (MT) models [(Longest, 2012); noted as VCU-MTs, VCU-MTM, VCU-MTL in the
following text] with quick-fit adapters to fit the Next Generation Impactor (NGI) and
Nephele Mixing Inlet (NMI). Dimensions of the modified MT geometries are described in
Appendix II.

Inhalation Profiles
IPs were simulated using the sinusoidal waveforms described in Chapter 4
(Equations 4.7–4.10) to represent the fast, moderate and slow inhalation used by subjects
in a lung scintigraphy study of Budelin Novolizer 200 mcg (Newman et al., 2000).
Variations in subjects’ inhalation maneuvers were estimated by adding and subtracting
two standard deviations (SD) from the mean values for peak inhalation flow rate (PIFR)
and inhaled volume (V) (Newman et al., 2000) to represent the 95% conference intervals
around each of the reported means. These values were paired (Table 5.1) to generate
the small, medium and large volume IPs for each inhalation condition (Figure 5.2).
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Table 5.1. Mean and likely confidence intervals for peak inhalation flow rate (PIFR) and
inhaled volume (V) at each of the reported inhalation conditions (Newman et al., 2000).
Inhalation Profile

Inhalation
Condition

PIFRa (L/min)

Va (L)

73
1.11
(Mean–2SD)
(Mean–2SD)
99
3.13
Fast
Medium
(Mean)
(Mean)
125
5.15
Large
(Mean+2SD)
(Mean+2SD)
59
1.30
Small
(Mean–2SD)
(Mean–2SD)
65
2.96
Medium
Moderate
(Mean)
(Mean)
71
4.62
Large
(Mean+2SD)
(Mean+2SD)
40
0.83
Small
(Mean–2SD)
(Mean–2SD)
54
2.77
Medium
Slow
(Mean)
(Mean)
68
4.71
Large
(Mean+2SD)
(Mean+2SD)
a
Mean values for PIFR and V for each inhalation condition were as reported (Newman et
al., 2000), whereas the ranges (large and small values) were estimated by adding and
subtracting two standard deviations [SD; also reported by Newman et al. (2000)] from the
mean.
Small

73

Flow Rate (L/min)
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Large IP
Medium IP
Small IP
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90
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0
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(a) Fast Inhalation

Flow Rate (L/min)
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0
0

1

2

3

4

5

6

7

Time (sec)

(b) Moderate Inhalation

Flow Rate (L/min)
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Medium IP
Small IP
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0
0
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3

4

5

6

7

Time (sec)

(c) Slow Inhalation

Figure 5.2. The small, medium and large simulated test IPs used to represent the median
and extremes (95% confidence intervals; see IP definition page xix) for the (a) fast, (b)
moderate and (c) slow inhalations described in the clinical study (Newman et al., 2000).
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Mixing Inlet–Cascade Impactor System
Apparatus
The NMI (Model III for NGI; RDD Online, Richmond, VA) is a precisely engineered
and patented tool for mixing high density, non-homogeneous aerosol clouds, like those
from inhalers, with variable volumes of dilution air. It contains a central tube for receiving
the aerosol clouds and an outer inlet for receiving and introducing dilution air; the design
enables a sheath air flow to be created around the aerosol flow to minimize wall losses
due to impaction. Losses within the NMI have been reported to be <2% (N. C. Miller, 1997;
N. C. Miller et al., 2000). The NGI (MSP Corporation, Shoreview, MN) was modified by
replacing the jets and orifice plates with those from the Westech W7 Cascade Impactor
(Westech Scientific Inc., Marietta, GA), a precisely-engineered copy of the original NGI
and purchased with detailed mensuration data and certification. The use of the W7 jet
plate enables the removal of individual jets and the Micro-Orifice Collector (MOC) when
these are found to create sonic (or critical) flow conditions in the instrument (i.e. situations
where the air flow rate through the impactor cannot be increased given further increase
of vacuum power). Notably, the unmodified NGI does not enable jet removal and high
flow rate testing. To extend the flow limits of NGI and allow its operation outside the
specific flow range for which it is calibrated [15–100 L/min; (Marple et al., 2003a; Marple
et al., 2004; U.S. Pharmacopeial Convention, 2013)], MOC was replaced with a high flow
internal filter holder containing an 81 mm diameter disposable type A/E glass fiber filter
(Pall Corporation, Port Washington, NY) capable of complete aerosol capture. The
programmable breath simulator ASL 5000-XL (a larger-volume version of the commercial
model ASL 5000, redesigned for VCU by IngMar Medical, Pittsburgh, PA), was used in
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this study to simulate the complete range of realistic IPs for Budelin Novolizer (Figure 5.2).
Two vacuum pumps were used to generate constant air flow through NGI: a lower
capacity ERWEKA vacuum pump VP 1000 (ERWEKA International, Annandale, NJ) for
air flow rates ≤100 L/min, and a higher capacity 3-phase DOERR vacuum pump LR22132
(Emerson Electric, St Louis, MO) for air flow rates >100 L/min.

Experimental Setup and General Procedure
The setup for characterizing the APSDs of drug exiting MT models, following
deaggregation and dispersion under realistic inhalation conditions, is illustrated in Figure
5.3. The NMI was placed atop the NGI-W7 impactor (noted as “NGI” in the following text),
with its upper inlet connected to the MT model for receiving aerosol clouds from Budelin
Novolizer, and side inlet connected to a compressed air source (with a pressure regulator
and a flow control valve) for receiving dilution air. The vacuum pump was connected to
the outlet of NGI, and depending on the PIFR of the test IP, either the lower capacity or
higher capacity pump was selected to draw air through NGI at the designated flow rate
(Table 5.2). The breath simulator was interposed between the NMI and compressed air
source using a T-junction. While not strictly necessary, Parafilm® M (Bemis, Oshkosh,
WI) over-wraps were used throughout to ensure airtight connections between apparatus
components.
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Figure 5.3. Experimental setup and apparatus used to measure aerodynamic particle
size distributions of drugs exiting the MT model under realistic inhalation conditions for
Budelin® Novolizer®. Equipment details are described in the text.

Prior to each experiment, internal surfaces of the MT models and NGI plates were
coated twice with Molykote® 316 silicone release spray (Dow Corning, Midland, MI) using
procedures described by Hindle et al. to avoid particle re-entrainment after impaction
(Hindle et al., 1996). After each spraying, excess coating solution was retained inside the
MT model, and the model shaken regularly to ensure uniform internal surface coverage.
The complete coating procedure took 30 minutes per coating, after which all solvents had
evaporated. The apparatus was assembled as shown in Figure 5.3 except that prior to
each test, a low-resistant digital flow meter SFM 3000 (Sensirion Inc., Westlake Village,
CA) was connected at the mouth opening of MT, in place of the inhaler, to monitor the air
flow rate entering MT with time. The vacuum pump was switched on to draw air through
the MT into the NGI and air flow was adjusted until it reached the designated flow rate for
the NGI in the chosen experiment (either 100 or 140 L/min in this study). The vacuum
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flow was then held constant, and compressed air introduced as dilution air to the side port
of NMI. This dilution air flow was adjusted until it balanced the vacuum flow through NGI
to produce a flow meter reading at the entry to MT = 0±2 L/min. The breath simulator,
programmed to create a chosen IP (Figure 5.2), was activated to draw air through MT
into NMI while constant air flow was maintained through NGI. The designated IP was
recorded at the mouth opening of MT to ensure that PIFR and V were within 2% of their
designated protocol values (Table 5.1). Once this condition was met, the setup was
accepted and the flow meter removed from the entrance to MT. Budelin Novolizer was
then primed, inserted into the MT model and sealed with Parafilm® M, and a single IP
used to disperse and draw a budesonide dose through the system. After commencing
the designated IP, the inhaler was removed from MT, and the compressed air source and
vacuum pump switched off in sequence. The apparatus was disassembled after each
dose, and budesonide was recovered by rinsing the inhaler (with drug cartridge removed),
MT, NMI, NGI stages 1–7 and filter using known volumes of 70%/30%:methanol/water
(v/v) and analyzed using high-performance liquid chromatography (HPLC). Budesonide
assay was performed using Symmetry® C18 column (3.5µm, 4.6×100mm, Waters,
Milford, MA), 69% methanol / 31% 0.1% (v/v) acetic acid buffer (v/v) as mobile phase
(flow rate: 1.0 mL/min), and UV detection at 280 nm (2996 Photodiode Array Detector,
1515 Isocractic HPLC Pump, 717 plus Autosampler, Waters). Injection volume was 100
µL and calibration curves were linear in the range of 0.2–10.0 mcg/mL (r2 > 0.999). The
limit of quantification (LOQ) = 0.025 mcg/mL.
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Aerodynamic Particle Size Distributions of Budelin’s TLDin vitro
The mixing inlet–cascade impactor system (Figure 5.3) and different VCU MT
models (Figure 5.1) were employed to enable drug clouds to be withdrawn from Budelin
Novolizer 200 mcg according to each of the designated IPs (Figure 5.2) so that the APSDs
of drugs exiting MT (TLDin vitro) could be characterized under constant flow conditions. To
evaluate the likely ranges of APSDs of Budelin’s TLDin vitro, the VCU-MTS, VCU-MTM, and
VCU-MTL were paired with the small, medium and large IPs, respectively, for each
inhalation condition (fast, moderate, slow). The NGI was operated either at 100 L/min if
PIFR for the test IP was smaller than 100 L/min or 140 L/min if PIFR > 100 L/min.
Combinations of MT models, IPs and NGI flow rates used for measurement of APSDs of
Budelin’s TLDin vitro are summarized in Table 5.2. Because NGI is only calibrated in the
flow range of 15–100 L/min (Marple et al., 2003a; Marple et al., 2004; U.S. Pharmacopeial
Convention, 2013), additional experiments were performed to evaluate the data collected
at 140 L/min. In practice, it was necessary to recalibrate the instrument at 140 L/min. To
to do this, four MT-IP combinations where PIFR of the test IP < 100 L/min were selected
from Table 5.2 (fast inhalation, small MT-IP and medium MT-IP; slow inhalation, medium
MT-IP and large MT-IP). The same MT-IP combinations were employed to determine the
apparent APSDs of TLDin vitro at the 140 L/min NGI flow condition given that the same
budesonide aerosol should be generated under the same conditions, regardless of the
change in NGI flow. In this way, the data collected at 100 L/min could be used as
polydisperse aerosol calibration standards to compare with the data generated at 140
L/min. All experiments were randomized. Single actuations were applied and five
replicates were performed for each protocol.
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Table 5.2. MT models, IPs and NGI flow rates used for measurement of APSDs of TLDin
vitro for Budelin Novolizer. IPs (small, medium, large) for each of the inhalation conditions
(fast, moderate, slow) in the literature (Newman et al., 2000) and as defined in Table 5.1
and Figure 5.2.
Inhalation Condition

MT Model

Fast

VCU-MTS

Small

100 and 140*

VCU-MTM

Medium

100 and 140*

VCU-MTL

Large

140

VCU-MTS

Small

100

VCU-MTM

Medium

100

VCU-MTL

Large

100

VCU-MTS

Small

100

VCU-MTM

Medium

100 and 140*

VCU-MTL

Large

100 and 140*

Moderate

Slow

Inhalation Profile

NGI Flow Rate (L/min)

*The MT-IP combination was tested at both 100 and 140 L/min NGI flow conditions to
evaluate the validity of APSD measurements of Budelin’s TLDin vitro at 140 L/min.

Data Treatment
The amount of budesonide depositing on inhaler, MT, NMI, NGI stages 1–7 and
filter were calculated from the products of drug concentrations and sample volumes.
Values for TLDin vitro were calculated as total amount of budesonide depositing on NMI
and NGI, and compared with TLDin

vivo

reported in the gamma scintigraphy study

(Newman et al., 2000) for each inhalation condition. The APSDs of TLDin

vitro

for

budesonide exiting the MT model were analyzed in accord with USP (U.S. Pharmacopeial
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Convention, 2013), where the cutoff aerodynamic diameters for NGI’s stages at a specific
flow rate ( Q ), D50,Q , were calculated using Equation 5.1:
D50,Q

 Qn 
 D50,Qn 

 Q 

x

Equation 5.1

Where Qn is the nominal flow rate (60 L/min) and D50,Qn is the stage cutoff diameter at
Qn . USP’s values for D50,Qn and the exponent x (Table 5.3) are based on an archival NGI

calibration that accords with NGI’s stage mensuration data and impaction theory in the
flow range of 30–100 L/min (Marple et al., 2003a). To facilitate initial data analysis,
Equation 5.1 was extrapolated so that values for D50,Q could be calculated for both the
100 and 140 L/min NGI flow conditions, assuming that the values for the exponent x
were unchanged (Table 5.3). Apparent APSDs of Budelin’s TLDin

vivo

measured at

different conditions were then compared by plotting the cumulative percent mass less
than the stated cutoff diameter vs. the cutoff diameter of the corresponding stage ( D50 )
(Equation 5.2). Statistical analyses were performed for total recovered dose and total drug
mass in NGI using one-way ANOVA and Student’s t-test at a significant level of 0.05 in
JMP Pro 11 (SAS Institute Inc., Cary, NC).

Cumulative % Mass  D50 of Stage i 

 Drug Mass Below Stage i 100%
TotalDrug Mass in NGI
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Equation 5.2

Table 5.3. The cutoff aerodynamic diameters for NGI’s stages at the nominal flow rate
( Qn ), D50,Qn , and the exponent x in Equation 5.1 (U.S. Pharmacopeial Convention, 2013).
Stage

D50,Qn

x

1

8.06

0.54

2

4.46

0.52

3

2.82

0.50

4

1.66

0.47

5

0.94

0.53

6

0.55

0.60

7

0.34

0.67

Re-calibration of NGI’s Stage Cutoff Diameters
While the theoretical value of the exponent x in Equation 5.1 is 0.5 given “ideal”
impaction theory (Reist, 1993), all impactors require experimental calibration corrections
so it is not surprising that x ranges 0.47 through 0.67 for NGI stages 1–7 in the flow rate
range of 30–100 L/min (Table 5.3) (U.S. Pharmacopeial Convention, 2013). In order to
employ NGI at a flow rate above this calibration limit (e.g. 140 L/min), it was necessary
to:
(a) Remove the last stage (MOC) from NGI to prevent flow limitation due to the flow
through the MOC becoming critical or sonic;
(b) Assess the validity of Equation 5.1 at 140 L/min with USP’s values for the exponent

x by comparing the APSDs of budesonide aerosols produced from Budelin under the
same MT-IP conditions when drawn into NGI at both air flow rates;
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(c) Amend the values of D50 for certain stages (perhaps by modifying the exponential
term x for those stages) at 140 L/min.
The recalibration of a cascade impactor using polydisperse pharmaceutical
aerosols was reported by Kotian et al. (2009) and a similar approach was employed here.
Four sets of n = 5 cumulative percent mass undersize data obtained from the NGI at 100
L/min from the experimental protocols described in Table 5.2 (fast inhalation: small MTIP, medium MT-IP; slow inhalation: medium MT-IP, large MT-IP) were used as calibration
standards. Data were fitted using least square nonlinear regression analysis to determine
best estimates for the mass median aerodynamic diameter (MMAD) and the geometric
standard deviation (GSD) of each cloud by fitting the data to the cumulative lognormal
distribution function (CDF) (Andrews, 1992; Kotian et al., 2009) shown in Equation 5.3:


 1 

 log e  x  - MEAN   
y  100   0.5  0.5ERF   0.5

 2  



Where ERF is the error function =

2

 0.5

e

 1 

   0.5  loge  x - MEAN  
  2  


Equation 5.3

2

dx , and e MEAN and e are the

MMAD and GSD of the lognormally distributed data. No weighting factors were assigned
and the analysis was performed using MATLAB® R2012b (MathWorks, Natick, MA). The
cumulative percentage of drug, y , depositing below the cutoff diameter, D50 , of each
stage at 100 L/min, x , was fitted by allowing MEAN and  to float in order to minimize
the sum of squared deviations of the data from the line of best fit for each MT-IP
combinations (Table 5.2). Best estimates of MMAD and GSD were tabulated for each
product, alongside their 95% confidence intervals (CI) in accord with Kotian et al. (2009).
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To recalibrate NGI at 140 L/min, the individual values for cumulative percent mass
penetrating below each stage were tabulated for that flow condition. The curves of best
fit for the NGI data at 100 L/min were assumed to also describe the NGI data at 140 L/min.
Values for MMAD and GSD for each aerosol at 100 L/min were fixed at their best
estimates following curve fitting, and solutions for the stage D50 values at 140 L/min were
then solved analytically using the cumulative lognormal distribution curves for each
aerosol and MT-IP combination. This was performed in Microsoft Excel 2013 (Microsoft
Corporation, Redmond, WA) by setting the value for the cumulative percent undersize ( y
in Equation 5.3) to its experimentally determined value for the chosen MT-IP combination
when tested with NGI flow = 140 L/min; the function was then solved for x using the
LOGNORM.INV function and the solution assigned to D50 for the selected stage and data
set. Mean values of each D50 were calculated for each stage from the four separate
calculations and assigned as the re-calibrated cutoff diameters for the NGI when operated
at 140 L/min.

5.3

RESULTS

Mass Balance
The mean total (SD) budesonide recovered from the deposition sites (mass from
inhaler mouthpiece, MT, NMI + NGI) ranged from 222.1±7.6 to 240.5±21.9 mcg showed
no statistical differences (one-way ANOVA, p>0.05) across all testing conditions (Table
5.4). This statement was true even through the combination of small MT and small IP
resulted in greater inhaler retention and reduced delivered dose in all cases. The same
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trend of reducing delivered doses was seen for Salbulin Novolizer (same inhaler, different
drug and formulation) as shown in Figure 3.4.
Table 5.4. Mean budesonide dose (±SD) collected from Budelin Novolizer 200 mcg
inhaler, mouth-throat model (MT), Nephele Mixing Inlet (NMI), Next Generation Impactor
(NGI) alongside the total recovered dose for different testing conditions. Total lung dose,
TLDin vitro, was designated as the drug dose exiting the MT model, or the sum of the drug
mass collected in NMI and NGI. Total recovered drug was calculated as the sum of drug
dose collected from inhaler, MT, NMI and NGI. Data were presented as mean±SD (n=5).
Drug deposition on NMI was <LOQ in most cases (noted as “0.0”).
Experimental Protocol

Inhaler
MT
Small
100
78.0
117.6
MT-IP L/min (17.6) (22.2)
Small
140
74.0
129.6
MT-IP L/min (28.0) (38.2)
Medium 100
21.9
137.9
Fast
(4.1)
(11.7)
Inhalationa MT-IP L/min
Medium 140
23.7
123.6
MT-IP L/min
(4.1)
(7.4)
Large
140
21.6
114.9
MT-IP L/min
(9.8)
(8.0)
Small
100
70.5
131.0
MT-IP L/min (16.3) (14.9)
25.0
152.5
Moderate Medium 100
(9.9)
(13.6)
Inhalationa MT-IP L/min
Large
100
22.2
150.6
MT-IP L/min
(3.4)
(18.7)
Small
100
62.4
162.2
MT-IP L/min (28.1) (35.3)
Medium 100
18.9
174.1
MT-IP L/min
(3.2)
(11.8)
Slow
Medium 140
25.1
172.8
Inhalationa MT-IP L/min
(8.6)
(7.2)
Large
100
20.0
147.5
MT-IP L/min
(4.6)
(6.5)
Large
140
20.3
154.7
MT-IP L/min
(7.1)
(7.2)
a
Newman et al. (2000) training conditions.

Budesonide Dose (mcg)
NMI
NGI
TLD
0.0
36.1
36.1
(0.0)
(5.2)
(5.2)
0.0
31.4
31.4
(0.0)
(8.9)
(8.9)
0.2
75.2
75.5
(0.5)
(6.1)
(5.9)
0.2
74.6
74.8
(0.5)
(4.9)
(4.7)
0.5
89.3
89.8
(0.7)
(9.9)
(10.5)
0.0
32.8
32.8
(0.0)
(7.9)
(7.9)
0.0
54.2
54.2
(0.0)
(7.0)
(7.0)
0.0
67.6
67.6
(0.0)
(8.1)
(8.1)
0.0
12.2
12.2
(0.0)
(2.9)
(2.9)
0.0
42.3
42.3
(0.0)
(6.1)
(6.1)
0.2
37.0
37.2
(0.5)
(2.5)
(2.9)
0.0
66.8
66.8
(0.0)
(1.7)
(1.7)
0.5
56.9
57.4
(0.7)
(4.4)
(4.9)

Total
231.7
(17.7)
235.0
(7.7)
235.3
(7.8)
222.1
(7.6)
226.3
(13.6)
234.3
(7.3)
231.7
(22.4)
240.5
(21.9)
236.7
(10.5)
235.2
(18.5)
235.1
(4.9)
234.4
(9.4)
232.3
(6.2)

Notably, the amount of drug collected in the NMI was <2% of TLDin vitro in all cases,
consistent with the claims for the NMI (N. C. Miller, 1997; N. C. Miller et al., 2000) and
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indicating that the addition of NMI to the NGI (Figure 5.3) had negligible effects on the
data for particle size distributions of TLDin

vitro.

This observation was consistent with

Olsson et al.’s findings (Olsson et al., 2010) and this again shows the advantage of NMI
over the Electronic™ Lung approach (Burnell et al., 1998b) when seeking to couple
realistic IPs with the constant flow conditions required for cascade impaction. The degree
of IP control that proved possible with the apparatus and general method described in
Figure 5.3 and associated text is illustrated in Figure 5.4.
For experiments using the same MT-IP combinations tested at two NGI flow
conditions (fast inhalation: small MT-IP, medium MT-IP; slow inhalation: medium MT-IP,
large MT-IP), the flow rate vs. time profiles, or IPs, measured at the mouth opening of MT
were indistinguishable and completely comparable for a selected inhalation condition,
regardless of the change in NGI flow rates (Figure 5.4). Because aerosol generation and
dispersion from Budelin is flow-dependent (de Boer et al., 2004), when the inhaler is
tested using the same MT-IP combination, the budesonide clouds and drug doses
collected from inhaler, MT, NMI and NGI should be comparable between the 100 and 140
L/min NGI flow conditions within the dosing variations imposed by the product. This
comparability was confirmed by the results from the small and medium MT-IP
combinations tested under fast inhalation conditions (Table 5.4, Row 2–5), and the
medium MT-IP combinations under slow inhalation conditions (Table 5.4, Row 11–12)
that showed no statistically significant differences in mass distribution across the columns
(e.g. for comparable MT-IP combinations). While small but statistically significant
differences (Student’s t-test, assuming equal-variance, p<0.05) were observed for the
collected mass in NGI between 100 and 140 L/min NGI conditions for the large MT-IP
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combination (slow inhalation; Table 5.4, Row 13–14), this was only seen once and the
variation was consistent with those reported for Novolizer (Munzel et al., 2005). It
appeared reasonable to believe that budesonide aerosols, generated from Novolizer
using the same MT-IP combinations, had comparable particle size distributions when
tested in the apparatus shown in Figure 5.3, irrespective of whether the flow rate through
the NGI was 100 or 140 L/min.
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Figure 5.4. Comparison of inhalation profiles recorded at the entrance to MT under the
same MT-IP combinations with NGI flow rates = 100 and 140 L/min, respectively.
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In Vivo – In Vitro Correlations
The method produced values for TLDin vitro (drugs recovered from NMI and NGI)
that were comparable to those described previously following aerosol capture in upper
airway models and filters (Delvadia et al., 2012) in spite of the fact that the method used
to simulate the IPs (Chapter 4 and Figure 5.2) differed slightly from the technique reported
for the Budelin Novolizer inhaler by Delvadia et al. (2012) and the large, fast IP utilized a
value for V = 5.15 L (Table 5.1) in the present study. The results produced the IVIVCs
shown in Figure 5.4 for the percent of the total recovered dose exiting MT, illustrating
once more the importance of variations in mouth-throat geometry and breath profiles for
aerosol drug delivery from Budelin Novolizer. For a selected inhalation condition, the
extremes of lung deposition seen clinically appeared to correlate to the values for TLDin
vitro

seen between the large MT–large IP and small MT–small IP test configurations (Figure

5.5). The in vitro lung doses determined using these test methods ranged from 11.5% to
45.8% for fast inhalation, from 10.1% to 31.0% for moderate inhalation, and from 3.5% to
31.2% for slow inhalation. These values are comparable to those reported by Delvadia et
al. (2012) for the same inhaler where TLDin

vitro

ranged from 9.7% to 40.4% for fast

inhalation, from 8.0% to 28.7% for moderate inhalation, and from 4.8% to 28.0% for slow
inhalation.
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TLD (% Recovered Dose)

50
In Vivo
Large MT-IP
Medium MT-IP
Small MT-IP

40
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20
10
0

Fast

Moderate

Slow

Figure 5.5. Comparison of in vivo and in vitro total lung dose (TLD) as % total recovered
drug dose (inhaler + MT + NMI + NGI) for Budelin Novolizer at fast, moderate and slow
inhalation conditions. Both the in vivo (Newman et al., 2000) and in vitro data were
presented as median (range) (n = 5). TLD values were calculated from the experiments
where NGI was operated at 100 L/min except for the large MT-IP combination tested at
fast inhalation which employed an NGI flow rate of 140 L/min.

Aerodynamic Particle Size Distributions
Deposition of TLDin vitro for budesonide within the NMI and NGI was determined for
each of the MT-IP and NGI flow rate conditions described above (Tables 5.2) in replicate
(n = 5). The mean results are shown in Table 5.5. Cutoff diameters for NGI stages were
first calculated for both 100 and 140 L/min flow conditions using Equation 5.1 with values
for x taken from Table 5.3, and the results are shown in Table 5.6.
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NMI
Small
100
0.0
MT-IP
L/min
(0.0)
Small
140
0.0
MT-IP
L/min
(0.0)
Fast
Medium
100
0.2
a
Inhalation
MT-IP
L/min
(0.5)
Medium
140
0.2
MT-IP
L/min
(0.5)
Large
140
0.5
MT-IP
L/min
(0.7)
Small
100
0.0
MT-IP
L/min
(0.0)
Medium
100
0.0
Moderate
a
MT-IP
L/min
(0.0)
Inhalation
Large
100
0.0
MT-IP
L/min
(0.0)
Small
100
0.0
MT-IP
L/min
(0.0)
Medium
100
0.0
MT-IP
L/min
(0.0)
Slow
Medium
140
0.2
Inhalationa
MT-IP
L/min
(0.5)
Large
100
0.0
MT-IP
L/min
(0.0)
Large
140
0.5
MT-IP
L/min
(0.7)
a
Newman et al. (2000) training conditions.

Experimental Protocol
S1
1.1
(0.1)
2.5
(0.3)
2.0
(0.2)
4.8
(0.3)
5.3
(0.5)
1.2
(0.2)
2.3
(0.1)
3.0
(0.5)
1.1
(0.2)
2.6
(0.4)
4.9
(0.5)
3.4
(0.3)
6.7
(0.6)
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S2
7.0
(0.7)
9.8
(1.9)
12.3
(0.5)
19.5
(1.0)
22.4
(2.7)
7.8
(1.1)
12.7
(1.1)
15.6
(0.9)
4.5
(0.7)
11.7
(1.4)
13.9
(0.7)
15.7
(0.3)
19.2
(1.1)

Budesonide Dose (mcg)
S3
S4
S5
7.5
13.0
6.0
(1.0)
(2.0)
(1.3)
6.6
8.9
3.0
(1.6)
(3.1)
(1.5)
14.1
26.6
15.4
(0.7)
(1.6)
(2.3)
14.2
22.7
10.4
(0.8)
(1.6)
(1.1)
16.7
27.6
13.2
(1.7)
(2.8)
(1.7)
7.4
11.3
4.5
(1.5)
(3.1)
(1.7)
12.0
17.7
7.9
(1.5)
(2.8)
(1.2)
14.3
22.3
10.1
(1.3)
(2.7)
(2.2)
2.8
3.1
0.6
(0.6)
(0.9)
(0.6)
9.5
12.8
4.9
(1.2)
(1.9)
(0.9)
7.1
8.3
2.5
(0.7)
(1.0)
(0.5)
13.8
21.6
9.9
(0.3)
(0.7)
(0.4)
11.0
14.1
4.8
(0.9)
(1.4)
(0.7)
S6
1.3
(0.3)
0.5
(0.5)
4.8
(1.3)
2.9
(0.5)
4.1
(0.9)
0.6
(0.6)
1.7
(0.3)
2.3
(0.8)
0.0
(0.0)
0.8
(0.4)
0.3
(0.4)
2.3
(0.2)
1.2
(0.2)

S7
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)

F
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)

Table 5.5. Mean deposition of budesonide TLDin vitro in micrograms (±SD) in NMI (Nephele Mixing Inlet), S1–S7 and F (NGI
stages 1–7 and filter of NGI) when tested using the “General Procedure” described in Methods. Drug deposition on NMI,
S6 and S7 was <LOQ in most cases (noted as “0.0”).

Table 5.6. Calculated cutoff diameters for NGI stages at 100 and 140 L/min flow rates
calculated from Equation 5.1 and Table 5.3.
Stage

D50, 100L/min

D50, 140L/min

1

6.12

5.10

2

3.42

2.87

3

2.18

1.85

4

1.31

1.11

5

0.72

0.60

6

0.40

0.33

7

0.24

0.19

Re-calibration of NGI’s Stage Cutoff Diameters
For the four selected MT-IP combinations tested at both the 100 and 140 L/min
NGI flow conditions (Fast Inhalation: small MT-IP, medium MT-IP; Slow Inhalation:
medium MT-IP, large MT-IP), data were plotted as the cumulative percent of drug mass
less than the stated cutoff diameter against the calculated stage cutoff diameters ( D50 )
from Table 5.6. While the same size distribution was expected and hoped for in the case
of each selected MT-IP combination at the different NGI flow rates, the profiles shown in
Figure 5.6 showed some discrepancies between the 100 and 140 L/min conditions for all
cases, mostly related to deposition on stages 1 through 3 of NGI. The jets above those
stages are associated with high Reynolds numbers (Re) and increasing airflow turbulence
(Marple et al., 2003b). This suggested that the USP calibration (Equation 5.1) (U.S.
Pharmacopeial Convention, 2013) failed to be applicable when calculating the stage
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cutoff diameters at 140 L/min, necessitating experimental recalibration of the cutoff
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Figure 5.6. Apparent cumulative percent of drug mass under size vs. calculated stage
cutoff diameters (Table 5.6) for budesonide collected in NGI following realistic aerosol
testing in different MT models. Data are presented as mean±SD (n=5) for the four
selected MT-IP combinations tested at the 100 and 140 L/min NGI flowrates.

92

The cumulative percent under size vs. stage cutoff diameter data for the four
selected MT-IP combinations tested at 100 L/min were fitted to the cumulative lognormal
distribution function (Equations 5.3–5.4) and results were shown in Figure 5.7. Values for
coefficients of determinations ( r 2 ) are greater than 0.997 for all cases, suggesting
aerodynamic particle size of aerosols exiting MTs can be well described using the
lognormal distribution model. Best estimation for MMAD ( e MEAN ) and GSD ( e ), and their
95% CIs, were summarized for each MT-IP combination in Table 5.7.

Table 5.7. Mean values and 95% confidence intervals for MEAN ,  , MMAD ( e MEAN ) and
GSD ( e ) estimated from the curves of best fit (Equation 5.3) for the four selected MT-IP
combinations when tested with NGI flow rate = 100 L/min.

MEAN



MMAD ( e MEAN )

GSD ( e )

(95% CI)

(95% CI)

(95% CI)

(95% CI)

0.73

0.60

2.08

1.82

Fast

(0.71-0.75)

(0.57-0.63)

(2.04-2.12)

(1.76-1.87)

Inhalationa

0.63

0.62

1.88

1.86

(0.61-0.65)

(0.59-0.65)

(1.84-1.91)

(1.81-1.92)

0.93

0.62

2.52

1.87

Slow

(0.91-0.95)

(0.59-0.65)

(2.47-2.57)

(1.81-1.92)

Inhalationa

0.82

0.64

2.27

1.90

(0.80-0.84)

(0.62-0.67)

(2.23-2.30)

(1.86-1.95)

Experimental Protocol

Small MT-IP

Medium MT-IP

Medium MT-IP

Large MT-IP
a

Newman et al. (2000) training conditions.

93

100

100
Data
Lognormal CDF

80

Cumulative % Under Size

Cumulative % Under Size

Data
Lognormal CDF

60

40

20

0

0

1

2

3

4

5

Cut-off Diameter (m)

6

80

60

40

20

0

7

(a) Fast Inhalation / Small MT-IP (100L/min)

0

3

4

5

Cut-off Diameter (m)

6

7

100
Data
Lognormal CDF

Data
Lognormal CDF

80

Cumulative % Under Size

Cumulative % Under Size

2

(b) Fast Inhalation / Medium MT-IP (100L/min)

100

60

40

20

0

1

0

1

2

3

4

5

Cut-off Diameter (m)

6

7

(c) Slow Inhalation / Medium MT-IP (100L/min)

80

60

40

20

0

0

1

2

3

4

5

Cut-off Diameter (m)

6

7

(d) Slow Inhalation / Large MT-IP (100L/min)

Figure 5.7. Cumulative percent of drug mass undersize vs. stage cutoff diameters for
drugs collected in NGI following realistic testing. Data are presented as mean±SD (n=5)
for the four selected MT-IP combinations tested at 100 L/min. Red circles are individual
data points, while the black profiles are results of curve fitting to the cumulative lognormal
distribution function (Equation 5.3). Coefficients of determination ( r 2 ) were > 0.997 in all
cases.
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The curves in Figure 5.7 were generated according to Equation 5.3, to describe
each budesonide APSD when characterized in NGI at 100 L/min. Calculated cutoff
diameters ( D50 ) for stages 1–5 when NGI was recalibrated at 140 L/min are shown as the
mean and standard deviations for the four selected MT-IP combinations in Table 5.8.
Cutoff diameters for stages 6-7 are not listed as drug deposition on those stages could
not be detected (washings resulted in budesonide mass < LOQ). The mean values for
each stage were assigned as the re-calibrated D50 values at 140 L/min, and the results
were compared with the USP calibrated cutoff diameter (U.S. Pharmacopeial Convention,
2013) in Table 5.9.

Table 5.8. Re-calibrated NGI stage cutoff diameters ( D50 ) at 140 L/min for selected MTIP combinations. Data are presented as mean±SD (n=5). Drug deposition on stages 6
and 7 was <LOQ in all cases.
Small MT-IP

Medium MT-IP

Medium MT-IP

Large MT-IP

(Fast)a

(Fast)a

(Slow)a

(Slow)a

1

4.81 (0.30)

4.82 (0.13)

5.08 (0.34)

4.86 (0.03)

2

2.42 (0.18)

2.48 (0.05)

2.49 (0.14)

2.44 (0.06)

3

1.75 (0.16)

1.83 (0.04)

1.82 (0.10)

1.77 (0.05)

4

0.98 (0.13)

1.06 (0.03)

1.02 (0.07)

1.01 (0.03)

5

0.63 (0.02)

0.63 (0.02)

0.68 (0.01)

0.60 (0.02)

6

NA

NA

NA

NA

7

NA

NA

NA

NA

Stage #

a

Newman et al. (2000) training conditions.
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Table 5.9. Comparison of NGI’s extrapolated USP calibration (U.S. Pharmacopeial
Convention, 2013) or cutoff diameters ( D50 ) at 140 L/min (assuming that Equation 5.1
and Table 5.8 are valid) with the overall means for D50 after recalibration (from Table 5.8).
USP D50 (µm)

Mean D50 (µm)

Experimental D50

(Theoretical; 140 L/min)

(Experimental; 140 L/min)

/Theoretical D50

1

5.10

4.89

0.96

2

2.87

2.46

0.86

3

1.85

1.79

0.97

4

1.11

1.02

0.92

5

0.60

0.63

1.05

6

0.33

NA

NA

7

0.19

NA

NA

Stage #

Aerodynamic Particle Size Distributions of Budelin’s TLDin vitro
Aerodynamic particle size distributions of TLDin vitro, designated as drugs exiting
the MT model following aerosol generation under realistic inhalation condition, were
analyzed for all the MT-IP combinations shown in Table 5.2. The mean cumulative
percent of budesonide depositing below D50 for each stage was calculated and plotted
against the cutoff diameters using the archival USP calibration (U.S. Pharmacopeial
Convention, 2013) when NGI flow = 100 L/min. In one case however, the high-flow IP
protocol (large IP, fast inhalation) where NGI flow = 140 L/min, recalibrated cutoff
diameters determined in the present study were applied (Table 5.9). No curve fitting was
used to generate the results shown in Figure 5.8 for all three inhalation conditions. Values
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for MMAD were calculated using linear interpolation for each MT-IP combination and data
were summarized in Table 5.10. Perhaps the most important observation for Budelin’s
budesonide aerosols was the variation seen in particle size distribution resulting from the
different MT-IP combinations, where the apparent MMADs ranged from 1.79 to 3.26 µm
across all test conditions (Table 5.10). The results suggested that in addition to total lung
dose, the size distribution for drugs likely to enter the trachea also depends on the
combined effects of each subjects’ MT geometry and inhalation profile. For Budelin, these
effects were most pronounced for the slow inhalation condition (Figure 5.8) described
clinically by Newman et al. (2000), where the mean values for MMAD varied from 2.17 to
3.26 µm. For all three inhalation conditions, the large MT-IP combination invariably
produced the smallest MMAD and the largest TLDin vitro, indicating that the best powder
emptying and the best dispersion from Budelin occurred under large IP conditions. The
amount of drug depositing on stage 1 was less than 10% of the total NGI dose in all cases,
illustrating the high collection efficiency of the MT; MT appears to reduce the possible
variations in APSDs significantly. There was also a lack of visually observable lactose
deposition in the NGI, suggesting that at least the large lactose particles in the formulation
were also captured by the coated MT models.
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Figure 5.8. Cumulative percent of drug mass undersize vs. stage cutoff diameters for
budesonide collected in NGI following realistic testing of Budelin Novolizer in the
Apparatus shown in Figure 5.3. Data are presented as mean±SD (n=5) for (a) fast, (b)
moderate and (c) slow inhalation conditions. NGI stage cutoff diameters were assigned
according to USP (U.S. Pharmacopeial Convention, 2013) except for the high-flow IP
protocol (large MT-IP, fast inhalation), where the NGI flow rate = 140 L/min and the recalibrated cutoff diameters shown in Table 5.9 were used to process the data.
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Table 5.10. Mass median aerodynamic diameter (MMAD) for different MT-IP
combinations. Data were presented as mean±SD (n = 5).
MMAD (µm)
Small MT-IP

Medium MT-IP

Large MT-IP

Fast Inhalation

2.03±0.05

1.88±0.06

1.79±0.03*

Moderate Inhalation

2.28±0.23

2.19±0.04

2.17±0.09

Slow Inhalation

3.26±0.27

2.54±0.09

2.17±0.03

*Calculated using cutoff diameters from Table 5.9.

5.4

DISCUSSION
The mixing inlet–cascade impactor system (Figure 5.3) allowed the aerodynamic

particle size distributions of budesonide powder aerosols exiting MT models to be
measured following testing of the DPI, Budelin Novolizer, according to realistic but
different MT-IP conditions of use. A pre-requisite of the system was that the cascade
impactor flow rate exceed the peak inhalation flow rate (PIFR) of the targeted breath
profile; this to allow successful breath simulation through the inhaler and the MT model.
Our previous clinical study (Chapter 4) showed that PIFR through an inhaler was
dependent on the inhaler’s airflow resistance, and that PIFR may well exceed 100 L/min,
the present upper limit of NGI’s calibration. Although the results described in Chapter 4
were for healthy adults only, studies performed on asthma or COPD patients also show
that PIFR values often exceed 100 L/min when inhaling through a powder inhaler (Azouz
et al., 2015a; Azouz et al., 2015b; Virchow et al., 2014). Therefore, to allow a complete
range of DPIs to be tested realistically, using the mixing inlet–cascade impactor system
shown in Figure 5.3, impactors like NGI must be modified and, if necessary recalibrated
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to allow their use under high flow rate conditions. While complete recalibration using
monodisperse, nonvolatile aerosols may be desirable (Marple et al., 2003a; Marple et al.,
2004), for practical purposes, polydisperse pharmaceutical aerosols may also be used to
estimate stage cutoff diameters outside the existing compendial specification range. This
approach was shown to be successful previously (Kotian et al., 2009) and it also worked
well in the present study. The largest difference between recalibrated cutoff diameters
and USP calibrations (U.S. Pharmacopeial Convention, 2013) were seen for stage 2 (2.46
µm vs. 2.87 µm; Table 5.7) where the magnitude of the error was the main source of the
discrepancies seen in APSD profiles between the 100 and 140 L/min NGI flow condition
for all selected MT-IP combinations (Figure 5.6). This may have been caused by the nonideal behavior of aerosols in NGI at high flow rates, where Re for stage 2 exceeds the
generally desirable range of 500–3000 for impactor design (Marple et al., 2003b)
(Calculated Re for stage 2 at 140 L/min= 6696).
What should also be noted is that the DPI, Budelin Novolizer, as used in the
present study, is a medium-resistance inhaler [airflow resistance = 0.0241 kPa0.5.L-1.min;
(Delvadia, 2012)]. Other DPIs with lower resistances (e.g. Aerolizer®), can enable
subjects to achieve a much higher PIFR when inhaling forcefully through the device
(Chapter 2). As even higher flow rates (>140 L/min) may be required to enable realistic
testing of low-resistance inhalers, a complete redesign of cascade impactors or some of
their stages may be needed to ensure correct measurement of particle size distribution
at high flow conditions using the setup described in Figure 5.3.
The present study successfully coupled realistic in vitro testing (Chapter 3) with
compendial cascade impactor methods (U.S. Pharmacopeial Convention, 2013). IPs
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generated by breath simulation were re-producible at the mouth entrance of MT when air
flow in the impactor is properly balanced with compressed air (Figure 5.4). Realistic MT
models, when coated properly, proved to be highly efficient “preseparators” that captured
large particles, thus eliminating the need to use an artificial preseparator before feeding
an aerosol into the cascade impactor. The approach described here is different from that
used elsewhere (Chrystyn et al., 2015; Goodey et al., 2014; Nadarassan et al., 2010;
Yakubu et al., 2013), and standardization of the methods may be needed to facilitate
application of realistic in vitro testing for inhaled drug products. Although other flowbalancing devices, for example the Electronic Lung™ (Brindley et al., 1994; Burnell et al.,
1998b; Tarsin et al., 2006), may also be used to couple breath simulation with the
constant flow needed for cascade impaction, yet the NMI was shown to minimize drug
losses from the aerosol cloud once formed (N. C. Miller, 1997; N. C. Miller et al., 2000)
by allowing sheath air flow to be generated and introduced around the central aerosol
cyclone to “protect” drug aerosols from interior device collisions and minimize wall losses
(<1% total recovered dose was lost in NMI across all experiments reported in this chapter).
An important observation in this study and the previously publications (Delvadia et
al., 2012; Olsson et al., 2013) is that the large inter-subject variations in total lung dose
seen in the gamma scintigraphy study for Budelin Novolizer (Newman et al., 2000) are
most likely predictable (Figure 5.5) by using realistic in vitro testing that incorporates
variations in human oropharyngeal geometry and the inhalation maneuver. The
compendial cascade impactor method however, produced much smaller variations in fine
particle fraction, FPF (designated as the percentage of particles likely to penetrate the
lung, d<5 µm), with standard deviation <5% of label claim when Budelin was tested at the
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flow rate equivalent to 4 kPa pressure drop (de Boer et al., 2004). Thus, the compendial
test method fails to characterize the clinical variations in dose and aerosol delivery from
powder inhalers like Budelin. Although FDA suggest that powder inhalers should be
tested at “three flow rates [around the] reference labeled flow rate, and ±50% of the
labeled flow rate” for the in vitro bioequivalent study (Saluja et al., 2014), in practice DPIs
are usually tested at 30, 60 and 90 L/min during product development (Harris, 2015). This
appears to be a gross oversimplification of the real situation as humans do not inhale at
constant flow, and the three suggested flow rates cannot really represent the flow range
that subjects were shown to produce in Chapter 4.
Variations in regional drug distribution in the lung, usually described as P/C ratio
[drug deposition in peripheral lung (P) to central lung (C) ratio] in the gamma scintigraphy
study, were also reported for Budelin (Newman et al., 2000). We showed in the present
study that the combination of different MT models and realistic IPs produced variable size
distributions for drugs exiting MT models, and the effects were most pronounced for the
slow inhalation condition (Figure 5.8). The results were consistent with the “critical
condition” reported for Budelin (de Boer et al., 2004), where the particle size distribution
was seen to change significantly when the inhaled flow rate dropped below a certain
threshold. This may partly explain the variations seen in the P/C ratios reported by
(Newman et al., 2000). However, particle size distribution is not the only factor affecting
aerosol deposition in the lung, many other factors like airway geometry and human
inhalation maneuvers are also critical in determining the final destination of inhaled drug
particles (De Backer et al., 2010; Farr et al., 1995; Newman et al., 1989). A better
understanding of aerosol deposition in the airways, and the need to build IVIVCs for
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regional drug distribution in the lung, require further studies using approaches like
mathematical modeling [e.g. ICRP model (International Commission on Radiological
Protection (ICRP), 1994)] or Computational Fluid Dynamic (CFD) simulations (Longest &
Holbrook, 2012), as such measurement is beyond the present state-of-the-art for in vitro
testing. A pilot study where realistic in vitro testing has been coupled with the modeling
approach shown in this chapter will be described in Chapter 6.
Demonstrating bioequivalence for locally acting drugs is always a challenge due
to the difficulty in proving equivalent [drug delivery] at the “site of action” ("Code of Federal
Regulations," 2015). For powder inhalers, FDA suggests in vitro bioequivalence be
demonstrated between inhalers for single actuation content and aerodynamic particle size
distribution (Saluja et al., 2014). While such approaches may be adequate to control batch
to batch quality, the difficulty in correlating the in vitro (e.g. fine particle dose) and in vivo
(e.g. drug dose penetrating the lung) data (Newman & Chan, 2008) make it challenging
to predict clinical performance for the test product. The present work and previous
publication (Delvadia et al., 2012) clearly show that IVIVCs can be achieved for total lung
dose, and more importantly, for clinical variations seen in dosing. We believe that if such
IVIVCs (mean and variations) can be demonstrated and validated in vitro, that in vitro
predicted lung dose may be considered to be a surrogate for some in vivo bioequivalence
studies. The approach may at least prove useful for drug developers to evaluate how a
change in device design or formulation may affect in vivo lung dose, especially for drugs
with low therapeutic windows. Although we have yet to demonstrate IVIVCs for regional
drug distribution in the lung, the methods reported in this study, when used to determine
the variations in particle size distribution for drugs entering the lung should provide a
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foundation for future studies when assessing the relationships between particle size
distributions, drug deposition in airways and the clinical effects produced by inhalers.

5.5

CONCLUSION
A new method was developed and evaluated to enable the prediction of variations

in APSDs of TLDin vitro from Budelin Novolizer 200 mcg. This powder inhaler, that doses
reproducibly when subjected to USP testing (de Boer et al., 2004; Delvadia et al., 2012),
showed significant variations in lung dose in vivo due probably to variations in
oropharyngeal (MT) geometry and the way that subjects inhaled. When realistic in vitro
tests were conducted, IVIVCs revealed and confirmed the importance of MT geometry
and IP variations. Coupling these realistic tests with cascade impactor methods to
evaluate the APSDs exiting the MT models from Budelin Novolizer 200 mcg, showed that
these methods were sufficiently precise to distinguish between the different aerosol doses
and aerosol sizes likely to enter the trachea. There is no reason to believe that the same
techniques used to study Budelin in this chapter cannot be extended to review the data
for other powder inhalers that are also used clinically by patients with variable MT
geometry and breathing patterns. The clinical importance of these observations requires
further evaluation.
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CHAPTER 6
EVALUATING COMPUTATIONAL FLUID DYNAMIC (CFD) SIMULATIONS OF
REGIONAL DRUG DEPOSITION FROM BUDELIN® NOVOLIZER® IN
COMBINATION WITH REALISTIC IN VITRO TESTING TECHNIQUES

6.1

INTRODUCTION
The in vitro test methods described in Chapters 3–5 clearly enable drug

development scientists to estimate the likely ranges of total lung dose (TLD) and the
aerodynamic particle size distributions (APSDs) of those doses entering the trachea from
DPIs like Budelin® Novolizer®. Even though an extensive primary and secondary
literature exists that purports to relate regional deposition of aerosols to their APSDs in
humans (International Commission on Radiological Protection (ICRP), 1994; Rostami,
2009; Stahlhofen et al., 1989), and several groups have converted such deposition
models into computer programs that in certain cases (W.H. Finlay, 2013), account for
inhaler effects on mouth-throat (MT) deposition for a DPI, neither models nor programs
can presently be used to predict regional drug deposition from powder inhalers. In part
this is because the methods used to determine APSDs for powder inhalers fail to account
for oropharyngeal geometry and variations in breath profiles; topics that have been
examined and for Budelin Novolizer at least, addressed in the earlier chapters of this
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thesis. Even given the data for Budelin’s APSD from Chapter 5 however, existing
deposition models fail to enable the prediction of regional lung deposition during a typical
powder inhalation profile (IP). It follows therefore, that the detailed regional drug
deposition in the lung from Budelin remains unknown in the sense that its dependence
on aerosol characteristics and breathing maneuvers cannot readily be determined.
Product development scientists can only make guesses about regional drug deposition
using clinical studies such as those reported by Newman et al. (2000). Fortunately
however, new CFD programs have recently been described by Longest et al. and Tian et
al. who reported that by using lung models consisting of realistic geometries of the VCU
mouth-throat (MT) model coupled to an airway model up to generation 15 (terminal
bronchioles) it was possible to facilitate the prediction of regional drug deposition from
DPIs (Longest et al., 2012a; Longest et al., 2012b; Tian et al., 2015a; Tian et al., 2011).
Very recently, the CFD modeling technique from those authors was used with the APSD
data determined and reported in this chapter to predict regional drug deposition for
Budelin Novolizer in both the MT and lung regions (Tian et al., 2015a). Because of the
importance of that work to this thesis (Tian et al., 2015a), the paper is reproduced in full
in Appendix III. The authors showed that their CFD predictions were consistent with the
regional deposition results reported by Newman et al. following a clinical gamma
scintigraphy study in which the subjects were instructed to target a 99 L/min peak
inhalation flow rate (PIFR) [referred to as fast inhalation in this chapter; (Newman et al.,
2000)] based on a selection of CFD model regions that were reported to be consistent
with the imaging study. In this chapter, the CFD model and programming methods
described by Tian and co-workers (Tian et al., 2015a) was applied with modifications and
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evaluated for its ability to predict Budelin’s regional deposition and the possible variations
in the results given different initial conditions for aerosol entry into the trachea in the form
of values for TLDin vitro and APSDs of TLDin vitro coupled to their corresponding breathing
maneuvers or IPs. This “hybrid method” eliminates the need to model deposition in the
MT geometry, and thus simplifies some of the more complex aspects of the CFD predictions.
The semi-empirical results for Budelin were compared with the theoretical values reported
earlier (Tian et al., 2015a) and the clinical assessments (Newman et al., 2000).
The motivation behind this study was to combine the new more realistic in vitro
methods of predicting MT loss and TLD determinations developed in this dissertation
together with CFD predictions of regional lung deposition to provide a more complete
picture of dose distribution through the lungs. In this approach, the relative strengths of
the in vitro and CFD methods could possibly be maximized while minimizing the
weaknesses. The previous study of Tian et al. (2015a) demonstrated whole-airway CFD
predictions of the aerosolized dose from a DPI with good agreement to in vivo data.
Previous studies have also demonstrated good agreement between CFD predictions of
MT depositional loss and in vitro predictions in identical geometries across a range of
inhalers (Delvadia et al., 2013b; Longest & Hindle, 2009; Longest et al., 2012a; Longest
et al., 2012b; Tian et al., 2011). Perhaps the most complex region of the whole-lung CFD
calculation of inhaler dose is the MT geometry due to the presence of highly turbulent
flow and the need to include transient flow effects (Tian et al., 2011). Furthermore, there
are a number of difficult-to-define variables for inhaler aerosol simulations in the MT
geometry, such as the exact emptying time course of a DPI for a given inhalation profile.
In contrast, the in vitro techniques developed in this dissertation can directly predict MT
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depositional loss and the particle size distribution entering the lungs on a realistic basis.
This study explores a method in which in vitro experiments are used to predict the MT
deposition fraction and APSD entering the lungs, and CFD simulations are then
implemented to investigate regional lung deposition of that TLD. By removing the MT,
the CFD simulations are significantly simplified. This reduction in complexity may enable
the method to be more widely applied by scientists who do not specialize in CFD
simulations. However, it is known that complex airflow currents and turbulence arising
from the presence of the inhaler and the MT geometry, including the larynx, can influence
flow patterns and particle deposition in the conducting airways, potentially down to the
6th generation (Xi et al., 2008). The extent to which removal of the MT influences regional
lung deposition predictions compared with previous CFD simulations (Tian et al., 2015a)
and in vivo data (Newman et al., 2000) for a DPI aerosol is not known. This study explores
this newly proposed hybrid in vitro-CFD method with the aim of showing it to be a
reasonably accurate new technique for predicting regional lung deposition of
pharmaceutical aerosols. As demonstrated in previous studies, these new regional
predictions of lung dose may possibly reveal important findings not available from current
in vitro and imaging methods, such as the aerosol deposition fraction in the terminal
bronchioles that are often involved with airway functional changes observed with asthma
and COPD.
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6.2

MATERIALS AND METHODS

Initial Particle Size Measurements
The APSDs from Budelin® Novolizer® 200 mcg (Meda Pharmaceuticals, Bishops
Stortford, U.K.) were characterized using cascade impaction in three different ways: (a)
a constant flow rate of 80 L/min (equivalent to a 4 kPa pressure drop across the device)
was applied for 3 seconds; this method was used here to provide results for use in Tian
et al.’s initial conditions for Budelin (Tian et al., 2015a); (b) a realistic breath profile or IP
without an MT model or induction port was employed by linking the inhaler to the NGI via
the Nephele Mixing Inlet (NMI; Model III; RDDonline, Richmond, VA); (c) three realistic
breath profiles or IPs were used in the presence of the VCU medium MT model as
described in Chapter 5. Experimental setups for the three different testing conditions are
shown in Figure 6.1.
Methods (a) and (b) were designed to directly measure the APSDs for drugs
emitted from the Budelin inhaler. Method (a) provided the initial conditions for use by Tian
et al. (2015a) who used the results for APSD to define the particle sizes of the
polydisperse aerosols entering the MT geometry of their CFD model. Method (a) was a
slight modification of the compendial approach (U.S. Pharmacopeial Convention, 2013),
where Budelin was connected directly to the pre-separator in the absence of a USP
induction port. An in-house manufactured adapter (Ten-to-One silicone rubber, MicroMark, Berkeley Heights, NJ) was placed between the inhaler and preseparator to ensure
airtightness of the system. The whole setup was flipped 90 degrees [i.e. preseparator
placed horizontally and next generation impactor (NGI) vertically] to ensure correct inhaler
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orientation. APSD was tested at 80 L/min to produce the 4 kPa pressure drop across the
inhaler, following procedures described in USP (U.S. Pharmacopeial Convention, 2013).
Method (b) added the NMI and dilution air supply between the inhaler and the NGI
preseparator to enable the inhaler to be tested using a realistic IP. The primary purpose
of the experiment was to determine the influence of the IP on this drug’s APSD from
Budelin, given that compendial test conditions [Method (a)] do not employ a transient
(variable) flow rate. The setup was kept similar to Method (a), but the NMI was placed
between inhaler and preseparator, with its side port connected to the breath simulator
(ASL 5000-XL, IngMar Medical, Pittsburgh, PA) and dilution air supplied at 100 L/min.
Method (c) was designed to measure the size distribution for drug aerosols exiting the
MT model (TLDin vitro), as described in Chapter 5. Methods (b) and (c) characterized the
APSDs using realistic inhalation profiles for inhaler testing as described in Chapter 5. A
schematic and the procedure for Method (c) was the same as that shown in Figure 5.3
and associated text. The three medium IPs described in Table 5.1 and shown in Figure
5.2 (orange curves; Chapter 5) were used for Method (c). These IPs are also shown in
Figure 6.2 and they were simulated to represent the average inhalation maneuvers used
by the human subjects under three different instruction protocols in the gamma
scintigraphy study for Budelin (Newman et al., 2000). Only the medium IP for fast
inhalation was used for Method (b) while the flow rate through NGI was maintained at 100
L/min for both Methods (b) and (c).

110

Next Generation Impactor

Preseparator

(a) Constant Flow Condition (80 L/min)

Preseparator
Next Generation Impactor
Mixing Inlet

(b) Realistic IP without MT Model
Mouth-Throat Model
Next Generation Impactor

Mixing Inlet

(c) Realistic IP with MT Model
Figure 6.1. Experimental setup for measurement of aerodynamic particle size
distributions (APSD) of drug aerosols delivered from Budelin® Novolizer® 200 mcg. (a)
Constant flow condition (80 L/min); (b) realistic IP without MT model; (c) realistic IP with
MT model. The latter is identical to the apparatus and procedures described in Chapter
5.2.
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Figure 6.2. Inhalation profiles (IPs) simulated to mimic the average inhalation maneuvers
used by subjects under three different instructions in the gamma scintigraphy study for
Budelin (Newman et al., 2000). These medium IPs are identical to those described in
Table 5.1 and shown in Figure 5.2 (Chapter 5). All three IPs were used for Method (c),
while only the medium IP for fast inhalation (the blue curve) was used for Method (b).
Experimental setups for methods (b) and (c) are shown in Figure 6.1.

Prior to all experiments, internal surfaces of the MT model, preseparator stage,
and NGI plates were coated twice with Molykote® 316 silicone release spray (Dow
Corning, Midland, MI) to avoid particle reentrainment after impaction. Single doses were
collected in each experiment and five replicates performed for each protocol; budesonide
deposition on inhaler, MT, NMI, preseparator, NGI plates and filter were collected using
known volumes of 70%/30%:methanol/water (v/v), budesonide concentrations were
determined using high-performance liquid chromatography (HPLC). The assay was
performed using a Symmetry® C18 column (3.5µm, 4.6×100mm) and an HPLC system
(Model 2996 Photodiode Array Detector, 1515 Isocratic HPLC Pump and 717 plus
Autosampler; Waters Milford, MA) with 69% methanol / 31% 0.1% (v/v) acetic acid buffer
(v/v) as mobile phase (flow rate: 1.0 mL/min), and UV detection at 280 nm. Injection
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volume was 100 µL and calibration curves were linear in the range of 0.2–10.0 mcg/mL
(r2>0.999). Statistical analyses were performed using one-way ANOVA and Student’s ttest at a significance level of 0.05 in JMP Pro 11 (SAS Institute Inc., Cary, NC).

CFD Simulation
The original airway model and CFD methods, designed for simulating particle
motion in the human respiratory tract after aerosol release from a powder inhaler, were
reported by Tian et al. (2015a). Briefly, the model consisted of a complete upper airway
geometry from MT to the third airway bifurcation (B3) followed by a stochastic individual
path (SIP) model from B4 to B15 of the left lower lobe (Figure 6.3a) with aerosol
introduction into the model simulated via an 0.6 cm diameter jet, as produced by the
Budelin Novolizer mouthpiece. To facilitate CFD simulation and prediction of budesonide
deposition from Budelin, the model was divided into four parts: MT, B1 to B3, B4 to B7,
and B8 to B15; particles penetrating beyond B15 (terminal bronchioles) were shown
based on calculations with deposition correlations to fully deposit in the alveolar airways.
Airflow appeared to be turbulent in the MT and B1 to B3 regions for the Novolizer, while
it transitioned to laminar flow in B4 to B15. In regions where turbulent flow was expected,
a low-Reynolds number (LRN) k–ω model was applied to characterize the airflow (Tian
et al., 2015a) (e.g. in MT through B3), where realistic, transient IPs were employed. In the
lower airways, steady-state flow simulations were used with average flow = V/T (ratio of
inhaled volume, V, to total inhalation time, T) condition was applied from B4 to B15.
Polydisperse aerosols consisting of nine types of spherical, monodisperse particles with
aerodynamic diameters equivalent to the midpoint of NGI’s stage cutoff diameters (D50)
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at 80 L/min flow condition (preseparator, stages 1-7, and filter), were used to represent
the budesonide particles delivered from Budelin Novolizer. The method then tracked
particles in the airflows after their “injection” as polydisperse aerosols into the mouth inlet
over a prescribed quick-and-deep (QD) inhalation profile lasting for 2.96 s. Particles were
released during the first 0 - 0.5 s of this inhalation profile, to simulate transient emptying
of the inhaler. During the simulation period, particle contact with the wall surface resulted
in particle "deposition", and the wall contact location was recorded. Particle deposition
data simulated in this way were then compared with the in vivo gamma scintigraphy data
for Budelin (Newman et al., 2000) (Appendix I) by dividing the airway model into central
(B1 to B7) and intermediate–peripheral (B8 to alveolar) regions (Tian et al., 2015a).
The same CFD method, described briefly here and in detail previously (Tian et al.,
2015a) was also used in this chapter to track budesonide particles from Budelin Novolizer
after their “injection” into the trachea as realistic APSDs known to exit MT, following
testing according to Chapter 5. Three replicates were performed for each two-day
simulation in this chapter. To couple the CFD simulation with the realistic in vitro test
methods described in Chapter 5, where APSDs were measured at the exit of MT model,
the original airway model and CFD methods (Tian et al., 2015a) were modified in the
following ways:

Airway Model
MT and its geometry was removed from the original airway model (Tian et al.,
2015a) to allow CFD simulation starting from the trachea (Figure 6.3b). Theoretical
“particle injection” began in this study at the trachea after which, CFD modeling used the
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programming methods of Tian et al. (2015a). Particles were released into the trachea
using a blunt spatial distribution pattern with a wall offset distance of 0.01 mm.

MT

Trachea to B3

Trachea to B3

B4 to B15

B4 to B15
(a) Original Model (Tian et al., 2015a)

(b) Modified Model (This Study)

Figure 6.3. Airway model (a) used for CFD simulations in Tian et al. (2015a), which began
at the entry to MT via an 0.6 cm jet to represent the inhaler outlet. Simulations in this
chapter used the modified model (b) and size distributions of TLDin vitro. Both models
include a complete geometry of the airways from trachea to B3, and a stochastic individual
path (SIP) model from B4 to B15 of the left lower lobe; in those respects, the model
geometries were identical.

Flow Conditions
The quick-and-deep inhalation profile employed by Tian et al. (2015a) and applied
in the trachea to B3 region of that study was refined and replaced by the IPs used to
mimic the average inhalation maneuvers of the subject groups trained by Newman et al.
(2000) (Figure 6.2) as advocated in Chapter 4 of this thesis. Accordingly, the steady-state
(constant) airflow rate applied from B4 to B15 region by Tian et al. (2015a) (60.8 L/min;
defined as V/T) was replaced by 63.0 L/min, 41.4 L/min, and 34.4 L/min corresponding to
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the average flow rates in the IPs for the fast, moderate, and slow inhalation conditions,
respectively (V/T; Figure 6.2) consistent with the values for V reported by Newman et al.
(2000).

Polydisperse Particles for Injection
The nine diameters of differently sized particles used in the simulations of Tian et
al. (2015a) were replaced by eight monodisperse particle diameters with aerodynamic
diameters equivalent to the midpoint of the upper and lower cutoff diameters of NGI’s
stages at the 100 L/min flow condition (Table 6.1). In the absence of the preseparator
[Method (c)], an upper size limit for particles depositing on stage 1 of the NGI had to be
assumed; a value of 10 µm was assigned based on the D50 value for the NGI preseparator
at 100 L/min. These particles sizes (Table 6.1) were used to represent the polydisperse
assembly of drug particles entering the trachea during an IP. 4,000 particles were used
from each of eight size bins (32,000 particles in total) and “injected" into the trachea inlet
over a period of 0–1.0 seconds at an initial velocity = V/(T*A), where V/T was equivalent
to the average volumetric flow rate of the test IP and A is the cross sectional area of the
tracheal opening. While Tian et al. (2015a) used 0–0.5 seconds for the particle injection
period, this was extended in the present study because the “Air Classifier Technology”
used by Novolizer was reported to prolong the inhaler’s powder dispersion and delivery
time (de Boer et al., 2006).
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Table 6.1. NGI’s stage cutoff diameters (D50) for the 100 L/min flow condition and the
corresponding aerodynamic diameters used to simulate the polydisperse aerosol
particles for “injection” at the tracheal inlet for CFD simulation in this study.

a
b

In Vitro Particle Size Characterization

Polydisperse Particles for

(NGI at 100 L/min)

CFD Simulation

D50a

Size Range

Midpoint

Aerodynamic diameter

(µm)

(µm)

(µm)

(µm)

Stage 1

6.12

6.12-10.00b

8.06

8.06

Stage 2

3.42

3.42-6.12

4.77

4.77

Stage 3

2.18

2.18-3.42

2.80

2.80

Stage 4

1.31

1.31-2.18

1.75

1.75

Stage 5

0.72

0.72-1.31

1.02

1.02

Stage 6

0.40

0.40-0.72

0.56

0.56

Stage 7

0.24

0.24-0.40

0.32

0.32

Filter

0.00

0.00-0.24

0.12

0.12

Calculated using USP calibration method (U.S. Pharmacopeial Convention, 2013)
The upper bound was given by the D50 value for the preseparator at 100 L/min

Analysis of Aerosol Deposition Data
Particle counts depositing (e.g intersecting with the airway walls) in each of the
regions [MT (Tian et al., 2015a), trachea to B3, B4 to B7, B8 to B15, and beyond B15
(alveolar)] were generated using the CFD program and the techniques were described in
detail by Tian et al. (2015a). Particle counts in each bifurcation were converted to mass
fraction [defined as deposition fraction (DF) by Tian et al. (2015a)] of the injected “dose”
by assuming that particle density and shape were size-independent and mass was
117

directly proportional to volume and diameter3. For example, the deposition fraction of
particles in the trachea was given by:
DFtrachea 

 m   N  CF 
 m   4000  CF 
j

j

j

j

Equation 6.1

j

Where m j is mass of a single particle of budesonide from size bin j and N j is the
number count of the corresponding particles trapped by the trachea. Because an equal
number of particles (4,000) were injected from each of the eight size bins, a conversion
factor ( CFj ) was used to scale the number of particles in the actual APSD that should
theoretically be injected; its value was given by:

M j mj

CFj

M


mj

j

 32000

4000

Equation 6.2

Where M j is mass fraction of budesonide with respect to the total mass of budesonide
in the impactor that deposited at the corresponding NGI stage. Assuming particles were
spherical, m j was given by:
1
m j     d j3
6

Equation 6.3

Where  is particle density. Geometric diameter, d j , was calculated from the
aerodynamic diameter ( d aej ) for the corresponding particle (Table 6.1) from:

dj 

d aej



Equation 6.4

All airway generations were treated similarly and values for regional drug deposition in
each airway segment calculated in the same way as described by Tian et al. (2015a).
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6.3

RESULTS AND DISCUSSION

Effects of Initial Conditions in the Original CFD Model (Tian et al., 2015a)
The CFD model developed by Tian et al. (2015a) allows particle motion and
deposition in the human respiratory tract following aerosol release from a DPI to be
simulated based on principles of fluid mechanics and known particle deposition
mechanisms (inertial impaction, gravitational sedimentation, and Brownian diffusion).
Simulations and particle tracking for Budelin Novolizer in Tian et al. (2015a) include the
jet at the inhaler mouthpiece (and retention in the inhaler) in addition to the deposition
analysis for polydisperse particles injected into the mouth inlet of the MT and the airway
model (Figure 6.3a). Table 6.2 shows an expanded form of Tian’s Table III (Tian et al.,
2015a) that enables the CFD results from the two different approaches to be compared
with the average in vivo results from Newman et al. (2000). Stated most simply, the results
shown in the right hand column of Table 6.2 (based on realistic testing of Budelin
according to the medium simulated IP and an APSD for TLDin vitro (as the initial condition
for drug entry to the trachea), showed that Tian et al.’s slight underestimation (relative
percent difference between in vivo and CFD: 2.7%) of Budelin’s central lung deposition
(Tian et al., 2015a) was further increased (new relative percent difference: 4.8%) by the
approach described in this chapter in favor of intermediate and peripheral deposition.
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Table 6.2. Deposition fractions (percent of aerosolized dosea) based on CFD predictions
compared with the mean in vivo data for Budelin Novolizer (Newman et al., 2000)
operated with a “QD waveform and PIFR of 99 L/min” as defined by Tian et al. (2015a) to
mimic Newman’s mean PIFR (99 L/min) and V (3.13 L) for normal human subjects trained
in fast inhalation. The QD waveform of Tian et al. (2015a) was replaced in the present
study with the breath-simulated curve shown in blue in Figure 6.2; size distributions for
TLDin vitro were determined exiting the VCU medium MT model using the same IP.
Regional drug deposition data for the in vitro–CFD method are presented as mean (SD),
n = 3.
In Vivo

CFD

In Vitro–CFD

(Newman et al.)b

(Tian et al.)

(This Chapter)

MP+MT

64.9

67.0

64.6

Central Lungc (Trachea Excluded)d

12.1

9.0

6.9 (0.2)

Intermediate and Peripheral Lunge

22.1

22.1

28.5 (0.2)

Trachea–B3 (Trachea Included)

2.7f

1.3 (0.1)f

B4–B7

8.2

5.6 (0.2)

B8–B15

1.8

2.3 (0.3)

Alveolar

20.3

26.2 (0.1)

Deposition Regions

a

As reported in Tian et al. (2015a).
The regional deposition reported by Newman et al. (2000) are percentages of the
metered dose and therefore includes drug retained in the inhaler and not aerosolized.
This fraction of the dose was not simulated during the CFD studies. In order to determine
the in vivo deposition as a percentage of the aerosolized dose, the % radioactivity on the
device was subtracted from the total recovered radioactivity to determine the total
aerosolized dose and the regional deposition values were scaled as a percentage of this
value.
c
The central lung was defined as the B1–B7 region by Tian et al. (2015a). The same
approach was applied in this chapter.
d
Newman et al. (2000) excluded tracheal deposition from their calculations for the lung
because swallowing and esophageal radioactivity interfered with the results for tracheal
deposition.
e
The intermediate and peripheral lung was defined as B8–alveolar region by Tian et al.
(2015a). The same approach was applied in this chapter.
f
Tracheal deposition accounted for 1.9% and 0.0% of the metered dose for Tian et al.
(2015a) and this study, respectively.
b
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While the exact deposition result breakdown is shown in Table 6.2 for the lung
regions of interest for this fast mode of inhalation, it is important to realize that the original
CFD approach used by Tian et al. (2015a) extended from the mouthpiece of the inhaler
using an aerosol APSD that was measured using the modified compendial method (U.S.
Pharmacopeial Convention, 2013) described as Method (a) above, where aerosol
generation and release was characterized from Budelin at a constant flow of 80 L/min for
3 seconds. This was not the medium realistic inhalation condition for fast inhalation
proposed for Budelin testing (Figure 6.2). For all passive DPIs, powder deaggregation is
believed to be dependent on airflow, where the use of constant flow vs. a realistic IP may
affect the APSD of the drug from the inhaler. In addition, the IP used for CFD simulation
[“quick-and-deep”, or “QD” profile for Budelin Novolizer (Tian et al., 2015a)] was different
from that proposed in Chapter 5.2 and employed here in realistic in vitro testing (Figure
6.2, fast inhalation). Thus, before seeking to study the use of this combined in vitro–CFD
approach further, it seemed prudent to answer two important questions: (a) to what extent
did the APSD exiting the inhaler change from the distribution seen under constant flow,
when Budelin was tested with the realistic IP for fast inhalation as shown in blue in Figure
6.2? and (b) how did the “QD” profile (Tian et al., 2015a) differ from the test IP employed
in vitro in this chapter?
The first question was answered by comparing budesonide particle size
distributions from Budelin, after testing at the exit of the inhaler under constant flow
conditions [80 L/min; Method (a); same data as those used in Tian et al. (2015a)] and
variable flow [realistic IP; Method (b)]. Data are summarized in Figure 6.4.
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Figure 6.4 Distribution (percent of metered dose) of budesonide from Budelin Novolizer
when tested in accord with Method (a) and (b), respectively [constant flow (80 L/min) or
the medium simulated IP for fast inhalation (Figure 6.2)]. Data are presented as mean±SD
(n = 5). The data generated from Method (a) in this study was used for CFD predictions
in Tian et al. (2015a). The NGI flow rate employed in Method (b) was 100 L/min. MP =
inhaler mouthpiece; NMI = Nephele Mixing Inlet. Total drug mass collected before (MP +
NMI/adapter) or within (preseparator + stages 1–7 + filter) the cascade impactor were
statistically comparable (Student’s t-test, p>0.05) in both cases. Note that the cutoff
diameters for each stage of NGI differ between the tests shown in this Figure because
D50 values are a function of the air flow rate through NGI.

There was no significant difference in the total mass fraction collected before (MP
+ NMI/adapter) or within (preseparator + stages 1–7 + filter) the cascade impactor
between the two methods (Student’s t-test, p>0.05). The data from the cascade impactor
was processed according to USP (U.S. Pharmacopeial Convention, 2013) and plotted as
cumulative % drug mass undersize to enable the APSDs determined at the different NGI
flow rates to be compared. Figure 6.5 showed, for Budelin Novolizer that the APSDs for
budesonide following testing using a realistic IP (Figure 6.2) or, a constant flow rate of 80
L/min for 3 seconds produced results that were effectively identical (Figure 6.5).
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Figure 6.5. Mean cumulative % mass under size (±SD; n = 5) vs. NGI stage cutoff
diameters (D50) for drugs delivered from Budelin Novolizer at constant flow [80 L/min;
method a; data used in Tian et al. (2015a)] and the test IP [Method (b)]. Size distributions
are based on analysis of drug deposition within the NGI, and the cutoff diameters for
NGI’s stages and the preseparator were adjusted during size analysis in accord with
USP’s archival flow calibration (Marple et al., 2003a; U.S. Pharmacopeial Convention,
2013).

A further investigation compared the IP used by Tian et al. [“QD” profile; (Tian et
al., 2015a)] to that used for realistic in vitro testing (Figure 6.2; fast inhalation) in this
chapter. Figure 6.6 shows that the two IPs differed with respect to the air flow rate
acceleration (linear vs. sinusoidal) but overall, the profiles were very similar.

This

agreement is because both studies attempted to match the fast inhalation conditions of
Newman et al. (2000), but with slightly different value assumptions and profile equations
(e.g., linear vs. sinusoidal inhalation). It is not clear from the data that Newman et al.
provided which of these inhalation profiles is most correct.
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Figure 6.6. IPs simulated to represent those used by subjects trained by Newman et al.
(2000). The red curve was reproduced from the “QD” profile reported by Tian et al.
(2015a); the blue curve was used for realistic testing in the in vitro study (Figure 6.2, fast
inhalation).

Based on these comparisons of Budelin’s APSDs and IPs used in testing, it
seemed reasonable to assume that comparable CFD results should be generated for
regional deposition within the lung if we were to replace the APSD and IP reported by
Tian et al. (2015a) with those advocated for realistic in vitro testing in this thesis (fast
inhalation; Chapters 5 and 6). The results in Table 6.2 however, show small but finite
differences in the CFD results for the individual segments. Trachea to B3 and B4 to B7
showed reduced deposition compared to the results of Tian et al. (2015a) while deposition
in B8 to B15 and the “Alveolar” remainder were increased. The reduced deposition seen
in the trachea itself [0.0% in the present study vs. 1.9% in Tian et al. (2015a); Table 6.2]
likely points to the importance of particle trajectories at the tracheal entry point. In the
present study, reduced particle impaction efficiencies were expected when particles were
introduced vertically into the trachea compared to the flow curvature seen when the MT
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was attached (Tian et al., 2015a). In addition, the exclusion of the larynx in Model (b)
(Figure 6.3) may have eliminated the effects of the laryngeal jet on air turbulence and
aerosol dynamics (Xi et al., 2008), resulting in an underestimation of aerosol deposition
in the large airways. Another possible difference between the present study and that of
Tian et al. (2015a) relates to the injection of particles in an accelerating transient flow over
0.5 seconds (Tian et al., 2015a) vs. an accelerating and plateauing flow over 1.0 second
(this study; see Figure 6.6). A difference that may also be significant relates to the
assignment of particle sizes introduced into the two models to “represent” and compute
the deposition of the polydisperse budesonide aerosols released from Novolizer. Because
of the difference in NGI flow rates that must be used to size the aerosols leaving the
inhaler [e.g. 80L/min; Method (a) in Tian et al. versus 100 L/min; Method (c) in realistic
testing], the midpoint of the size bins used to represent large particles in each of the CFD
simulations differed. The difference in individual particle mass between the CFD-assigned
diameter for particles landing on stage 1 of the NGI at 100 L/min (this study) could be
about 5/7 (8.063/9.153) of the individual particle mass that was used in Tian et al. (2015a)
and this may be expected to influence computed values for upper airway deposition.

APSDs of Budesonide Particles Entering Trachea
Budesonide particle size distributions at the exit of the MT were measured with
Method (c) using the three IPs shown in Figure 6.2. Those IPs were simulated to mimic
the average inhalation maneuvers of subjects trained under the three different breathing
instructions in the gamma scintigraphy study for Budelin Novolizer (Newman et al., 2000).
The medium IP for fast inhalation (the blue curve in Figure 6.2) was selected to match the
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flow condition used in the CFD simulation by Tian et al. (2015a); that IP and the
associated APSD of the drug exiting MT were used as initial conditions for the modified
CFD model to evaluate whether the predicted regional drug deposition results were
comparable with those produced by Tian et al. (2015a) as shown in Table 6.2. The
medium IPs for moderate and slow inhalation (the orange and green curves in Figure 6.2,
respectively) and their associated APSDs were used to further evaluate the method’s
ability to predict variations in regional drug deposition in the lung. Because only the
medium airway model is currently available for CFD simulation, the small and large IPs
and APSDs of Budelin’s TLDin

vitro

produced from the small MT-IP and large MT-IP

combinations (Chapter 5) were not studied or discussed in this chapter.
APSDs of budesonide aerosols exiting the MT for the mean fast, moderate and
slow inhalation conditions are summarized in Figures 6.7 and 6.8. The three medium IPs
in Figure 6.2 produced significantly different results for budesonide mass depositing in
MT and on NGI stages 1, 3, 4, 5, and 6 (one-way ANOVA, p<0.05; Figure 6.7). The data
from NGI was also processed according to USP (U.S. Pharmacopeial Convention, 2013),
and the cumulative percent mass under size vs. NGI’s stage cutoff diameters in Figure
6.8 clearly illustrate the variations in the APSDs of drugs likely to enter the trachea across
these inhalation conditions. Values for the mass median aerodynamic diameters (MMAD)
ranged from 1.88±0.06 µm for fast inhalation, to 2.19±0.04 µm for moderate inhalation,
and 2.54±0.09 µm for slow inhalation.
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Figure 6.7. Distribution (percent of metered dose) of budesonide from Budelin Novolizer
when tested in accord with Method (c) using IPs shown in Figure 6.2. Data are presented
as mean±SD (n = 5). The NGI flow rate employed in this method was 100 L/min. MT =
mouth-throat; NMI = Nephele Mixing Inlet. Significantly different values were observed for
drugs depositing in MT and on NGI stages 1, 3, 4, 5, and 6 across the three inhalation
conditions (one-way ANOVA, p<0.05).
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Figure 6.8. Mean cumulative percent mass under size (±SD; n = 5) vs. NGI stage cutoff
diameters (D50) for budesonide particles exiting MT when tested with Method (c) using
IPs shown in Figure 6.2. Values for D50 (stage cutoff diameters) were plotted for the 100
L/min airflow test condition in accord with USP’s archival flow calibration (Marple et al.,
2003a; U.S. Pharmacopeial Convention, 2013).
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Aerosol Deposition Results
Whole-Airway CFD Methods vs. Combined In Vitro–CFD Methods
One purpose of this chapter was to evaluate whether the CFD model and
programming methods developed by Tian et al. (2015a), in which deposition was also
modeled in MT, could be modified and coupled to the realistic in vitro test methods
described in Chapter 5. The main differences between the two methods were the aerosol
particle injection site at which particle tracking begins and their associated APSDs, and
the effects of the existence or absence of the laryngeal jet on air turbulence and flow
profiles entering the trachea. Given the absence of significant differences between the
aerosol that enters a theoretical MT from Budelin in Tian et al. (2015a) and that entering
the model MT (Figures 6.4 and 6.5), as well as the use of comparable IPs in both cases
(Figure 6.6), Tian et al.’s CFD predictions for MT deposition (Tian et al., 2015a) should
compare well with those seen experimentally with the caveats noted in the discussion
above. Indeed, the percent of the drug dose depositing in MT and the inhaler from both
techniques appeared to be comparable with the in vivo results for fast inhalation as shown
in Table 6.2. There were discrepancies however. The APSD data used in the CFD
simulations in both cases is presented in Figure 6.9a where the difference between the
curves should represent MT deposition; this experimental data, and the CFD data on file
from Tian et al. (2015a) enabled computation of the CFD-predicted APSD for MT
deposition that in turn enabled computation of the theoretical APSD entering the trachea
according to Tian et al. (2015a) (Figure 6.9b; red curve). While the curves were broadly
similar at aerodynamic diameters ≤9 µm, the discontinuity in the red profile at
approximately 11 µm indicated the injection of almost 5% of the dose into the trachea as
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large particles in Tian et al. (2015a). This difference in APSD entering the trachea
between the two methods appeared to justify the experimental determination of both
TLDin vitro and the APSD of the aerosols exiting MT and entering the trachea. This being
said however, it is quite possible that variations within and between inhalers (as well as
the use of the mixing inlet as a conduit to NGI) may also contribute to the apparent
reduction seen in large particles exiting MT when realistic testing was employed.
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Figure 6.9. (a) APSD data used in CFD simulations for fast inhalation by Tian et al.
(2015a) and in this chapter (particles introduced into trachea). These data were produced
experimentally using Methods (a) and (c) described above. (b) APSD data for aerosols
exiting the MT model. In vitro–CFD results (blue curve) are identical to those shown in
the left panel. Results from Tian et al. (2015a) (red curve) were computed from the CFD
results of Tian et al. (2015a) by subtracting the predicted MT deposition for fast inhalation
(Tian, 2015). Data are presented as the mean percent of the metered dose vs. the
midpoint of the upper and lower stage cutoff diameters at the designated flow rates in the
fashion of Tian et al. (2015a).
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Variations in Regional Drug Deposition in the Lung
To evaluate the ability of the in vitro–CFD method as a means of predicting
variations in regional drug deposition in the airways, additional CFD studies were
performed using different IPs and APSDs for Budelin’s TLDin vitro and introducing these to
the trachea of the modified airway model (Figure 6.3b). IPs were simulated to mimic the
subject groups’ moderate and slow inhalation conditions as described by Newman et al.
(2000) (Figure 6.2); these IPs were paired with the mean APSDs produced using Method
(c) [presented as the mean percent of the aerosolized dose depositing on a selected
stage vs. the midpoint of the upper and lower stage cutoff diameters at the designated
flow rates in the fashion of Tian et al. (2015a) as shown in Figure 6.10] and used as initial
conditions for CFD simulations. Regional lung deposition results were compared across
all three inhalation conditions (fast, moderate, slow) and also with the in vivo lung
deposition data reported by Newman et al. (2000) in Figure 6.11 and Table 6.3.
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Figure 6.10. APSD data for the CFD simulations used for fast, moderate and slow
inhalation conditions. Data are presented as the mean percent of the aerosolized dose
depositing on a selected stage vs. the midpoint of the upper and lower stage cutoff
diameters at the designated flow rates in the fashion of Tian et al. (2015a). These
experimental results were calculated from the data shown in Figures 6.7 and 6.8 and
produced using Method (c).
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Figure 6.11. Regional drug deposition in the lung model as predicted using the in vitro–
CFD approach for fast, moderate and slow inhalation conditions. Data are presented (a)
as % total lung dose in vitro (TLDin vitro; ±SD; n = 3) and (b) as % aerosolized dose (±SD;
n = 3) for budesonide from Budelin Novolizer depositing theoretically at trachea to B3, B4
to B7, B8 to B15, and alveolar (>B15) regions of the modified lung model (Figure 6.3b).
Significant differences were observed for the percent of TLDin vitro depositing in the B4 to
B7, B8 to B15, and alveolar regions across the three inhalation conditions (one-way
ANOVA, p<0.05).
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2.3 (0.3)
26.2 (0.1)

B8–B15

Alveolar

19.3

9.0

71.0

In Vivoc

16.2 (0.4)

5.5 (0.4)

3.6 (0.1)

0.9 (0.1)g

21.7 (0.1)

4.5 (0.1)

73.7

In Vitro–CFD

Moderate Inhalation

16.4

7.8

75.6

In Vivoc

12.9 (0.4)

3.6 (0.4)

2.3 (0.1)

0.7 (0.1)g

16.5 (0.0)

3.0 (0.0)

80.5

In Vitro–CFD

Slow Inhalation

b
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As reported in Tian et al. (2015a)
Data for fast inhalation are identical to those shown in Table 6.2.
c
The regional deposition reported by Newman et al. (2000) are percentages of the metered dose and therefore includes
drug retained in the inhaler and not aerosolized. This fraction of the dose was not simulated during the CFD studies. In
order to determine the in vivo deposition as a percentage of the aerosolized dose, the % radioactivity on the device was
subtracted from the total recovered radioactivity to determine the total aerosolized dose and the regional deposition values
were scaled as a percentage of this value.
d
The central lung was defined as B1–B7 region by Tian et al. (2015a) and the same approach was applied in this chapter.
e
Newman et al. (2000) excluded the tracheal deposition from their calculations for the lung because swallowing and
esophageal radioactivity interferes with the tracheal count.
f
The intermediate and peripheral lung was defined as B8 to alveolar region by Tian et al. (2015a) and the same approach
was applied in this chapter.
g
CFD-predicted tracheal deposition accounted for 0.0% of the metered dose for all three inhalation conditions.

a

5.6 (0.2)

28.5 (0.2)

B4–B7

22.1

Intermediate and Peripheral Lungf

6.9 (0.2)

1.3 (0.1)g

12.1

Central Lungd (Trachea Excluded)e

64.6

In Vitro–CFD

Trachea–B3 (Trachea Included)

64.9

In Vivoc

MP+MT

Deposition Regions

Fast Inhalationb

Table 6.3. Deposition fractions (percent of aerosolized dosea) based on in vitro–CFD predictions compared with the mean
in vivo data for Budelin Novolizer (Newman et al., 2000) operated with the three breath simulated curves shown in Figure
6.2; size distributions for TLDin vitro were determined exiting the VCU medium MT model using the same IPs. Regional drug
deposition data for the in vitro–CFD method are presented as mean (SD), n = 3.

Budesonide aerosol deposition in trachea to B3, B4 to B7, B8 to B15, and alveolar
(>B15) regions are summarized as %TLDin vitro in Figure 6.11a. For all three inhalation
conditions, <5% of TLDin vitro deposited in trachea to B3, while the majority (>60% of TLDin
vitro)

deposited in the alveolar region. When comparing the regional deposition of TLDin vitro

across the three inhalation conditions, significant differences were observed for B4 to B7,
B8 to B15, and alveolar (one-way ANOVA, p<0.05), suggesting that the combination of
subjects’ IPs and the associated APSDs in this study affected the regional drug deposition
of the likely lung dose in each case. The effect was most pronounced for the fast
inhalation condition, where much lower deposition was observed in B8 to B15 (and much
higher deposition in alveolar) than those for the moderate and slow inhalation conditions,
indicating the importance of the smaller aerosol produced during fast inhalation (Figure
6.8). Aerosol deposition data are also presented as % aerosolized dose in Figure 6.11b
and Table 6.3 to evaluate the likely variations in regional drug dose in the lung. In general,
fast inhalation produced the highest theoretical deposition in trachea to B3, B4 to B7 and
the alveolar regions, but the lowest deposition in B8 to B15 among these three inhalation
conditions. When comparing these data with the in vivo lung deposition results (Newman
et al., 2000), we again found that the combined in vitro–CFD approach [when coupled
with the airway mapping technique developed by Tian et al. (2015a)] appeared to
underestimate drug deposition in the central lung and overestimate delivery to the
periphery. However, because the fraction of peripheral overlap of the central airways
assigned by gamma scintigraphy is unknown, a direct comparison between CFD
prediction and two-dimensional (2D) scintigraphy has limitations. Future studies may be
needed therefore, before making firm conclusions about the validity of either of approach.
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Overall, theoretical regional drug deposition predicted using in vitro results coupled
to the modified CFD model [Figure 6.1c coupled with Tian et al.’s CFD programming
method (Tian et al., 2015a) in the modified lung model] were compared with those
reported by Tian et al. (2015a) for fast inhalation and the in vivo data of Newman et al.
(2000) for fast, moderate and slow inhalation. For ease of comparison with Tian et al.
(2015a), Table 6.2 and 6.3 were constructed in the fashion of (Tian et al., 2015a). Both
methods produced comparable results with the in vivo deposition data for fast inhalation
(Newman et al., 2000) for drug retention on the inhaler and MT (“MP+MT”). To compare
the regional lung deposition results based on CFD simulation with the in vivo data, Tian
et al. (2015a) defined B1 to B7 as the central lung and B8 to alveolar as the intermediate
and peripheral lung and used these regions to compare to those defined by Newman et
al. (2000). This was based on using the lung division method of Newman et al. (2000)
and applying it to the SIP CFD-based lung model. These same definitions were used in
this chapter. The CFD methods used by Tian et al. (2015a) showed lower deposition in
the central lung and higher deposition in the intermediate and peripheral lung than the
published in vivo results (Newman et al., 2000) (Table 6.2), but a general trend of
agreement between in vivo and in vitro–CFD results was seen to occur as the IP slowed
from “fast” through “slow” inhalation (Table 6.3). Tian et al. (2015a) suggested that their
underestimation of central lung deposition (which was within 10% relative error of the in
vivo results) could be due to its overestimation by 2D gamma scintigraphy [because a
significant fraction of the peripheral airways are captured in the central region by
scintigraphy]. Their explanation is highly plausible. The “underestimation” of budesonide’s
central lung deposition seen by Tian et al. (2015a) was magnified by the combined in
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vitro-CFD approach described here, in large part because of the absence of air turbulence
introduced by the laryngeal jet (Xi et al., 2008) and values assigned for the APSD of each
TLDin vitro (Figure 6.9b and 6.10) as aerosols entering the trachea.
In practice, the regional airway deposition of aerosols delivered from inhalers is
known to be difficult to assess clinically. Extensive overlap between the central and
peripheral airways can be expected when the three-dimensional (3D) lung geometry is
projected onto the 2D plane in gamma scintigraphy studies. Schroeter et al. (2005)
developed a 3D airway model using human morphological data and quantified the
composition of different airways in the central, intermediate and peripheral lung (as those
defined in gamma scintigraphy studies) by superimposing those regions on the planar
view of their model. They found that over 18% of alveolar airways (>B17 in Schroeter et
al.’s model) were captured in what appeared to be the central lung, and that these airways
comprised about 80% of the total volume of airways in that region (Schroeter et al., 2005).
Given that a large proportion of budesonide aerosols (>60% of TLD; Table 6.2) were
predicted to deposit in the alveolar region (>B15) using both CFD methods discussed
here, it appears to be necessary to account for a significant “peripheral fraction” appearing
as central deposition when comparing results from CFD airway modeling with in vivo data
from gamma scintigraphy.
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6.4

CONCLUSION
A new technique was developed and evaluated to combine the realistic in vitro test

methods described in Chapter 5 and a CFD model to maximize the strengths of both
approaches in predicting total and regional drug deposition in the lung. Results for
theoretical regional drug deposition in the airways were evaluated for the powder inhaler,
Budelin Novolizer 200 mcg, under three inhalation conditions using this hybrid in vitro–
CFD approach. Variations in results for drug deposition indicated that IPs and the APSDs
of TLDin vitro appeared to affect drug deposition in the MT and airways of a model human
adult respiratory tract. While future studies may be needed to incorporate variations in
airway geometries across a population as well as effects of age and disease on those
geometries, the combined approach appeared to show promise for predicting aerosol
deposition in the lung. While changes in the inhalation profiles used by subjects using
powder inhalers appeared likely to modify the dose of drug reaching the lung and its
deposition across the airways, the model appeared to indicate that most of the dose from
Budelin that escapes the MT region, was likely to reach beyond generation 15 into the
lung periphery. This result indicated that the fraction of “peripheral deposition” that is
usually reported in gamma scintigraphy studies is disproportionally low; a proportion of
the counts usually attributed to deposition in the “central region” of the lung should be
shifted to the periphery to allow for the presence of significant numbers of small
(peripheral) airways that overlay the “central regions” in 2D lung scintigraphs.

136

CHAPTER 7
SUMMARY AND CONCLUSIONS

Realistic in vitro testing of inhaled drug products, coupling human mouth-throat
(MT) models and inhalation profiles (IP) to allow drug aerosol generation from an inhaler
and transport into the human respiratory tract to be mimicked under clinically-relevant
conditions, has shown its potential in establishing in vitro–in vivo correlations (IVIVCs) for
drug doses likely to enter the lung (TLD). The application of this approach however,
remains challenging and scientists are left to decide which MT model(s) to choose and
how to select representative IP(s). Furthermore, regional drug deposition in the lung
remains unclear, although studies have shown that the deposition site of inhaled drugs
may well be relevant to their therapeutic effects (Anderson & Newman, 2009; Usmani,
2015; Usmani & Barnes, 2012; Usmani et al., 2005). This dissertation describes the
continuing research to develop realistic in vitro performance test methods for dry powder
inhalers (DPI), with efforts to standardize and improve the existing DPI test methods to
(a) enable the use of realistic in vitro tests by drug development scientists and regulators,
and (b) explore the truth about the ranges of the aerodynamic particle size distributions
(APSD) of drugs that are likely to enter the lung (TLDin vitro) of healthy human adults from
a marketed DPI. These goals were achieved through the four specific aims described in
Chapter 2. In brief, these were: (i) select representative MT models for realistic in vitro
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testing of DPIs; (ii) develop a general method for simulating the ranges of IPs for use with
a DPI of known airflow resistance; (iii) develop methods for measuring APSDs of
Budelin’s TLDin vitro across different ranges of IPs; (iv) couple computational fluid dynamic
(CFD) simulations with realistic in vitro testing techniques to predict regional lung
deposition of budesonide aerosols from Budelin® Novolizer®. All these aims were
achieved and the results presented in Chapters 3–6 were consistent with the
accompanying hypotheses (Chapter 2).
The methods of selecting representative MT models for realistic in vitro testing
were described in Chapter 3. Three main types of realistic MT models [the small, medium
and large Virginia Commonwealth University (VCU) models, the small, medium and large
Oropharyngeal Consortium (OPC) models, and the medium Alberta Idealized Throat
(AIT)] were included in the study because those are commercially available and have
been reported to produce IVIVCs with certain inhalers. The USP induction port was also
included as a pharmacopeial control. A study was designed to evaluate the effect of MT
model geometry on drug aerosol retention under realistic human inhalation conditions.
This was accomplished by testing the eight, internally-coated MT models across a range
of realistic IPs with Salbulin® Novolizer®. The models produced different values for TLDin
vitro

and most notably, the three medium MT models (VCU, OPC, AIT) did not show

statistically comparable results. Interestingly however, the USP induction port produced
comparable results with VCU and AIT models when tested with Salbulin in this study
perhaps indicating some geometric similarities between those realistic MT models and
the standardized USP induction port employed routinely for quality control of inhalers.
Although we have yet to identify which medium MT is most “representative”, as these
138

models were designed based on different philosophies and no clinical lung deposition
data for Salbulin are available for evaluating its in vitro properties, the study suggested
that caution should be applied when using different MT models to predict TLDin vivo. A
further implication of this study, and one that is perhaps more important, is that it may be
necessary to incorporate both the variations in MT geometries and IPs when testing
inhalers. The present study showed that the VCU and OPC models produced much larger
ranges for TLDin vitro than the single medium AIT model and the USP induction port. Based
on the previous studies (Delvadia et al., 2012; Olsson et al., 2013) that clinical variations
seen in lung deposition could be accounted for by coupling the extremes of MT geometry
with expected ranges of IPs, both the VCU and OPC models appeared to produce realistic
variations in TLDin vitro. While the practical advantages of the VCU models overweighed
their disadvantages for the purposes of this thesis, future studies may be needed to test
these realistic MT models across different inhalation systems (e.g. MDIs, Respimat®) and
formulations (e.g. solution-based vs. suspension-based MDIs), before selecting the most
representative MT models. In addition, CFD simulations may be applied to further our
understanding of the flow and aerosol behaviors in these different MT geometries.
Chapter 4 describes the methods of selecting and simulating the range of
representative IPs for use when testing a DPI with known airflow resistance. This study
was designed to enable drug development scientists to select IPs for a new DPI a priori
and predict inhaler performance in the clinic using realistic in vitro testing techniques. To
achieve this goal, inhalation profile data from an existing VCU clinical trial (Delvadia, 2012)
were reanalyzed, where a group of inhaler-naïve, mixed-gender, healthy human adults
were trained (a) by leaflet reading and (b) by professional instruction to inhale through a
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range of airflow resistances (R) typical of those used in commercial DPIs. Elaborate
statistical analyses were performed by Delvadia (2012) and peak inhalation flow rate
(PIFR) was found to have a linear correlation with 1/R, while time to reach PIFR (TPIFR)
and inhaled volume (V) did not show significant correlations with R. Based on those
analyses, three equations were derived for PIFR as a function of R from the pooled data
to enable the 10, 50 and 90 percentile values to be predicted for a DPI of known airflow
resistance for each training status. Because TPIFR and V were independent of R, their 10,
50 and 90 percentile values could be selected from the cross-gender data regardless of
the DPI resistance. These statistically-derived inhalation variables allowed representative
IPs and their realistic variations to be simulated using sinusoidal equations derived from
curve fitting of the subjects’ IPs (Chapter 4 and Appendix IV). The study provided a
general method of selecting standard IPs for use in realistic in vitro tests of DPIs during
the drug development process. Although the data analyses were based on profiles
collected from healthy adults of both genders, and this was because clinical trial usually
begins with healthy subjects or largely asymptomatic patients, the method is likely to be
extended to select representative IPs and their likely variations for target patient groups
(e.g. asthma patients, COPD patients) or age groups (e.g. pediatric patients, elderly
patients). The data also showed clearly that professional training affected the subject
group’s inhalation maneuvers. This was consistent with reports in the literature (Azouz et
al., 2015a; Azouz et al., 2015b). To fully evaluate DPI performance in vitro, it may be
necessary to include IPs representative of patients who are “insufficiently trained” in the
sense that they are left to figure out themselves how to use their inhalers. In addition, IPs
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for other inhalation systems (e.g. MDIs, MDIs with spacers, Respimat®) may need to be
collected and generalized to standardize realistic in vitro tests for those inhalers.
The selection of representative MT models and IPs enabled realistic in vitro test
methods for DPIs to be developed further, to characterize the likely ranges of APSDs for
TLDin vitro from Budelin® Novolizer® across different inhalation conditions (Chapter 5).
The realistic in vitro test methods described in Chapters 3 and 4 were coupled to the
compendial cascade impactor methods (U.S. Pharmacopeial Convention, 2013) by using
the Nephele Mixing Inlet (NMI) supplied with dilution air to maintain constant airflow
through a Next Generation Impactor (NGI). The modified test method enabled APSDs for
the in vitro lung dose to be determined across a complete range of realistic IPs. To
evaluate the method’s ability to predict inter-subject variabilities in total and regional lung
deposition, the small, medium and large VCU MT models were paired with the three sets
of small, medium and large simulated IPs to mimic those used by subjects in the gamma
scintigraphy study used with the inhaler that became Budelin® Novolizer® (Newman et
al., 2000). Because the NGI was operated outside its specific flow range, over which the
archival calibration is known to function (15–100 L/min), additional studies were designed
to assess the validity of the theoretical stage cutoff diameters when these were calculated
according to USP at high flow rate. Four sets of MT-IP combinations were tested at 100
and 140 L/min NGI flow conditions; the former was used as the calibration standard to
recalibrate NGI’s stage cutoff diameters at 140 L/min by curve fitting. An important
observation from this study is that Budelin Novolizer, the DPI known to deliver consistent
doses when subjected to USP testing (U.S. Pharmacopeial Convention, 2013), showed
significant variations in lung dose in vivo (Newman et al., 2000); when realistic in vitro
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tests were conducted and variations in MT geometries and IPs were accounted for, the
inter-subject variabilities in the in vivo lung doses were likely to be predicted. IVIVCs were
observed for all three inhalation conditions and this again revealed and confirmed the
importance of incorporating MT geometry and IP variations in realistic in vitro tests of
DPIs. Further analyses of the APSDs of Budelin’s TLDin

vitro

showed that the size

distributions of drug aerosols likely to enter the lung were also a function of both MT
geometry and the subject’s inhalation maneuver; the largest variations in APSDs were
seen for the slow inhalation condition, suggesting that the methods developed in the
present study were sufficiently precise to distinguish between the different aerosol doses
and the aerosol sizes likely to enter the trachea. There was no reason to believe that the
same techniques could not be extended to review the data for other powder inhalers that
are also used clinically by patients with variable MT geometries and breathing patterns.
The biggest limitation of the present study was that the APSDs measured at the exit of
the MT could not be compared directly with the regional lung deposition data from the
clinical gamma scintigraphy study (Newman et al., 2000). Therefore, to explore the clinical
importance of the results for APSD, an effort was made in Chapter 6 to predict regional
drug deposition in the airways using computational fluid dynamic (CFD) simulations in
combination with the in vitro testing techniques described in Chapter 5. It should be noted
that the methods described in the present study are different from those used elsewhere
(Chrystyn et al., 2015; Goodey et al., 2014; Nadarassan et al., 2010; Yakubu et al., 2013)
and standardization of methods may be needed to facilitate application of realistic in vitro
tests. Furthermore, some redesign of cascade impactors like NGI and/or their stages to
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better enable aerosol characterization at high flow conditions may be required to enable
other DPIs to be characterized across the range of realistic IPs.
The last study of this dissertation (Chapter 6) was designed to explore regional
lung deposition and its variation for Budelin Novolizer under three inhalation conditions
using a new hybrid in vitro–CFD approach. To facilitate coupling of the realistic in vitro
test methods described in Chapter 5 to CFD simulations, a published airway model and
the CFD methods described by (Tian et al., 2015a) was modified to allow the values for
APSDs of Budelin’s TLDin vitro and the associated IPs to be used as the initial conditions
for CFD simulation at the tracheal opening. When comparing the regional deposition
results produced using the hybrid in vitro–CFD approach with those from Tian et al.
(2015a), small but finite differences were observed for the individual segments. This may
be caused by differences in IPs between the two studies, as well as changes in particle
injection time and particle trajectories at the tracheal inlet. Most likely however, the
existence or absence of air turbulence introduced by the laryngeal jet, and differences in
the APSDs of particles entering the trachea in both techniques appeared to produce
differences in predicted regional deposition in the airways. The present study also showed
that variations in IPs and the APSDs of TLDin vitro appeared to affect drug deposition in the
airways of a model human adult respiratory tract; but regardless of the variations, most
of the dose from Budelin that escaped the MT region appeared likely to reach beyond
generation 15 into the lung periphery. The predicted regional deposition results using the
in vitro–CFD approach were believed to be consistent with those reported in the gamma
scintigraphy study (Newman et al., 2000), although our work demonstrated that a
proportion of the counts usually attributed to deposition in the “central region” of the lung
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should be shifted to the periphery to allow for the presence of significant numbers of small
(peripheral) airways that overlay the “central regions” in two dimensional lung scintigraphs.
It should be noted that the CFD model used by Tian et al. (2015a) and that used in the
present study was designed to represent the “average” geometry of a healthy human
adult. To further evaluate inter-subject variabilities in regional lung deposition, variations
in airway geometries across a population may need to be incorporated. In addition,
aerosol deposition patterns in the patient’s lung may be altered by changes in airway
morphologies and physiologies (e.g. airway wall thickening, mucus hypersecretion,
bronchoconstriction, etc.) caused by pulmonary diseases like asthma and COPD (Wang
et al., 2014). An extensive study on the airway geometries of patients with different
pulmonary diseases may be needed in future to generalize and select representative
geometries for specific patient groups.
Overall, the realistic in vitro test methods described in this dissertation allow total
and regional drug deposition in the lung of healthy human adults and their inter-subject
variabilities to be predicted for DPIs. Such methods may benefit both product
development scientists and regulators as it produces more meaningful in vitro data than
standard compendial tests (U.S. Pharmacopeial Convention, 2013). While efforts have
been made to standardize and improve the existing realistic in vitro test methods, how to
incorporate these methods into bioequivalence studies and guidance documents, and
ease the development process for generic inhalers, remains to be discussed. More study
and discussion of this topic and collaboration between different research groups and
regulators appears to be needed.
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APPENDIX I
REGIONAL DRUG DEPOSITION FROM POWDER INHALERS: LUNG
SCINTIGRAPHY STUDIES IN HEALTHY HUMAN ADULTS

AI.1

INTRODUCTION

A literature review was performed to identify clinical studies of inhalers in humans
that provided aerosol drug deposition data according to well-characterized inhalation
maneuvers that could feasibly be mimicked in vitro using realistic or “bio-relevant” tests
and models; whence to compare the results of such tests and create in vitro–in vivo
correlations (IVIVCs). This thesis was focused on assessing the likely regional deposition
of budesonide from Budelin® Novolizer® 200 mcg based on that inhaler’s in vitro
performance during realistic testing and subsequent computational fluid dynamics (CFD)
modeling. Accordingly, the results were compared with the extensive work done by
Newman et al. [1] on that inhaler using 2D gamma scintigraphy. This Appendix describes
the process of selection and the merits of that study [1] from the broader aerosol drug
deposition literature.
In vivo lung deposition studies for orally inhaled drug products are usually
performed using gamma scintigraphy studies or pharmacokinetic (PK) studies in which a
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charcoal block technique to prevent drug absorption from the gastrointestinal (GI) tract.
Although both approaches allow total lung dose (TLD) to be evaluated, regional drug
deposition can only be characterized using gamma scintigraphy. To select representative
inhaler(s) that enable the in vitro measured TLD and CFD predicted regional drug
deposition results to be compared with the in vivo data, a literature review was initially
performed to retrieve and evaluate gamma scintigraphy studies for dry powder inhalers
(DPI), metered dose inhalers (MDI) and soft mist inhalers (SMI). The results of this are
shown for DPIs in this Appendix.

AI.2

METHODS

A literature search of peer reviewed journals and conference proceedings was
performed using Pubmed, Web of Science and RDDonline with the following keyword
combinations and total results (dated to March 26, 2015):
An “All Fields” search in Pubmed was performed for:
(scintigraphy OR planar imaging OR 2D imaging OR two dimensional imaging OR
lung imaging) AND (inhaler OR pulmonary drug OR inhalation drug OR respiratory
drug OR aerosol OR lung deposition OR MDI OR DPI OR nebulizer) AND (human
OR adult OR volunteer OR subject) AND healthy; a total of 387 references were
found.
A “topic” search in Web of Science was performed for:
(scintigraphy OR planar imaging OR 2D imaging OR two dimensional imaging OR
lung imaging) AND (inhaler OR pulmonary drug OR inhalation drug OR respiratory
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drug OR aerosol OR lung deposition OR MDI OR DPI OR nebulizer) AND (human
OR adult OR volunteer OR subject) AND healthy; a total of 204 references were
found.
A “keywords” and “title” search in RDDonline was performed for:
scintigraphy; 62 references were found for “keywords” search and 8 references
were found for “title” search.

Initial screening of these articles was performed by reading all titles and abstracts,
after which replicate references were discarded. 93 references were selected from the
total and tabulated for individual reviews based on the possibility that they contained
information where all of the following were reported: (a) lung deposition data in a group
of healthy human adults following the use of radiolabeled formulations from inhalers
described either within the reference itself or elsewhere, (b) inhalation profile (IP)
variables used by the subjects in the study , and (c) pharmaceutical aerosol deposition.
Many of the 93 references failed to provide aspects of this information and were rejected.
However, 21 studies appeared to be promising for DPIs [1-21]. Data from those was
tabulated and reviewed further.
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AI.3

RESULTS AND DISCUSSION
Inhalers, drugs, inhalation profile parameters and related gamma scintigraphic

deposition data in healthy volunteers from the 21 possible DPI studies are compiled in
Table 1. These studies covered the publication period 1992 to 2009. Notably, over half of
the studies included in Table AI.1 (14 out of 21) were performed by Newman and
colleagues who generally used standardized techniques; other research groups
employed their own (alternate) methods to perform and assess lung deposition results
[e.g. different attenuation factors, definition of lung regions of interest (ROI), etc.]. This
was not surprising because the studies in Table AI.2 were performed before efforts were
made to standardize methods in 2012 [2] when it was noted that experimentaldifferences
in gamma scintigraphic techniques should be carefully considered when selecting
inhalers for realistic in vitro tests, as cross-study comparisons may be needed to assess
an resulting IVIVCs.
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Beclomethasone
Dipropionate

LAS 31025
(lactose)

Clickhalera

Cyclohalerb

Budesonide
(PulmoSphere)

Aclidinium
Bromide

Elips

Genuaird

Easyhalerc

Diskhaler

Cyclohalerb

Budesonide

Clickhalera

Budesonide
(solid lipid
microparticles,
physical blend)
Budesonide
(solid lipid
microparticles,
matricial)
Zanamivir
(lactose)
Beclomethasone
Dipropionate
(lactose)

Drug

Inhaler

Volume (L)

3.4±1.1
3.3±1.0
3.4±0.9

104.0±35.8

105.5±24.0

106.9±26.5

79.0±9.4

3.91±0.72
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30.1±7.3

57.0±6.5

29±3

18.9±9.5

13.2±4.0

57.7±7.8

2.62±0.97

2.77±1.02

49.9±3.7

62.8±4.9

17.5±3.6

19.5±4.5

20.9±10.2

19.1±7.6

30.8±7.2

26.8±6.8

%TLD

44±5

53±11

84.0±16.5

Subjects practiced breathing
maneuver with an empty device.
Breath holding for 5 sec.

3.5±1.0

98.8±24.8

72.9±38.1
3.5±1.2
(35-200)
(1.6-6.4)
Follow instructions in the
manufacturers’ info sheets

PIFR (L/min)

20.6±2.5

20.0±2.6

6.4±3.1

4.2±1.3

16.9±2.0

22.1±2.4

5.6±1.3

6.3±1.5

6.7±3.3

6.4±3.0

%Intermediate

19.2±5.3

19.7±6.1

6.7±3.6

3.9±1.0

17.4±2.6

22.0±3.9

4.9±1.3

5.8±2.3

5.9±2.7

5.2±1.9

%Peripheral

Lung was divided into 6 regions, with mean
values of 9.9% and 2.6% for the innermost and
outermost regions (data for 6 regions available)

17.2±2.1

17.9±4.1

5.8±3.3

5.1±2.2

15.6±2.3

18.6±2.6

7.1±1.9

7.4±1.6

8.4±5.1

7.4±3.2

%Central

1.1±0.5

1.2±0.6

1.2±0.3

0.9±0.4

1.1±0.3

1.2±0.4

0.7±0.3

0.8±0.3

0.9±0.4

0.8±0.4

2.3±0.7
(sC/P)
1.49±0.37
(sC/P)

P/C Ratio

Table AI.1. Summary of lung scintigraphy data from the literature for passive dry powder inhalers (DPIs) some of which are
available commercially. References were published in the period 1992–2009 and were included if they contained
descriptions of the IPs used by lung-normal subjects. Abbreviations are: PIFR = peak inhalation flow rate; TLD = total lung
dose; P/C Ratio = %Peripheral/%Central.

[10]

[9]

[8]

[7]

[6]

[5]

[4]

[3]

Ref.

Budesonide
(lactose)

Salbutamol
(lactose)

Sodium
Cromoglycate

Novolizere

Pulvinaf

Spinhaler

Turbuhalerg

Turbuhalerg

Turbuhalerg

Budesonide

Terbutaline
Sulphate
Terbutaline
Sulphate
Terbutaline
Sulphate

Nacystelyn

Monodose
Miat Inhaler

Turbuhalerg

Salbutamol
(lactose)

Tiotropium
Bromide
Salbutamol
(lactose)

MAGhaler

Leiras

Handihaler

36 (32-38)

58 (53-64)

57 (52-61)

55±7

57.8±5.6

2.95 (1.974.09)
2.90 (2.074.97)
2.54 (1.363.72)

2.41±0.50
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14.8±3.3

27.7±9.5

27.0±7.7

26.9±3.8

21.4±6.1

12.3 (6.6-21.1)

2.59 (1.7-4.9)
2.54±0.87

17.1 (7.8-28.3)

2.86 (2.2-4.1)

5.5 (1.6-9.7)

11.7±2.3

2.94 (2.0-4.2)

3.23±0.74

27.8±2.5

14.1±3.2

13.1 (3.7-22.1)

3.11±0.67

46.0±4.4

19.9 (8.8-26.6)

25.0 (12.1-37.4)

32.1 (9.4-41.0)

2.78 (1.7-4.0)

2.77±0.97

54±7

119.9 (107-130)
(Tilted, BH)
62.8 (58-71)
(Tilted, BH)
120.4 (106-128)
(Normal, BH)
117.9 (110-132)
(Tilted)

2.96±0.83

65±3

3.13±1.01

31.0±11.5

Exhale, and then inhale with a
nonmaximal inspiratory effort for
~4 sec, and hold breath for 5 sec
99±13

21.1±5.1

3.31 (2.1-4.5)

36.3 (29.0-42.0)

26.4±4.3

3.11 (1.6-4.1)

23.9±1.4

18±5
(18-22)

62.1 (46.0-73.0)

Inhale according to the
description in the patient’s info
Inhale ASAP through the device
and hold breath for 10 sec

7.2±1.9

9.2±1.4

8.7±0.6

8.3±2.3

10.0±2.2

8.1±0.5

5.7±0.9

5.5±1.5

3.8±0.9

4.9±1.3

6.3 (2.3-8.4)

7.8 (3.7-11.8)

10.6 (3.013.4)

8.4±1.0

7.1±2.0

3.7±0.8

4.3±1.0

6.7 (3.2-9.9)

8.9 (4.6-12.2)

10.9 (3.8-15.9)

12.9±2.2

8.8±2.9

4.2±0.9

4.9±1.1

6.5 (3.4-8.8)

7.8 (3.7-13.4)

8.5 (2.5-13.4)

No specific definition of central, intermediate
and peripheral regions

5.6±1.7

7.2±1.5

7.1±0.5

Lung was divided into two rectangular regions:
central (25% ROI) and peripheral (75% ROI)

1.82±0.62

1.72±0.45

2.03±0.48

2.28±0.22

1.62±0.39

1.37 (0.82.3)
1.49 (0.82.1)
1.27 (0.72.0)

1.7 (0.9-2.3)

1.2±0.3

1.0±0.2

1.0 (0.7-1.5)

1.0 (0.8-1.3)

0.9 (0.6-1.3)

0.50±0.20

1.5±0.6

1.4±0.3

1.2±0.1

0.73±0.22
(C/P)

[19]

[18]

[17]

[16]

[15]

[1]

[14]

[13]

[12]

[11]

Budesonide

Tobramycin

Nedocromil
Sodium
(lactose)

Turbuhalerg

Turbospin

Ultrahaler

2.61±0.63

3.7±1.0
4.0±1.2

75.3±19.0

42.5±8.6

73.3±31.2
3.4±0.9
(35-142)
(2.1-6.1)
Targeted PIFR of 60 L/min;
Exhale, inhale rapidly to TLC,
and hold breath for 5 sec

58±6

9.8±3.5

13.3±4.8

34.3±5.8

15.8±6.6

21.4 (4.7-29.2)

3.2±1.3

4.5±2.0

9.3±3.3

5.9 (1.7-10.0)

3.1±1.2

4.5±1.8

11.3±2.7

7.3 (3.2-11.0)

3.5±1.4

4.3±1.3

13.6±3.3

4.8 (2.5-9.1)

1.2±0.4

1.1±0.3

1.6±0.4

1.9±0.7
(sC/P)

0.9 (0.5-1.6)

Ultrahaler
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HMR 1031
Targeted PIFR 60 L/min
24.6±7.3
8.6±3.9
8.3±2.5
7.7±1.8
1.1±0.5
(lactose)
aAvailable as Asmabec Clickhaler (beclometasone dipropionate) (RPH Pharmaceuticals, U.K.)
bAvailable as Foradil Aerolizer (formoterol fumarate) (Novartis)
cAvialable as Easyhaler Salbutamol, Easyhaler Budesonide, Formoterol Easyhaler, Easyhaler Beclometasone (Orion Pharma, U.K.)
dAvialable as Eklira Genuair (aclidinium bromide) and Duaklir Genuair (formoterol fumarate dehydrate, aclidinium bromide) (Astrazeneca, U.K.)
eAvialable as Budelin Novolizer (budesonide) and Salbulin MDPI Novolizer (salbutamol sulfate) (Meda Pharmaceuticals, U.K.)
fAvialable as Pulvinal (salbutamol) and Pulvinal (beclometasone dipropionate) (Chiesi, Italy)
gAvialable as Bricanyl Turbohaler (terbutaline sulphate), Oxis Turbohaler 12 (formoterol fumarate dehydrate), Pulmicort Turbohaler (budesonide),
Symbicort Turbohaler (budesonide, formoterol fumarate dehydrate) (Astrazeneca, U.K.)

Budesonide

Turbuhalerg

[22]

[21]

[20]

[3]

[1]

A closer look at the 21 possible studies in Table AI.1 showed that many were
unsuitable for use when attempting to construct IVIVCs. Not all inhalers (or inhaler-drug
combinations) were commercially available, and a lack of well described inhalation
maneuvers and regional lung deposition data in some studies limited our choices further.
In order to test the in vivo predictability of our methods the following additional criteria
were established to define acceptable studies for the purpose of IVIVC comparisons:
(a) Drug inhalers used in the gamma scintigraphy studies must be commercially
available (to enable in vitro testing);
(b) Validation of the labeling procedure should be described. In short, a comparison
between the radiolabel and the drug in a standardized testing situation should
ensure a comparable aerodynamic size distribution between the drug (from the
unlabeled inhaler) and the label (from the labeled version);
(c) Inhalation profile (IP) variables used by subjects in each study should be reported
with statistics so that it is possible to simulate realistic IPs for in vitro testing. In
short, values and statistics were required that described peak inspiratory flow rates
(PIFR) and either total volume inhaled (V) or total inhalation time [before breath
holding] (T).
(d) Regional deposition data should be reported to describe the % of each lung dose
deposited in well-defined lung regions (e.g. central, intermediate and peripheral);
The references and data shown in Table AI.2 were selected for further
consideration.
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Turbohaler

Turbohaler

Budesonide

Terbutaline
Sulphate
Terbutaline
Sulphate

Salbutamol
(lactose)

Pulvina

Turbohaler

Budesonide
(lactose)

Zanamivir
(lactose)
Beclomethasone
Dipropionate
(lactose)
Aclidinium
Bromide
(lactose)

Drug

Novolizer

Genuair

Easyhaler

Diskhaler

Inhaler

3.11±0.67
3.23±0.74

46.0±4.4

27.8±2.5

58±6

55±7
2.61±0.63

2.41±0.50

2.54±0.87

2.77±0.97

54±7

57.8±5.6

2.96±0.83

3.13±1.01

99±13

65±3

3.91±0.72

2.62±0.97

2.77±1.02

Volume (L)

79.0±9.4

53±11

84.0±16.5

PIFR (L/min)
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21.4 (4.7-29.2)

26.9±3.8

21.4±6.1

11.7±2.3

14.1±3.2

19.9 (8.8-26.6)

25.0 (12.1-37.4)

32.1 (9.4-41.0)

30.1±7.3

18.9±9.5

13.2±4.0

%TLD

6.4±3.1

4.2±1.3

%Intermediate

6.7±3.6

3.9±1.0

%Peripheral

5.9 (1.7-10.0)

5.7±0.9

5.5±1.5

3.8±0.9

4.9±1.3

6.3 (2.3-8.4)

7.8 (3.7-11.8)

10.6 (3.0-13.4)

7.3 (3.2-11.0)

8.4±1.0

7.1±2.0

3.7±0.8

4.3±1.0

6.7 (3.2-9.9)

8.9 (4.6-12.2)

10.9 (3.8-15.9)

4.8 (2.5-9.1)

12.9±2.2

8.8±2.9

4.2±0.9

4.9±1.1

6.5 (3.4-8.8)

7.8 (3.7-13.4)

8.5 (2.5-13.4)

Lung was divided into 6 regions, with mean values
of 9.9% and 2.6% for the innermost and outermost
regions (data for 6 regions available)

5.8±3.3

5.1±2.2

%Central

Table AI.2. Selected lung scintigraphy references for further discussion.

0.9 (0.5-1.6)

2.28±0.22

1.62±0.39

1.2±0.3

1.0±0.2

1.0 (0.7-1.5)

1.0 (0.8-1.3)

0.9 (0.6-1.3)

1.2±0.3

0.9±0.4

P/C Ratio

[1]

[18]

[17]

[15]

[1]

[10]

[8]

[7]

Ref.

Selection of Budelin® Novolizer®
The ASTA Medica DPI Device and formulation tested clinically by Newman et al.
[1] became Budelin Novolizer and was marketed by Meda Pharmaceuticals in the EU.
This thesis is focused on that device primarily because reference [1] had the advantage
that Budelin was labeled and tested using a cross-over deposition study in the clinic that
clearly showed the dosing variations and reginal drug deposition results after asking each
volunteer to inhale at three different peak inspiratory flow rates. We expected to be able
to see differences in deposition in vitro that resulted from similar variations in the breath
profiles simulated to mimic each of Newman et al.’s 3 clinical study cohorts [1]. In practice,
and in the future, however, it may well prove possible to test the IVIVCs by employing the
data in references [1, 7, 8, 10, 15, 17, 18] that describe the deposition of drug from
RelenzaTM DiskhalerTM (5 mg zanamivir, GlaxoSmithKline), Easyhaler® (200 mcg
beclomethasone, Orion Pharma, U.K.), Eklira® Genuair® (322 mcg aclidinium,
AstraZeneca, U.K.), Budelin® Novolizer® (200 mcg budesonide, Meda Pharmaceutics,
U.K.), Pulvinal® (200 mcg salbutamol, Chiesi, Italy), Bricanyl® Turbohaler® (0.5 mg
Terbutaline Sulphate, AstraZeneca, U.K.), and Pulmicort® Turbohaler® (100 mcg
budesonide, AstraZeneca, U.K.) (Table IA.2).
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APPENDIX II
GEOMETRY OF THE MODIFIED VCU MOUTH-THROAT MODELS

Three dimensional (3D) geometries of the original small, medium and large Virginia
Commonwealth University (VCU) mouth-throat (MT) models are available at
www.rddonline.com. These models were modified as shown below by adding a quick-fit
adapter to allow an airtight connection between the MT and the Next Generation
Pharmaceutical Impactor or NGI. Dimensions of the NGI quick-fit adapter were the same
for all three MT models and the dimensions are shown in the figure below in mm. The exit
of MT was centralized in the adapter in all cases.
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APPENDIX III
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APPENDIX IV
CURVE FITTING METHODS FOR SIMULATING HUMAN INHALATION PROFILES

AIV.1 INTRODUCTION
Simulated inhalation profiles (IP) and equations described in Delvadia et al. [1-3]
require the assignment of Thold, an arbitrarily defined variable, or time to maintain the peak
inhalation flow rate. Delvadia et al. [1] held the value of Thold constant at 0.15 sec. In this
thesis, a new process was proposed and published [4], which avoided the need to assign
values to this variable. As a result, it was possible to advocate methods to simulate ranges
of human IPs for DPI testing (Chapter 4) based solely on the clinical results from Delvadia
[3] and a knowledge of the airflow resistance of the inhaler being tested. Essentially, the
data presented in Delvadia [3] was reanalyzed in the present study in order to find optimal
mathematical equations for IP simulation in the absence of Thold.
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AIV.2 METHODS
A variety of equations were assessed for their ability to describe the IPs presented
in Delvadia [3]. Several different orders of polynomial equations and a combined
exponential /sine equation FR(t )   A0e

 k1t

 t 
 A0 cos    were explored and rejected
2 T

because their parameters (e.g. A0, k1) could not be directly assigned to the variables with
physical meanings in a typical IP such as that shown in Figure 4.4. Therefore, the
equations described in Delvadia et al. [1] were used as the basis for this study, and curve
fitting analyses were performed to define values for Thold in the hope that curve-fits would
be no better in the case where Thold→0. These equations are rewritten below (Equations
AIV.1–AIV.3) as initially defined in Delvadia [3] and integrated using Mathematica 9.0.1
(Wolfram, Champaign, IL) to solve the relationship between T (total inhalation time) and
Thold:
 t 
FR (t )  PIFR  sin 

 2 TPIFR 

FR(t )  PIFR

0  t  TPIFR

Equation AIV.1

TPIFR  t  TPIFR  THold 

   t  TPIFR  THold   
FR(t )  PIFR  cos 

 2 T  TPIFR  THold   



Equation AIV.2

TPIFR  THold   t  T

Equation AIV.3

Inhaled volume [V; area under the flow rate (FR) vs. time curve from t = 0 to t = T)
can be described as a function of the peak inhalation flow rate (PIFR), time to achieve
PIFR (TPIFR), time to maintain PIFR (Thold), and the total inhalation time (T) from:
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V

TPIFR



FR(t ) 

TPIFR THold



T

FR (t ) 

FR (t )

TPIFR THold

TPIFR

0



PIFR  TPIFR PIFR  THold PIFR  (T  TPIFR  THold )



30
60
30

V

2
PIFR  [ (T  THold )  THold ]



Equation AIV.4

Equation AIV.5

60

Or:
T 



60V
 THold )  THold
2 PIFR
(

Equation AIV.6

The real data in 10, 50, and 90 percentile FR vs. time profiles for all six resistances
(red inhalation profiles in Figure 4.5 of Chapter 4) were used for curve fitting, and a total
of 18 Text files [defined as an input format in MATLAB® R2012b (MathWorks, Natick,
MA); 3 profiles for each resistance, 6 resistances in total) were created to store the FR
vs. time data. In practice, each curve contained > 300 individual data points with a time
interval of 0.005 sec. For each profile, values for PIFR were selected using the MAX
function across all flow rates in Microsoft Excel 2013 (Microsoft Corporation, Redmond,
WA), and the values for V under each IP were obtained by calculating the area under
each curve trapezoidally. To facilitate curve fitting, values for TPIFR were fixed at three
selected values: 0.276 sec, 0.493 sec, and 0.885 sec that corresponded to the 10, 50 and
90 percentile values of the 240 TPIFR values from the trial population (Figure 4.5 of Chapter
4). Non-linear least-squares curve fitting was then used with Thold floating in Equations
AIV.1–AIV.3 to assess the goodness of fit for each data set. Combinations of PIFR, V and
TPIFR that were employed at summarized in Table 1. All analyses were performed in
MATLAB® R2012b. Examples of MATLAB scripts are shown in Figures AIV.1 and AIV.2.
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Table AIV.1. Combinations of PIFR, V and TPIFR used to curve fit the 10, 50 and 90
percentile IPs across six resistances. Each of the 18 inhalation profile data sets was
analyzed for all three TPIFR conditions to determine the best estimate for the Thold.
Resistance

PIFR

V

(L/min)

(L)

10 Percentile

45.781

1.352

50 Percentile

58.297

2.557

90 Percentile

74.456

4.432

10 Percentile

52.556

1.389

50 Percentile

65.564

2.694

90 Percentile

78.977

4.369

10 Percentile

60.773

1.466

50 Percentile

73.085

2.575

90 Percentile

93.259

4.428

10 Percentile

76.887

1.43

50 Percentile

98.160

2.723

90 Percentile

126.241

4.64

10 Percentile

92.543

1.469

50 Percentile

110.811

2.7

90 Percentile

147.181

4.862

10 Percentile

95.286

1.435

50 Percentile

122.947

2.733

90 Percentile

162.254

4.773

Profile
(kPa0.5 L-1 min)

0.0462
(Tube 1)

0.0432
(Tube 2)

0.0344
(Tube 3)

0.0241
(Tube 4)

0.0200
(Tube 5)

0.0179
(Tube 6)
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Figure AIV.1. MATLAB scripts for defining functions used for curve fitting. The above
example was shown for the 50 percentile profiles from Tube 4. Values for PIFR, V and
TPIFR were assigned and THold was defined as the unknown (floating) parameter in each
case.
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Figure AIV.2. MATLAB scripts for curve fitting of Thold using non-linear least-squares
approach. The above example was shown for the 50 percentile profiles of Tube 4. Data
were imported as a matrix where “t” refers to inhalation time and “Q” refers to flow rate.
“lsqcurvefit” function was used to perform non-linear least-squares curve fitting.
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AIV.3 RESULTS
Best estimates for Thold and the statistical parameters resulting from each of the
profiles are summarized for the three tested TPIFR conditions in Tables AIV.2–AIV.4. The
results showed that the best estimate for Thold was zero in 52 out of 54 cases. Only in two
of 54 cases (10 percentile profile for Tube 1 in Tables AIV.2–AIV.3) was a small positive
value for Thold seen to be a better estimate value than zero. Based on these analyses,
the finite variable choice of Delvadia [3] for Thold = 0.15 sec eliminated from Equations
AIV.1–AIV.3 and the Equations AIV.7–AIV.8 shown below used for simulating human
inhalation profiles in this thesis.
 t 
FR (t )  PIFR  sin 

 2 TPIFR 

0  t  TPIFR

   t  TPIFR  
FR(t )  PIFR  cos 

 2 T  TPIFR  

TPIFR  t  T

Equation AIV.7
Equation AIV.8

Equations AIV.7–AIV.8 are the same as those presented in the simulation in Chapter 4
(Equations 4.7–4.8) and reference [4].
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Table AIV.2. Best estimates for Thold and statistical parameters from curve fitting the 10,
50 and 90 percentile profiles across six resistances (TPIFR = 0.276 sec; 10 percentile value
in the total population). RMSE = root mean square error (used to measure the difference
between predicted value and observed value); r2 = coefficient of determination (used to
assess how well the data fit a model).
Resistance
0.5

(kPa

-1

L min)

Thold
(Best Estimate; sec)

95% CI
RMSE

r2

(Lower, Upper)

0.067

-0.029

0.163

6.79

0.751

0.000

-0.076

0.076

4.84

0.880

0.000

-0.084

0.084

7.33

0.857

0.000

-0.109

0.109

9.58

0.600

0.000

-0.066

0.066

5.48

0.902

0.000

-0.049

0.049

4.72

0.954

0.000

-0.090

0.090

9.33

0.669

0.000

-0.052

0.052

5.57

0.932

0.000

-0.067

0.067

8.31

0.888

0.000

-0.092

0.092

15.65

0.548

0.000

-0.049

0.049

8.50

0.918

0.000

-0.053

0.053

10.22

0.928

0.000

-0.129

0.129

29.24

0.047

0.000

-0.053

0.053

11.13

0.897

0.000

-0.040

0.040

9.57

0.958

0.000

-0.113

0.113

26.99

0.198

0.000

-0.054

0.054

13.48

0.878

0.000

-0.051

0.051

14.29

0.917

0.0462
(Tube 1)

0.0432
(Tube 2)

0.0344
(Tube 3)

0.0241
(Tube 4)

0.0200
(Tube 5)

0.0179
(Tube 6)
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Table AIV.3. Best estimates for Thold and statistical parameters from curve fitting the 10,
50 and 90 percentile profiles across six resistances (TPIFR = 0.493 sec; 10 percentile value
in the total population). RMSE = root mean square error (used to measure the difference
between predicted value and observed value); r2 = coefficient of determination (used to
assess how well the data fit a model).
Resistance
0.5

(kPa

-1

L min)

Thold
(Best Estimate; sec)

95% CI
RMSE

r2

(Lower, Upper)

0.025

-0.020

0.071

3.22

0.944

0.000

-0.050

0.050

3.24

0.946

0.000

-0.087

0.087

7.78

0.839

0.000

-0.059

0.059

5.42

0.872

0.000

-0.031

0.031

2.65

0.977

0.000

-0.055

0.055

5.40

0.940

0.000

-0.046

0.046

5.01

0.905

0.000

-0.021

0.021

2.35

0.988

0.000

-0.064

0.064

8.05

0.894

0.000

-0.043

0.043

7.96

0.883

0.000

-0.027

0.027

4.85

0.973

0.000

-0.053

0.053

10.56

0.923

0.000

-0.079

0.079

19.75

0.565

0.000

-0.019

0.019

4.33

0.984

0.000

-0.036

0.036

8.76

0.965

0.000

-0.062

0.062

16.40

0.704

0.000

-0.020

0.020

5.15

0.982

0.000

-0.057

0.057

16.70

0.887

0.0462
(Tube 1)

0.0432
(Tube 2)

0.0344
(Tube 3)

0.0241
(Tube 4)

0.0200
(Tube 5)

0.0179
(Tube 6)
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Table AIV.4. Best estimates for Thold and statistical parameters from curve fitting the 10,
50 and 90 percentile profiles across six resistances (TPIFR = 0.885 sec; 10 percentile value
in the total population). RMSE = root mean square error (used to measure the difference
between predicted value and observed value); r2 = coefficient of determination (used to
assess how well the data fit a model).
Resistance
0.5

(kPa

-1

L min)

Thold
(Best Estimate; sec)

95% CI
RMSE

r2

(Lower, Upper)

0.000

-0.070

0.070

5.11

0.859

0.000

-0.102

0.102

6.76

0.765

0.000

-0.116

0.116

10.79

0.690

0.000

-0.053

0.053

5.31

0.877

0.000

-0.077

0.077

6.91

0.844

0.000

-0.097

0.097

9.97

0.795

0.000

-0.072

0.072

8.57

0.721

0.000

-0.077

0.077

9.09

0.818

0.000

-0.093

0.093

12.33

0.753

0.000

-0.041

0.041

9.14

0.846

0.000

-0.074

0.074

14.82

0.750

0.000

-0.088

0.088

18.80

0.756

0.000

-0.040

0.040

12.72

0.820

0.000

-0.068

0.068

17.08

0.758

0.000

-0.075

0.075

20.12

0.816

0.000

-0.034

0.034

11.78

0.847

0.000

-0.065

0.065

19.88

0.735

0.000

-0.093

0.093

29.63

0.644

0.0462
(Tube 1)

0.0432
(Tube 2)

0.0344
(Tube 3)

0.0241
(Tube 4)

0.0200
(Tube 5)

0.0179
(Tube 6)
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